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ABSTRACT 
 Parkinson’s disease (PD) is a progressive neurodegenerative disorder that was first 
described by the physician James Parkinson in 1817 as the shaking palsy. PD is now 
recognized as the most common neurodegenerative movement disorder affecting over 2% of 
the population and placing a severe economic burden on societies, particularly those with 
ageing populations. The pathological hallmark of PD is a progressive loss of dopaminergic 
neurons in the substantia nigra of the midbrain resulting in striatal dopamine depletion which 
manifests as a range of motor and nonmotor deficits. Progressive nigral dopaminergic 
degeneration is also accompanied by a chronic neuroinflammatory response that is 
characterized by increased microgliosis and the presence of dystrophic astrocytes. Research 
over the last decade has provided compelling evidence that the sustained microglial 
neuroinflammatory response can be neurotoxic and exacerbate dopaminergic degeneration. 
Therapeutic targeting of microglial activation has also been shown to mitigate dopaminergic 
degeneration in pre-clinical models of PD. However, the mechanisms by which microglial 
activation and neuroinflammation lead to dopaminergic neurotoxicity remain poorly 
understood. A major objective of this work was to characterize important signaling pathways 
activated during neuroinflammation, which could be therapeutically targeted to achieve 
neuroprotection in PD. Protein Kinase C delta (PKCδ), a novel member of the PKC family, 
has been shown to be an oxidative stress sensitive kinase that is proteolytically activated by 
caspase-3 following dopaminergic insults and mediates apoptosis of dopaminergic neurons. 
Significantly, blocking PKCδ using small molecule kinase inhibitors is neuroprotective in 
animal models of PD making it a potentially important therapeutic target for PD.  However, 
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the role of PKCδ in regulating microglial activation and neurotoxicity has not been studied. 
Since the PKCδ signaling pathway is a crucial regulator of innate immune cell activation and 
proinflammatory responses outside the central nervous system (CNS), we hypothesized that 
PKCδ could be also be involved in regulating microglial activation and dopaminergic 
neurotoxicity during sustained neuroinflammation in PD. We tested this hypothesis using cell 
culture and animal models of neuroinflammation and PD.  Herein, we demonstrate for the 
first time that PKCδ is proteolytically activated in dopaminergic neurons by tumor necrosis 
factor alpha (TNFα), an important proinflammatory cytokine, via the extrinsic cell death 
pathway to mediate dopaminergic degeneration. We also demonstrate that PKCδ is 
proteolytically activated in vivo using the intranigral LPS injection model of 
neuroinflammation and that targeting PKCδ protects against dopaminergic neurotoxicity 
induced by TNFα. In microglial cells, we show that PKCδ is highly induced during 
microglial activation and is a crucial regulator of microglial proinflammatory responses. 
Importantly, we demonstrate that microglia from PKCδ knockout mice have reduced 
proinflammatory responses and that PKCδ knockout mice are protected from dopaminergic 
degeneration in the MPTP model of PD. We also describe a novel method for isolation of 
pure primary microglia from postnatal mice by magnetic separation which provides the 
highest yield of microglial cells to date. While characterizing the effect of TNFα on 
dopaminergic degeneration, we serendipitously discovered that Prokineticin-2 (PK2), a novel 
member of the AVIT family, is highly induced in dopaminergic cells following neurotoxic 
insults. The final chapter of this work characterizes a novel and clinically relevant function 
for PK2 in the pathophysiology of PD and demonstrates for the first time that PK2 protects 
vi 
 
 
dopaminergic cells from oxidative stress and neurotoxicity in vitro. These findings have 
immense implications for prokineticin-2 signaling in the pathophysiology of Parkinson’s 
disease and establish a novel paradigm for prokineticin signaling during neurodegeneration 
and neuroinflammation.  Collectively, the research described herein provides novel and 
important insight into PKCδ and Prokineticin-2 signaling during neuroinflammation and the 
pathophysiology of Parkinson’s disease. These results have fundamental implications for 
therapeutic targeting of these crucial signaling pathways to mitigate progressive 
dopaminergic neuron loss in Parkinson’s disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
CHAPTER I 
 GENERAL INTRODUCTION 
 
Thesis Layout and Organization 
The alternative format was chosen for this thesis and consists of manuscripts that are 
published, under peer review or being prepared for submission. The dissertation contains a 
general introduction, four research papers and a conclusion section that discusses the overall 
findings from all chapters. The references for each manuscript chapter are listed at the end of  
that specific section. References pertaining to the background and literature review as well as 
those used in general conclusion section are listed at the end of the dissertation. The 
introduction section under chapter I provides a background and overview of the idiopathic 
Parkinson’s disease. The first background and literature review section covers current 
evidence implicating a pathogenic role for reactive microgliosis in mediating  progressive 
dopaminergic neuron loss in Parkinson’s disease. It also discusses the current knowledge of 
protein kinase C delta (PKCδ) signaling in dopaminergic degeneration and immune cell 
activation and provides an overview of the research objectives pertaining to chapters II, III 
and IV.  The second literature review pertains to chapter V and provides an introduction to 
prokineticin-2 (PK2) signaling mechanisms and known physiological functions in the central 
nervous system and elsewhere. It covers the structural and functional aspects of PK2 
signaling based on the current literature and provides contextual background for the research 
results described. The manuscript from Chapter II was recently communicated to the journal 
Neurobiology of Disease and Chapter III to the Journal of Neuroscience. Chapter IV 
describes a novel method for high-yield isolation of primary microglia by magnetic 
separation using Tetrametic Antibody Complexes (TACS) and has been published in the 
Journal of Neuroscience Methods. Chapter V describes research results pertaining to a novel 
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function for prokineticin-2 signaling during dopaminergic degeneration and is a manuscript 
that will be shortly communicated to the Journal of Neuroscience. 
All of the research described by the author in this thesis was performed during the 
course of the author’s doctoral studies at Iowa State University under the guidance of his 
major professor and principal investigator Dr. Anumantha G. Kanthasamy.  
 
Introduction 
Idiopathic Parkinson's disease (PD) is a chronic, progressive neurodegenerative 
disorder characterized by extrapyramidal motor deficits including akinesia, bradykinesia, 
rigidity and postural instability. First described by James Parkinson in 1817 as the shaking 
palsy, it is recognized today as the second most common neurodegenerative disorder 
affecting about 1 million people in the United States and over 4 million worldwide (von 
Bohlen und Halbach et al., 2004). Idiopathic PD has a median onset of around 60 years and 
its occurrence increases with age. The well-known pathological hallmark of PD is a 
significant loss of melanized dopaminergic neurons in the substantia nigra compacta, 
resulting in severe dopamine depletion in the caudate putamen. Typically, when motor 
symptoms are manifest at the time of diagnosis, around a 60% loss of dopaminergic cell 
bodies in the substantia nigra is evident with about an 80% depletion in striatal dopamine 
levels (Dauer and Przedborski, 2003). The conspicuous presence of Lewy bodies containing 
aggregated -synuclein and other cellular degradation products is a characteristic feature of 
the disease in humans but is not reproduced well in animal models of PD. Reactive 
microgliosis is another prominent pathological feature of PD that is evident in clinical 
subjects and all animal models of the disease. Interestingly, although the extent of 
dopaminergic degeneration is greater in the striatum, reactive microgliosis is highest in the 
vicinity of dopaminergic cell bodies of the substantia nigra (Mosley et al., 2006; Bartels and 
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Leenders, 2007; Whitton, 2010). Until recently, the glial reaction accompanying nigral 
dopaminergic degeneration was presumed to be an innocuous consequence of extensive 
dopaminergic degeneration. Over the last two decades however, a wealth of evidence has 
accumulated that now strongly supports an active role for reactive microgliosis in the 
pathogenesis of PD, particularly in the progressive phase of the disease.  
Various autonomic, non-motor symptoms have recently been associated with PD and 
are apparent in many but not all patients with the disease. The non-motor symptoms, which 
include sleep disorders, constipation, olfactory deficits and cardiovascular dysfunction, can 
in many cases precede the onset of motor symptoms by many years. Mild cognitive 
impairment is also seen in many PD patients (Magerkurth et al., 2005; Chaudhuri et al., 
2006). Despite several decades of research into the etiology of PD, a cogent mechanistic 
basis for the selective vulnerability and progressive loss of nigral dopaminergic neurons has 
not been established. The emerging view appears to be that Parkinson’s disease results from 
complex interactions between environmental, genetic and cellular processes that cause 
dopaminergic cell death over time, (Sulzer, 2007; Obeso et al., 2010b).  A ‘multiple-hit’ 
hypothesis of disease onset has been proposed wherein different causative factors and 
multiple neurotoxic insults either accumulate over a lifetime or converge on the intrinsic 
vulnerability of nigrostriatal system, resulting in an idiopathic onset of PD (Carvey et al., 
2006).   
Six major genetic defects including alpha-synuclein, Parkin, DJ-1, LRRK2, PINK1 
and Uch-L1 were identified as risk factors in certain genetic forms of PD but these account 
for fewer than 5% of the clinical cases, the rest being sporadic (Gwinn-Hardy, 2002; Dawson 
and Dawson, 2003; Vila and Przedborski, 2004). Environmental mechanisms, however, 
remain a major  risk factor for development of sporadic PD.  Several environmental factors 
including pesticides and heavy metals, well-water, pre- and post-natal exposure to 
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inflammatory agents and head trauma have been associated with an increased risk of 
developing PD (Di Monte et al., 2002; Lai et al., 2002). However, studies into the genetic 
forms of PD have provided fundamental insight into potential cellular and molecular 
mechanisms by which environmental factors can promote dopaminergic degeneration. 
Extensive research over the last few decades has shown that oxidative stress, mitochondrial 
dysfunction, and proteasomal impairment are important causative factors that can initiate 
dopaminergic degeneration in both idiopathic and genetic forms of PD (Przedborski, 2005; 
Jenner and Olanow, 2006; Olanow, 2007). However, neither oxidative stress nor 
mitochondrial and proteasomal dysfunction can by themselves sufficiently explain the 
progressive neuron loss that occurs in PD. Chronic neuroinflammation and sustained reactive 
microgliosis have been proposed to explain the progressive nature of dopaminergic 
degeneration in PD (Block et al., 2007a; Whitton, 2007). This hypothesis has recently gained 
increasing support from studies in experimental models of PD which demonstrate that 
microglial neurotoxicity can exacerbate local oxidative stress in the substantia nigra and 
sustain dopaminergic degeneration initiated by other idiopathic mechanisms (Block and 
Hong, 2005; Glass et al., 2010). Again, the precise mechanisms by which microglial cells 
become chronically activated and promote dopaminergic neuron loss remain to be 
established.  
The emerging consensus suggests that PD is a complex, heterogeneous disease with 
multifactorial mechanisms of pathogenesis acting in concert with ageing to bring about 
disease onset and progression. The fact that many interacting factors appear to be responsible 
for the development of PD makes therapeutic intervention an immense challenge particularly 
at early stages of the disease (Obeso et al., 2010a). All of the approved treatment options for 
PD currently in use today including L-DOPA and deep brain stimulation only alleviate the 
symptoms of the disease and have no effect on the degenerative process. Therefore, 
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identifying common signaling pathways and therapeutic targets that are relevant across 
multiple modalities of disease pathogenesis would likely be an effective therapeutic strategy 
against PD. However, given the complex and heterogeneous nature disease pathogenesis, 
identifying such common downstream signaling pathways that are activated by distinct 
initiating mechanisms of disease pathogenesis would be difficult but necessary if early 
therapeutic intervention is to be achieved. Given that there are no known biomarkers for 
clinical PD that could enable early detection of dopaminergic degeneration, most patients are 
diagnosed at advanced stages of the disease process. Therefore, therapeutic intervention 
during the progressive phase of the disease process would be more feasible. Since 
neuroinflammatory processes and microglial neurotoxicity have been shown to be important 
mechanisms driving progressive dopaminergic neuron loss, targeting the microglial 
activation process and microglial neurotoxicity could be effective at slowing disease 
progression. Nonetheless, a more fundamental understanding of both the mechanisms of 
disease onset and its progression through neuroinflammatory processes would be necessary 
in order to rationally design effective therapeutic interventions.  
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Background and Literature Review I  
Reactive Microgliosis and Protein Kinase Cδ Signaling Mechanisms in the 
Pathophysiology of Parkinson’s disease  
 Neuroinflammation has been consistently documented in several chronic 
neurodegenerative diseases including Alzheimer’s disease, Huntington’s disease, 
Amyotrophic lateral sclerosis, and Parkinson’s disease (Liu et al., 2003; Minghetti, 2005; 
Block et al., 2007b). Within the CNS, the hallmark of neuroinflammation is a persistent and 
localized activation of the resident brain glial cells, the astrocytes and microglia, at the site of 
neurodegeneration. For many years, the primary role of reactive gliosis accompanying 
neurodegeneration was intuitively believed to be phagocytic clearance and immune 
surveillance for activated microglia and neurotrophic support by astrocytes. During neuronal 
development and in the normal adult brain, activated glial cells participate in maintaining 
neuronal homeostasis during development and facilitate neuronal survival by providing 
neurotrophic support (Streit, 2002; Marin-Teva et al., 2004; Bessis et al., 2007). They also 
participate in neurogenesis and neural repair by directing the migration of neuronal 
progenitors to the sites of brain injury (Aarum et al., 2003; Walton et al., 2006). Rapid 
activation of microglia and astrocytes is also evident following acute brain injuries or 
infection and the gliosis that ensues is essential for neural repair and regeneration. In most 
cases of acute brain injury or infection, the neuroinflammatory responses are transient and 
subside once the infection is cleared or homeostasis is restored at the site of injury. In chronic 
neurodegenerative disorders such as Parkinson’s disease, however, the neuroinflammatory 
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response is both chronic and progressive, with reactive gliosis being evident even in 
postmortem brains.  
Microglial activation and reactive microgliosis in Parkinson’s disease 
 Microglia are the resident macrophages in the brain and spinal cord. They were first 
described by Rio Hortega who identified their phagocytic properties and suggested that they 
could function similar to macrophages. This was confirmed several decades later in the 1988 
by Hickey and Kimura when they demonstrated the perivascular microglia are antigen-
presenting cells and express high levels of MHC class II. The exact origins of microglia were 
unclear until recently when it was confirmed that they originate in the bone marrow, are 
derived from myeloid cells and migrate into the brain early during development.  Microglia 
make up about 10 to 15% of the total cells in the brain and their numbers vary according to 
region. The hippocampus, basal ganglia, olfactory telencephalon, and substantia nigra were 
found to have the highest microglial cell density in the CNS.  
Microglial activation is the earliest and most evident response to neuronal injury in 
both acute and chronic neurodegenerative states (Figure 1).  In the normal adult brain, 
microglia are typically present in their so called ‘resting state’ with a ramified morphology. 
In recent years, in vivo two photon microscopy has revealed that resting microglia are not 
dormant cells but are in fact highly dynamic and efficient in forming processes and scanning 
the neuronal microenvironment (Nimmerjahn et al., 2005). With adjacent microglia 
surveying overlapping regions of the brain parenchyma, recent studies estimate that the entire 
neuronal network of the brain can be scanned within a few hours (Davalos et al., 2005; 
Nimmerjahn et al., 2005; Hanisch and Kettenmann, 2007).  In response to acute neuronal 
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injury or pathogenic stimuli, microglia undergo a rapid and dynamic transformation to 
reactive amoeboid forms with concurrent upregulation of various cell surface proteins 
including MHC molecules, cytokine and chemokine receptors. Again, in vivo imaging 
studies elegantly demonstrate that resting microglia can respond to chemoattractants and 
morphologically realign themselves within seconds or minutes. Transcriptional activation of 
several stimulus-specific sets of response genes also occurred rapidly in activated microglia 
with functional proteins being produced at around two hours. As would be necessary, the 
activation of microglia is both a dynamic and tightly regulated process relying on constant 
‘ON’ and ‘OFF’ signals from neurons, astrocytes and the extracellular milieu  and can be 
rapidly shut down once homeostasis has been attained  (Kreutzberg, 1996) 
Figure 1: Morphology of resting and activated microglial cells 
 Activated microglia generate a large number of secreted factors including proteases, 
pro-inflammatory mediators, cytokines and chemokines that can alter the local neuronal 
microenvironment in the brain parenchyma in a stimulus-specific manner. Transient and 
regulated activation of microglia typically facilitate a microenvironment that promotes 
neuron survival and homeostasis (Glezer et al., 2007; Simard and Rivest, 2007; Napoli and 
Neumann, 2010). Activated microglia can respond with the release of anti-inflammatory and 
neurotrophic factors including BDNF, GDNF, IL-10 and TGF1 from microglia, which can 
stimulate anti-apoptotic survival signaling pathways including Akt/PI3K in neurons. 
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Microglia have been shown to protect neurons from excitotoxicity by upregulating GLT-1, a 
glutamate uptake protein under conditions where astrocyte glutamate uptake is impaired 
(Persson et al., 2005; Shaked et al., 2005). Microglial activation facilitates phagocytic 
removal of dead cells at the site of injury and can participate in regeneration of neural 
connections by synaptic stripping. In the entorhinal cortex, for example, activated microglia 
facilitate the physical removal of synapses and entire dendritic structures following neuronal 
injury. The synaptic stripping and phagocytic removal of cellular debris allow for the 
formation new synaptic connections and restoration of local neuronal homeostasis (Trapp et 
al., 2007). Microglia can directly promote neurogenesis and direct the migration of adult 
neural stem cells and in the brain. They can also negatively regulate neurogenesis by 
inducing a pro-inflammatory microenvironment (Butovsky et al., 2006)  
Microglial activation in neurodegenerative disorders 
In contrast to the transient and highly regulated activation profile seen during acute 
neuronal injury or during microglial housekeeping functions in the brain, microglial 
activation in progressive neurodegenerative disorders is morphologically and functionally 
distinct.  Sustained microglial activation at the site of neuronal injury is a hallmark of most 
chronic neurodegenerative disorders. Prominent reactive microgliosis has been documented 
in postmortem brains of patients in most progressive neurodegenerative disorders. The 
microglia display their fully activated amoeboid state and increased microglial cell density at 
the sites of neurodegeneration. The microglial reaction observed in chronic 
neurodegenerative diseases has generally been regarded as an initial neuroprotective 
response. However, several lines of evidence from clinical and epidemiological studies, 
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animal models and in vitro now support the view that sustained neuroinflammation and 
reactive microgliosis can be neurotoxic and exacerbate progressive neuron loss. In the 
diseased brain microenvironment, persistently activated microglia can augment oxidative 
stress levels and secrete proinflammatory mediators, which can be neurotoxic over time 
(Aschner et al., 1999; Glass et al., 2010). The following section reviews the current evidence 
for microglial neurotoxicity in the pathophysiology of Parkinson’s disease.  
Figure 2: Activated microglia cells in the substantia nigra of MPTP-treated mice 
Experimental evidence for microglial neurotoxicity in the pathophysiology of 
Parkinson’s disease 
Clinical evidence and epidemiological data: In postmortem studies of PD patients, 
extensive microglial activation is well documented in the nigrostriatal system, particularly 
around the most vulnerable melanin-containing dopaminergic neurons of the substantia nigra. 
Elevated levels of inflammatory mediators are also present in the cerebrospinal fluid of PD 
patients indicative of an ongoing inflammatory reaction that persists for the life of the 
patients (McGeer et al., 1988; Vawter et al., 1996; Banati et al., 1998; Whitton, 2007).  
Proinflammatory mediators, including TNF, IL1β, and IFN, are markedly elevated in PD 
brains and the role in the degenerative process has been characterized in experimental animal 
models (McGeer et al., 1988; Hunot et al., 1997b; Mogi et al., 2000b; Hirsch et al., 2005).  
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The activation of caspase-3 and caspase-8 has been reported in PD patients with caspase 
activity being required for microglial activation (Hartmann et al., 2000; Hartmann et al., 
2001; Burguillos et al., 2011). Microglial activation has been observed in the striatum and the 
rest of the basal ganglia by real-time PET imaging in living patients with idiopathic PD 
(Gerhard et al., 2006). Significantly, the microglial activation is evident in PD patients 
irrespective of the number of years with the disease when compared to healthy age-matched 
controls. Prominent nuclear translocation of NFkB, a crucial regulator of oxidative stress and 
proinflammatory responses, is evident in brains of PD patients (Hunot et al., 1997a). In 
support of the function of NFkB in PD, the use of highly specific NFkB inhibitors was shown 
to be efficacious in protecting against nigrostriatal dopaminergic degeneration in mouse 
models by mitigating the microglial neuroinflammatory responses and oxidative stress. 
Emerging evidence also suggests that the adaptive arm of the immune response might 
influence the degenerative process in PD. In postmortem patients, CD8+ and CD4+ T cells 
but not B cells were found in the substantia nigra in the absence of blood brain barrier 
damage (Brochard et al., 2009). Further, animal studies demonstrate that the T cells enter the 
brain following neuronal damage during the course of degeneration. Recent reports also 
suggest that the type of T cell response can both influence microglial activation and 
contribute to either dopaminergic neuron loss or neuroprotection (Benner et al., 2004; 
Reynolds et al., 2007; Kosloski et al., 2010; Reynolds et al., 2010). Postmortem analysis of 
humans who developed rapid-onset Parkinsonism after being exposed to the Parkinsonian 
toxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) show abundant reactive 
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microgliosis in the substantia nigra indicative of a sustained neuroinflammatory response that 
is perpetuated for the life of the disease (Langston et al., 1999).  
Genetic linkage studies in cohorts of PD patients have also uncovered specific single 
nucleotide polymorphisms in promoter regions of proinflammatory genes that are linked to 
the development of PD or early onset PD possibly through transcriptional mechanisms 
(Kruger et al., 2000; Hakansson et al., 2005). The G-174C SNP in the IL-6 promoter is 
linked to the development of early onset PD in a study with 258 PD patients and 308 
controls.  Similar polymorphisms in position -511 of the IL-1beta gene promoter and position 
-1031 in the tumor necrosis factor (TNF) gene promoter have also been reported (Nishimura 
et al., 2000; Nishimura et al., 2001). The experimental evidence and confirmation by meta 
analyses for these promoter polymorphism studies, however, is lacking except in the case of 
TNFα which has been shown by independent research groups to have a neurotoxic role in PD 
pathogenesis in different animal models. Epidemiological studies provide further evidence 
implicating inflammatory mechanisms in PD (Schwarzschild et al., 2003). Continual use of 
non-steroidal anti-inflammatory drugs (NSAIDs) has been shown to lower the risk of PD by 
about 46% in human populations and this has been confirmed in animal models of PD (Chen 
et al., 2003; Chen et al., 2005a).  More recent epidemiological studies, however, have shown 
that only certain classes of NSAIDs such as ibuprofen lower the risk for PD over a long 
period of time (Wahner et al., 2007).  Strong epidemiological evidence also supports a role 
for caffeine consumption in decreasing the risk of developing PD (Checkoway et al., 2002).  
Evidence from neurotoxin-based models of Parkinson’s disease: Neurotoxin-based 
models of PD using rodents, non-human primates and cell culture systems have provided 
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valuable insight into disease pathology and molecular mechanisms since the early 1980 when 
MPTP was found to cause rapid-onset Parkinsonism in humans (Hisahara and Shimohama, 
2010; Potashkin et al., 2010; Duty and Jenner, 2011). Although neither of the neurotoxin-
based models recapitulates all of the pathological features of PD, they have been particularly 
useful in characterizing the microglial neuroinflammatory response, which correlates well 
between animal models and clinical pathology (Bartels and Leenders, 2007; Yokoyama et al., 
2011). In fact, most of the findings from postmortem patients supporting a role for reactive 
microgliosis and neuroinflammation in PD pathology have also been verified using animal 
models of the disease. Reactive microgliosis and localized neuroinflammation in the 
nigrostriatal system are evident in all neurotoxin models of PD both in rodents and non-
human primates (Czlonkowska et al., 1996; Kurkowska-Jastrzebska et al., 1999). Further, the 
magnitude of the microglial neuroinflammatory response is greater in the substantia nigra 
than in the striatum in animal models similar to what is seen in PD patients and postmortem 
human studies. Over the last decade, substantial evidence obtained with experimental animal 
models has strongly implicated a role for microglial neurotoxicity in the pathophysiology of 
PD, particularly in disease progression and delayed loss of dopaminergic neurons  
The primary neurotoxin-based models of PD are the MPTP model and the 6-
hydroxydopamine (6-OHDA) model, both of which recapitulate most of the cardinal 
symptoms of PD in non-human primates and rodents. The primary pathological mechanism 
of MPTP is the selective inhibition of complex-1 activity in dopaminergic neurons resulting 
in mitochondrial oxidative stress and delayed dopaminergic degeneration. A robust 
microglial neuroinflammatory response is evident in the substantia nigra of humans exposed 
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to MPTP and in non-human primate models of PD. In rodents treated with MPTP, microglial 
activation is accompanied by an increase in MHC class 1 and II expression and upregulation 
of iNOS in both the substantia nigra and striatum. Several pro-inflammatory cytokines and 
chemokines are also elevated with 24 hours of dopaminergic neuron insult including IL-1β, 
IL-6, IL-12 and TNFα (Grunblatt et al., 2001; Youdim et al., 2002). Fractalkine signaling 
was recently implicated in regulating microglial activation with dysregulated microglial 
activation and increased dopaminergic neurotoxicity evident in Fractalkine receptor 
(CX3CR1) knockout mice. Similar results were obtained with TNFα knockout mouse or TNF 
receptor knockouts, which showed better protection against MPTP-toxicity compared to 
wildtype mice. A similar neurotoxic role for FAS signaling and glucocorticoid receptor 
signaling involving increased microglial neurotoxicity has been demonstrated in using 
knockout mice with the MPTP model (Hayley et al., 2004; Ros-Bernal et al., 2011). The 
MAC-1/CD11b complex on microglia has also been implicated in microglia neurotoxicity 
using CD11b knockout mice that were shown to have reduced production of reactive oxygen 
species and dopaminergic neurotoxicity (Hu et al., 2008).  
The most compelling mechanistic evidence for microglial neurotoxicity in the MPTP 
model comes from multiple studies and independent research groups, which have 
consistently demonstrated that microglial activation amplifies local ROS production in the 
substantia nigra to exacerbate dopaminergic degeneration. Components of the NADPH 
oxidase system are elevated following MPTP treatment in the mouse substantia nigra and 
also in human PD patients (Gao et al., 2003d; Wu et al., 2003; Zhang et al., 2004; Zhang et 
al., 2007d). The membrane-bound component of the NADPH oxidase is highly induced 
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following MPTP treatment and localizes to activated microglia, which were shown to be the 
primary producers of reactive oxygen species in vivo using dihydroedthidine histochemistry. 
Most importantly, NADPH deficient mice are protected dopaminergic degeneration and 
microglial oxidative stress in vivo (Wu et al., 2003; Qian et al., 2007). Targeting the NADPH 
oxidase system using small molecule inhibitor drugs or with antioxidants that scavenge the 
ROS species have been effective in protecting the nigrostriatal system from MPTP-induced 
damage with some being tested in clinical trials. Microglial iNOS is elevated following 
MPTP treatment and contributes to local ROS levels in the substantia nigra with knockout 
mice demonstrating robust neuroprotection from MPTP toxicity. (Kurkowska-Jastrzebska et 
al., 1999; Liberatore et al., 1999). Targeted inhibition of iNOS has also shown efficacy in the 
MPTP model of PD and in vitro. Signaling through the NFkB pathway regulates the 
production of several pro-inflammatory cytokines and chemokines as well as iNOS and 
components of the NADPH oxidase system in microglia and other innate immune cells. 
NFkB activation could therefore be a common downstream target of  multiple activation 
pathways that result in downstream production of ROS species and pro-inflammatory 
mediators. Indeed, targeting NFkB activation using specific NBD peptide inhibitors 
effectively protects against dopaminergic degeneration in the MPTP model with attenuation 
of microglial neurotoxicity being a major protective mechanism (Ghosh et al., 2007; Ghosh 
et al., 2009).  
Lipopolysaccharide based neuroinflammatory animal models of PD: Perhaps the 
strongest mechanistic basis and proof of concept for microglial neuoinflammation in the 
pathophysiology and progression of PD comes from animal and cell culture models using the 
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bacterial endotoxin lipopolysaccharide (LPS) to induce microglial neurotoxicity. LPS is a 
potent microglial activator and induces a strong inflammatory response and delayed 
dopaminergic degeneration when infused directly into the substantia nigra or given 
systemically (Castano et al., 1998b; Herrera et al., 2000; Castano et al., 2002; Hsieh et al., 
2002; Qin et al., 2007). Importantly, the LPS-induced dopaminergic degeneration in mice 
appears to be permanent, being evident even up to a year after LPS injection. This suggests 
that transient inflammatory insults can initiate dopaminergic neurotoxicity which is sustained 
in a self-perpetuating manner (Liu et al., 2000; Castano et al., 2002; Gao et al., 2002; Block 
et al., 2007a). The LPS-based models are mechanistically distinct from neurotoxin models in 
that dopaminergic degeneration results from microglial neurotoxicity and not direct neuronal 
damage since LPS by itself is not directly toxic to neurons. Further, the results from  
neurodegeneration studies with LPS demonstrate that nigral neuroinflammation alone is 
sufficient to both initiate and sustain  dopaminergic degeneration in the brain providing a 
rational for therapeutic targeting of the neuroinflammatory response. 
 In mice and rats, a single intranigral injection of LPS is sufficient to cause selective 
neurodegeneration of nigral dopaminergic neurons within two weeks, with the dopaminergic 
degeneration being evident even upto a year later. Nigral LPS infusion does not appear to 
damage to other types of neurons such as GABAergic and serotonergic neurons, or when 
injected in other regions of the brain, suggesting a selective vulnerability of the dopaminergic 
neurons to inflammatory insults (Castano et al., 1998a; Gao et al., 2002). Qin et al (2007) 
first demonstrated that a single intraperitoneal injection of LPS (5mg/kg) results in a 
protracted neuroinflammatory response in the brain long after the systemic inflammatory 
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responses in the serum and liver have subsided. Interestingly, the levels of TNFα remained in 
the brain even ten months after the systemic LPS insult while they returned to basal levels 
within a week in the serum and liver. In this model, dopaminergic degeneration becomes 
significant around ten months after the single LPS injection, although other modifications of 
this model with more multiple injections of systemic LPS can cause dopaminergic 
degeneration in two weeks (Qin et al., 2007; Lee et al., 2008). LPS can also act 
synergistically with MPTP and toxins including rotenone, paraquat and manganese to 
accelerate nigrostriatal degeneration (Gao et al., 2003a, c; Zhang et al., 2010b), implying that 
environmental toxicants, which have been heavily implicated as causative factors in 
idiopathic PD, can exacerbate neurotoxic inflammatory processes and vice-versa. In the 
presence of an LPS-induced neuroinflammatory response, the doses of neurotoxicants such 
as MPP
+
 and rotenone required to cause dopaminergic neurotoxicity in mixed neuron-glial 
cultures are much lower than those required without the ongoing inflammation. Further, 
microglial ROS generation from the NADPH oxidase complex were shown to be required for 
this effect. Emerging evidence also suggests that prenatal exposure to LPS or other 
inflammogens in utero can prime the neuroinflammatory response in the adult mouse brain 
resulting in greater susceptibility to dopaminergic degeneration (Wang et al., 2009; 
Granholm et al., 2011). Further studies and epidemiological evidence would be required to 
conclusively demonstrate that exposure to inflammatory insults, either prenatally or during 
childhood, could be a risk factor for the development of PD several decades later in life.  
 The primary signaling mechanism relevant to LPS-induced microglial activation  is 
NFkB nuclear translocation via TLR4 signaling with the subsequent activation of 
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downstream proinflammatory genes including iNOS, components of the NADPH complex 
and various cytokines and chemokines. (Qin et al., 2004; Wang et al., 2004; Dutta et al., 
2008). The major neurotoxic mechanisms mediating dopaminergic degeneration in the LPS 
model are microglial ROS production via NADPH and iNOS as well as the production of 
proinflammatory cytokines, particularly TNFα (McCoy et al., 2006; Hunter et al., 2007; Qian 
et al., 2007; Cheret et al., 2008; Dutta et al., 2008). LPS-induced neurotoxicity on 
dopaminergic neurons can be effectively mitigated by various classes of drugs  that target the 
microglial activation response including anti-inflammatory drugs, antioxidants, NADPH 
oxidase inhibitors, NFkB modulators and dominant-negative inhibitors of TNFα. In some 
cases almost complete preservation of the dopaminergic neurons in the substantia nigra has 
been demonstrated indicating  potential for targeting neuroinflammation therapeutically in 
the progression of PD (Wang et al., 2004; Zhang et al., 2005a; McCoy et al., 2006; Qian et 
al., 2007; Hernandez-Romero et al., 2008; Zhang et al., 2010a).  
Signaling pathways regulating microglial activation during dopaminergic degeneration 
The mediators and signaling mechanisms responsible for sustained microglial 
activation in the substantia nigra during dopaminergic degeneration remain to be defined and 
are currently an active area of research. Although microglial activation through TLR-4 
during LPS-induced dopaminergic degeneration is obvious, the signaling pathways 
regulating dopaminergic neuron-microglial interactions and the mechanisms regulating 
sustained activation of the microglia that eventually result in neurotoxicity are yet to be 
established.  
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Table 1: Microglial activation factors relevant to dopaminergic degeneration 
Activation 
Stimulus 
Activation 
Mechanism 
Functional Response 
in Microglia 
References 
Alpha synuclein Phagocytosis from 
DA neurons 
ROS generation  
Cytokine production 
(Zhang et al., 
2005b; Lee et 
al., 2010) 
Neuromelanin Phagocytosis from 
DA neurons 
ROS generation 
NFkB activation 
Cytokine production 
(Wilms et al., 
2003; Zhang et 
al., 2011) 
Active MMP-3 Secreted from DA 
neurons 
Possibly binds to 
protease receptors 
ROS generation 
Cytokine production 
(Kim et al., 
2005; Kim et 
al., 2007) 
HSP60 Released from 
apoptotic DA neurons 
Activates TLR4 
iNOS activation 
Nitric oxide production 
Microglial 
neurotoxicity 
(Lehnardt et al., 
2008; Stefano et 
al., 2009) 
RGS10 Modulates Gα i/o 
signaling in microglia 
RGS deficient 
microglia show 
increased activation 
&dopaminergic  
neurotoxicity 
(Waugh et al., 
2005; Lee et al., 
2008) 
Fractalkine  Negatively regulates 
microglial activation 
via fractalkine 
receptor signaling 
Knockout mice show 
increased microglial  
activation & 
dopaminergic  
neurotoxicity 
(Cardona et al., 
2006; Shan et 
al., 2011) 
Gagnliosides Component of DA 
neuron membranes 
Activate microglia by 
surface galectins 
ROS generation 
iNOS activation 
cytokine production 
(Pyo et al., 
1999; Min et 
al., 2004) 
Paraquat 
&Rotenone 
Mechanism unknown ROS generation 
Potentiates microglial 
neurotoxicity 
(Gao et al., 
2003b; Wu et 
al., 2005) 
TNFα Signals through 
TNFR1 and TNFR2  
ROS generation 
iNOS activation 
nitric oxide production 
(Barcia et al., 
2011; McCoy et 
al., 2011) 
Diesel exhaust 
nanoparticles 
Phagocytosis by 
microglia 
ROS generation (Block et al., 
2004) 
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Recent studies have implicated both secreted proteins and intracellular components from 
degenerating dopaminergic neurons in the activation of microglia by diverse mechanisms and 
distinct functional outcomes. Secreted molecules from degenerating dopaminergic neurons 
include MMP-3, which can activate microglia through protease-activated receptors (Kim et 
al., 2007). Aggregated alpha synuclein and neuromelanin, which are abundant in 
degenerating dopaminergic neurons, have been shown to be taken up by microglial 
phagocytosis.(Wilms et al., 2003; Zhang et al., 2005b; Liu et al., 2007; Gao et al., 2008). 
Both aggregated alpha-synuclein and neuromelanin can promote NADPH oxidase activation 
and generation of ROS in primary microglia and drive dopaminergic degeneration in the 
substantia nigra and in mixed neuron-glial cultures (Wilms et al., 2007; Zecca et al., 2008; 
Zhang et al., 2011). Intriguingly, some of the signaling mediators released from injured 
dopaminergic neurons activate TLR-4 signaling similarly to LPS-induced activation of 
microglia. The known regulators of microglial activation during dopaminergic degeneration 
are summarized in Table 1.  
Mechanisms of microglial neurotoxicity during dopaminergic degeneration  
 A wealth of evidence over the last decade from clinical studies, animal models and 
mechanistic in vitro experiments strongly supports a deleterious role for sustained microglial 
activation during progressive dopaminergic neuron loss (Whitton, 2007; Glass et al., 2010). 
Although it is now more widely accepted that persistent microglial activation can be 
neurotoxic, a mechanistic basis for microglial neurotoxicity on dopaminergic degeneration 
remains to be established. The substantia nigra is known to have a relatively higher 
population of resident microglia than most other regions in the brain (Lawson et al., 1990) 
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and this has been linked to increased dopaminergic neuron vulnerability to microglial 
neurotoxicity. For example, when LPS is injected at equivalent doses in other brain regions 
such as the hippocampus and cortex, no neurotoxicity is evident although robust microglial 
activation is apparent (Kim et al., 2000).  Dopaminergic neurons also intrinsically exist in a 
pro-oxidant microenvironment due to their high dopamine and iron contents and their 
apparent glutathione deficiencies (Loeffler et al., 1994; Jenner and Olanow, 1996; Nakamura 
et al., 1997; Zeevalk et al., 1998; Zigmond et al., 2002) making them uniquely vulnerable to 
elevated levels of oxidative stress resulting from local microglial activation. As would be 
expected, the microglial activation response in the healthy brain is tightly controlled with 
inherent protective mechanisms to prevent excessive microglial activation that would be 
detrimental. Cannabinoids and glucocorticoids have been identified as potent endogenous 
signaling mechanisms that can negatively regulate the microglial inflammatory response and 
thus protect neurons from deleterious microglial activation (Nadeau and Rivest, 2003; 
McCarty, 2006; Rivest, 2006; Glezer et al., 2007; Cabral and Griffin-Thomas, 2008; Ros-
Bernal et al., 2011). Similarly, the regulator of G-protein signaling 10 (RGS10) and signaling 
via the fractalkine receptor in microglia have both been identified as endogenous regulatory 
mechanisms that regulate microglial activation during dopaminergic degeneration. Both 
RGS-10 knockout mice and fracktalkine receptor knockouts show increased dopaminergic 
degeneration resulting from dysregulated activation of microglia (Lee et al., 2008).  
The chronically activated, neurotoxic microglial response that accompanies 
dopaminergic degeneration implies that the inherently neurotrophic process of microglial 
activation gradually breaks down and is transformed into one that is deregulated and 
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progressively neurotoxic in the diseased state.  Based on current evidence supporting a 
pathogenic role for sustained neuroinflammation and microglial neurotoxicity, it has been 
suggested that in PD, the degenerating dopaminergic neurons eventually lose their capacity 
to produce the signaling mediators that keep microglial activation in check, setting the stage 
for a vicious cycle of self-propelling neurotoxicity where uncontrolled reactive microgliosis 
further potentiates dopaminergic cell death (Figure 3). This line of thought fits well with the 
complex, multifactorial etiology that is thought to underlie the pathogenesis of sporadic PD. 
It also supports the multiple-hit hypothesis that has been proposed recently, wherein transient 
inflammatory and neurotoxic insults over the course of several decades can initiate a 
breakdown of regulatory mechanisms, resulting in a self-sustained process of chronic 
microglial activation and progressive dopaminergic neurodegeneration. Sustained microglial 
activation through ROS generation and proinflammatory cytokine responses can augment 
oxidative stress, which can further exacerbate the vulnerability of dopaminergic neurons.  
Figure 3: Self-sustaining mechanisms of reactive microgliosis and dopaminergic 
neurotoxicity in PD models  
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TNFα signaling during neuroinflammation and PD progression  
 Recently, TNFα has emerged as an important signaling mediator that can act on both 
microglia and dopaminergic neurons to potentiate microglial activation as well as initiate 
direct dopaminergic neurotoxicity (Barnum and Tansey, 2011; McCoy et al., 2011). TNF 
signaling was first implicated in PD when both the soluble ligand and the TNFR1 receptor 
were found to be elevated in the brain and CSF of PD patients (Mogi et al., 1994; Bessler et 
al., 1999; Mogi et al., 1999; Nagatsu et al., 2000). In cohorts of PD patients, A specific TNFα 
promoter polymorphism (-1031 C), identified by two independent studies, appears to 
increase the risk of early onset of PD in cohorts of patients. (Nishimura et al., 2001; Wu et 
al., 2007). In these individuals, the polymorphism is believed to increase transcriptional 
activity at the promoter and increase TNF levels, potentially contributing to an earlier onset 
and progression of the disease.  
 TNFα expression is also increased in both the MPTP and 6-OHDA models of PD 
being elevated within hours of dopaminergic neuron insult in the substantia nigra. (Mogi et 
al., 1999, 2000a; Rousselet et al., 2002; Barcia et al., 2005; Ghosh et al., 2007). In the 
stereotaxic LPS models of nigral dopaminergic degeneration, a rapid increase in microglial 
TNFα production is one of the earliest activation responses (Herrera et al., 2000; Li et al., 
2004). In primary microglial cultures, TNFα production is a common response to microglial 
activation by distinct stimuli relevant to dopaminergic degeneration (Table-1) including 
aggregated alpha-synuclein, gangliosides, activated MMP-3, neuromelanin and thrombin 
(Pyo et al., 1999; Wilms et al., 2003; Kim et al., 2005; Lee et al., 2005; Lee et al., 2010). In 
the systemic LPS injection model, TNF levels in the brain remain highly elevated for up to 
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10 months after the initial endotoxic shock, whereas the levels of TNFα in the serum and 
liver return to basal values within a few days (Qin et al., 2007). This suggests that the 
inflammatory response in the brain could be sustained for long periods of time after transient 
peripheral inflammatory insults and that TNFα may be play a key role in sustaining the 
inflammatory response in the brain.  
 Some of the strongest supporting evidence implicating a role for TNFα in mediating 
microglial toxicity and dopaminergic neuron loss comes from mechanistic studies using 
targeted inhibition of soluble TNF signaling with dominant negative mutants as well as 
experiments with knockout mice for TNF and its receptors. Mice deficient in both TNF 
receptors were shown to be resistant to MPTP-induced dopaminergic damage with attenuated 
microglial activation shown to be a potential mechanism involved (Sriram et al., 2002, 2006). 
However, in knockout mice lacking only a single TNF receptor (either TNFR1 or TNFR2), 
MPTP-induced striatal damage is reduced but no differences were seen in nigral neuron loss. 
Partial protection of the nigrostriatal system was also evident in TNFα knockout mice 
(Rousselet et al., 2002; Ferger et al., 2004). Dominant-negative mutants of TNFα were 
designed to inactivate signaling by soluble TNF but not by membrane bound TNF or reverse 
signaling by membrane bound forms (Steed et al., 2003). The dominant-negative mutants are 
engineered with specific mutations in the TNFα protein that almost completely inhibit 
binding and activation of TNF receptors and thus shutdown soluble TNF signaling. In both 
the LPS and the 6-OHDA model, dominant negative TNF effectively shuts down signaling 
by soluble TNFα and attenuates both microglial neurotoxicity and direct dopaminergic 
degeneration. In mixed neuron glial cultures, dominant negative TNFα also rescues loss of 
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TH-positive dopaminergic neurons when added to the cultures several hours after LPS or 6-
OHDA treatments.  (McCoy et al., 2008; Harms et al., 2011). These results were confirmed 
by independent studies in which dominant-negative TNF was stably expressed in the 
substantia nigra using adenoviral vectors. Again, the ablation of soluble TNFα signaling in 
vivo preserved the nigrostriatal system from 6-OHDA neurotoxicity and could rescue 
dopaminergic neuron loss (McCoy et al., 2008; Harms et al., 2011).  On the other hand, the 
stable overexpression of endogenous TNFα using adenoviral vectors results in significant 
microgliosis and delayed dopaminergic neuron loss (De Lella Ezcurra et al., 2010).   
 Collectively, the evidence from PD patients, pharmacological studies and 
epidemiological data support a role for TNFα signaling as an important pathogenic mediator 
of dopaminergic neuron loss. The mechanism and signaling pathways, by which TNF elicits 
dopaminergic degeneration however are yet to be determined. Since receptors for TNFα are 
expressed on both dopaminergic neurons and microglia, it is possible that functional TNF 
signaling can occur in both these cells. TNF can potentiate microglial neurotoxicity and 
sustain microglial activation by maintaining high levels of ROS through NFkB activation  
(Block et al., 2007a; Gordon et al., 2011). Indeed, a recent study using TNF knockout mice 
demonstrated a critical role for TNFα and IFNγ in initiating and sustaining microglial 
activation in vivo (Barcia et al., 2011). Studies have also demonstrated that recombinant TNF 
can be directly toxic to dopaminergic neurons by mechanisms independent of microglial 
activation (Aloe and Fiore, 1997; McGuire et al., 2001; Carvey et al., 2005).  Therefore, 
identifying key downstream signaling pathways activated by TNF in dopaminergic neurons 
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and microglial cells may provide additional therapeutic targets to mitigate dopaminergic 
neuron loss and further our understanding of TNFα signaling in dopaminergic degeneration.   
 
Protein Kinase C delta signaling immune cells and experimental models of PD  
 The protein kinase C (PKC) family is comprised of multiple related serine/threonine 
kinases that regulate diverse physiological processes including apoptosis and immune 
function. The PKC family consists of ten different isoforms classified into three distinct sub-
family groups based on their functional activation requirements. Conventional PKCs include 
PKC, βI, βII, and , which require intracellular calcium concentrations and diacylglycerol 
(DAG).  The novel PKCs include PKC, ε, ε, and ζ. They are activated by DAG but are 
calcium independent.  PKCδ and PKC make up the atypical PKCs, which require neither 
calcium nor DAG phospholipids for activation.  The mature PKC isoforms are typically a 
single polypeptide with an N-terminal regulatory domain and a conserved catalytic domain 
containing the ATP binding site required for kinase activity. The regulatory domain at the N-
terminus contains an autoinhibitory pseudosubstrate domain and two membrane-targeting 
domains (C1 and C2). The N-terminal regulatory domain is structurally and functionally 
distinct between the three sub-types of PKCs  
PKCδ protein structure: Protein kinase C delta (PKC) was first cloned in 1987 from the 
rat brain. Being a member of the novel PKC subfamily, PKCδ contains a C-terminal catalytic 
domain with two conserved regions, C3 and C4 that are critical for catalytic competency and 
binding specific substrates. The amino terminal regulatory domain contains an auto-
inhibitory pseudosubstrate sequence and two cysteine-rich Zn-finger-like sequences in the 
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C1domain that is essential for lipid binding. A caspase-3 cleavage site (SGN-DIPD-NNG) is 
present in the linker regions between the catalytic and regulatory domain. Proteolytic 
cleavage of  PKCδ by caspase-3 is a common pro-apoptotic signaling mechanism in many 
cell types and constitutively activates the kinase. A nuclear localization sequence at the C-
terminal catalytic domain between amino acids 610 and 630 regulates nuclear translocation 
of both full-length and proteolytically cleaved PKCδ. An activation loop is present on the 
catalytic domain of all PKC enzymes and is the site for priming phosphorylation events that 
are required for classical activation and translocation of PKCs to the membrane. In PKCδ the 
activation loop site is Threonine-505 (T505). A hydrophobic motif (S662) and a turn motif 
(S643) have been described for most PKC isoforms.  Phosphorylation at specific serine 
residues in the  hydrophobic motif also differentially regulates activation by various PKC 
agonists.  
 
Figure 4: Domain structure of PKCδ showing critical residues involved in activation 
and function 
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PKC activation mechanisms: Like with most novel and conventional PKC isoforms, 
classical activation of PKCδ involves membrane translocation regulated by DAG binding to 
the cysteine-rich, zinc-finger-like motifs in the C1 domain. A series of sequential 
phosphorylation events at the C-terminus are required to prime the activation state and 
stabilize the PKC enzymes in a catalytically active, closed conformation that is resistant to 
protease degradation.  Phosphorylation on the activation loop (Thr-505 in PKCδ) has been 
shown to align critical residues at the catalytic site but has been shown to be less important in 
PKCδ activation since the negative charge provided by the glutamate at position 500 (E500) 
can compensate for phosphorylation at T505. A glutamate-500 mutation (E500A) results in 
around 80% loss of PKCδ kinase activity. PKCδ has been shown to be catalytically active 
even in the absence of Thr-505 phosphorylation in vitro. Nevertheless, the kinase activity of 
PKCδ is increased considerably by phosphorylation at Thr-505. In PKCδ, the turn motif 
(Serine-643) has been shown to be an autophosphorylation site but its precise role, if any, in 
regulating PKCδ activity is unclear. Phosphorylation of PKCδ both at the turn motif and the 
hydrophobic motif appear to be stable in culture conditions and independent of most agonists 
unlike other PKC enzymes. Tyrosine phosphorylation has been identified as another crucial 
regulatory mechanism for PKCδ activation, translocation and substrate targeting. Key 
tyrosine phosphorylation sites (Tyrosine-52, -155, -187, -311, -332, -512, -523, and -565) 
have been defined in both the catalytic and regulatory domains of PKCδ. Phosphorylation at 
one or more of these tyrosine residues has been shown to regulate critical aspects of PKCδ 
activation in a cell and stimulus-specific manner (Steinberg, 2004).  More recently, tyrosine 
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phosphorylation has also been shown to regulate translocation of PKCδ to the mitochondria 
and nucleus.  
In addition to priming serine/threonine phosphorylation, membrane translocation and 
tyrosine phosphorylation, proteolytic cleavage of PKCδ by caspase-3 is a unique activation 
response that promotes apoptosis in various cell types including HeLa cells, salivary gland 
cells, keratinocytes, adenocarcinoma cells, and neutrophils (Ghayur et al., 1996; Pongracz et 
al., 1999; Reyland et al., 1999; Kanthasamy et al., 2003a). During apoptotic signaling, 
caspase-3 cleaves PKC adjacent to the Asp 327 at its recognition site (DIPDN) located 
within the hinge region between the catalytic and regulatory domains. Proteolytic cleavage 
releases the regulatory subunit from the catalytic subunit and yields a catalytically active 41-
kDa fragment with constitutive kinase activity that is essential to promote apoptosis. 
Overexpression of caspase-3 cleavage-resistant mutants of PKCδ in various cells protects 
against apoptosis induced by diverse stimuli. Further, some studies have identified a potential 
positive feedback amplification loop between PKCδ and caspase-3 signaling.  
PKC signaling during dopaminergic degeneration: PKCδ was first cloned from the rat 
brain and its expression in the developing and adult brain has been characterized in detail. 
PKC is expressed in different areas of the brain including the cerebellum, thalamus, 
habenula, and the septum (Barmack et al., 2000). PKCδ was also detected in glial cells and 
its expression varied ontogenically in both neurons and glial cells (Goldberg and Steinberg, 
1996). Important functions for PKCδ have been described in the healthy brain and in various 
neurodegenerative disorders including stroke and AD. Previous studies from our laboratory 
have demonstrated that PKCδ is highly expressed in nigral dopaminergic neurons and can 
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bind to and phosphorylate tyrosine hydroxylase, the rate limiting enzyme in dopamine 
synthesis (Zhang et al., 2007b). Activation of caspase-3 has been shown to occur during 
dopaminergic degeneration in animal models of PD and active caspase-3 has been detected in 
postmortem PD brain. During dopaminergic degeneration induced by various neurotoxicants, 
caspase-3 activates PKCδ by proteolytic cleavage at the hinge region to promote neuronal 
cell death (Anantharam et al., 2002; Kanthasamy et al., 2003b; Kaul et al., 2003b). The 
proteolytic cleavage of PKCδ was shown to be dependent on phosphorylation at tyrosine-311 
near the caspase-3 cleavage site (Kaul et al., 2005). Further, PKC can modulate upstream 
caspase-3activity via a positive feedback amplification loop resulting in sustained caspase-3 
activation and amplification of apoptosis during dopaminergic degeneration (Kaul et al., 
2003a; Kitazawa et al., 2003). Importantly, targeting PKCδ by pharmacological inhibition, 
siRNA knockdown or using PKCδ cleavage-resistant mutants effectively protects and 
rescues dopaminergic cell death induced by various neurotoxicants (Kaul et al., 2003b; 
Anantharam et al., 2004; Latchoumycandane et al., 2005; Kanthasamy et al., 2006; Sun et al., 
2006).  Further, therapeutic targeting of PKCδ using the small molecule kinase inhibitor 
rottlerin, could effectively protect against nigrostriatal degeneration in the MPTP animal 
model of PD demonstrating an important role for PKCδ during dopaminergic degeneration in 
vivo.  
Functions of PKCδ in immune cell activation and inflammatory responses: PKCδ is 
ubiquitously expressed in immune cells and regulates various facets of the adaptive and 
innate immune response in addition to promoting apoptosis of immune cells. Some of the 
first studies using PKCδ knockout mice demonstrated an important role for PKCδ in 
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regulating B-cell tolerance. PKCδ knockout mice showed hyperactivation of B cells with 
autoimmunity and the presence of autoreactive antibodies to DNA and nuclear components 
(Mecklenbrauker et al., 2002; Miyamoto et al., 2002). In both B and T lymphocytes, nuclear 
localization of PKCδ mediates apoptosis in the absence of survival factors that prevent its 
nuclear accumulation of PKCδ (Scheel-Toellner et al., 1999; Mecklenbrauker et al., 2004). 
Similarly, the spontaneous apoptosis of neutrophils is mediated by PKCδ signaling 
(Kilpatrick et al., 2002).   
 A wealth of literature supports a role for classical PKCδ signaling in regulating the 
activation of innate immune cells and proinflammatory responses. Dendritic cell activation 
and antigen presentation was shown to be mediated by PKCδ signaling (Majewski et al., 
2007; Guler et al., 2011). In human asthmatic eosinophils, PKCδ is required for migration, 
increased CD11b expression and MMP-9 granule release (Langlois et al., 2009).  During 
macrophage activation by distinct stimuli, PKCδ participates in the production of TNFα, 
IL1β and IL10 (Meldrum et al., 1998; Lee et al., 2004; Leghmari et al., 2008). In acute 
pancreatitis, PKCδ was shown to mediate proinflammatory signaling by activating pancreatic 
NFkB, activator protein-1, and mitogen-activated protein kinases. Further, the targeted 
inhibition of PKC delta reduced myeloperoxidase activity and edema in the lung (Ramnath et 
al., 2010).  Several reports have elucidated distinct functions for PKCδ in neutrophils with 
extensive crosstalk between TNFα and PKCδ signaling in these cells. PKCδ mediates the 
production of superoxide in TNFα-activated neutrophils (Kilpatrick et al., 2010) and directly 
regulates TNFα-dependent neutrophil survival signaling both at the level of the TNFR1 
receptor and by modulating downstream survival signaling pathways (Kilpatrick et al., 2000; 
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Kilpatrick et al., 2002; Kilpatrick et al., 2006). PKCδ signaling also mediates the activation 
of NADPH oxidase and superoxide production in response formyl-methionyl-leucyl-
phenylalanine (fmlp) in COS-7 cells (Cheng et al., 2007). Two recent studies also implicated 
a role for PKCδ signaling in mediating septic shock both systemically and in the lung with 
targeted inhibition of PKCδ effectively protecting against lung injury following sepsis.  
Summary and perspectives:  
 Proapoptotic PKCδ signaling during dopaminergic cell has already been 
demonstrated using neurotoxins that activate caspase-3 via the intrinsic cell death pathway 
through mitochondrial oxidative stress. However, caspase-3 can also be activated via the 
extrinsic apoptotic pathway through death receptor signaling as in the case of TNF 
superfamily members. As described above, results from several studies support a neurotoxic 
role for TNFα in animal models of PD. Since classic TNFα death receptor signaling activates 
caspase-3, it is possible that TNF can promote the degeneration of dopaminergic neurons via 
the extrinsic apoptotic pathway involving downstream activation of PKCδ by caspase-3 
mediated proteolytic cleavage. This hypothesis was explored in studies presented in chapter 2 
of this dissertation which were designed to study the involvement of PKCδ in dopaminergic 
cell death by inflammatory mediators particularly TNFα. Given the known roles of PKCδ in 
immune function, particularly the activation of proinflammatory responses in innate 
macrophages and neutrophils, it is possible that similar signaling pathways be involved in the 
functional activation of microglial cells, which are brain macrophages that develop from the 
myeloid lineage. Evidence implicating PKC in microglial activation is limited.  The PKC 
inhibitor rottlerin has been shown to inhibit LPS-induced microglial iNOS induction in N9 
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murine microglial cells (Byers et al., 1998). PKC was also shown to mediate paraquat-
induced cell death in C6 glioma and BV-2 microglial cells (Miller et al., 2007).  In studies 
with stroke models, microglial activation by thrombin was shown to induce tyrosine 
phosphorylation of PKCδ which could modulated the production of suppressor of cytokine 
signaling-3 (SOCS-3). Recently, caspase-3 activity was shown to regulate the microglial 
immune response and implicated PKCδ as a potential substrate for proteolytic cleavage in the 
process of microglial activation (Burguillos et al., 2011). Collectively, evidence indicates that 
PKCδ can potentially regulate microglial responses downstream of activation stimuli relevant 
to dopaminergic degeneration (Table-1). The studies performed in chapter 3 were based on 
this hypothesis and were designed to elucidate the potential functions of PKCδ in regulating 
microglial responses during activation by stimuli relevant to PD.  
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Background and Literature Review II 
Prokineticin-2 Signaling 
The Prokineticins (PK1 and PK2) constitute a pair of recently identified cysteine-rich 
secreted proteins belonging to the AVIT protein family that includes other homologs such as 
the mamba intestinal toxin-1 (MIT1) and endocrine gland derived vascular gland endothelial 
growth factor (EG-VEGF). The characteristic feature of the proteins in the AVIT family is 
the conserved N-terminal AVIT amino acid motif and the presence of 10 cysteine residues 
with almost identical spatial distribution that form a colipase-like fold motif with 5 disulfide 
bridges (Kaser et al., 2003; Bullock et al., 2004). The prokineticins were first identified and 
cloned in 2001 by three different groups and named based on their unique prokinetic property 
of gastrointestinal smooth muscle contraction. A decade of research since then has 
established that the prokineticins regulate a diverse range of physiological functions in 
different tissues including gut motility, circadian rhythms, angiogenesis, pain perception, 
hematopoiesis and olfactory bulb biogenesis. Recent evidence also suggests that 
prokineticins might be associated with pathologies of reproductive development, myocardial 
infarction, immune regulation and tissue-specific cancer initiation. The mature prokineticin 
protein forms of PK-1 and PK-2 are 86 and 81 amino acids long respectively.  They have a 
predicted molecular weight of about 12 kDa and are highly conserved across species. PK-1 
and PK-2 have around 45% identity in their amino acid sequences and are expressed on 
different chromosomes. In humans, the PK1 gene is located on chromosome 1p21 while PK2 
maps to 3p21.1. A remarkable aspect of prokineticin signaling is the ability of these two 
ligands to regulate such complex and diverse biological processes. The emerging consensus 
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suggests that the differential expression of the two prokineticins and their receptors by tissue-
specific gene regulation networks might account for this diversity of functions.  
 
Figure 5: Amino acid sequences of PK1 and PK2 depicting the conserved AVIT motif 
and ten cysteine residues  
 
Prokineticin Receptors 
A few years after the initial discovery of prokineticins, their two G-protein coupled 
receptors PKR1 (GPR73A) and PKR2 (GPR73B) were identified and cloned (Lin et al., 
2002a; Masuda et al., 2002). The two prokineticin receptors belong to the neuropeptide Y 
family and have an unusually high degree of similarity (~85% amino acid identity) with most 
of the variation around the N-terminal region. Human PKR1 is located on chromosome 2q14 
and PKR2 on 20p13. The two GPCRs couple to Gq, Gi or Gs in a cell-specific manner to 
mobilize intracellular calcium and turnover of phosphoinositol and cyclic AMP 
accumulation. The specific signaling pathways activated downstream of the prokineticin 
receptors however remain to be elucidated. Interestingly, both prokineticin ligands PK1 and 
PK-2 can bind to either receptor with apparent non-selectivity (Lin et al., 2002a) suggesting 
that the expression and availability of the ligand and receptor pair are likely to determine the 
specific signaling axis that is involved in a tissue-specific physiological process. Both 
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prokineticin receptors have been shown to be expressed in the ovaries, testes, adrenal glands, 
uterus and intestinal tract. In the bone marrow and the blood, both PKR1 and PKR2 have 
been detected in mature blood cells and hematopoietic stem cells (Lin et al., 2002a; Soga et 
al., 2002; LeCouter et al., 2003; Battersby et al., 2004; Hoffmann et al., 2006, 2007). In the 
placenta and the heart, PKR1 appears to be the major prokineticin receptor that is involved in 
regulating cardiomyocyte survival. (Urayama et al., 2007). In the brain, PKR2 is more 
ubiquitously expressed than PKR1 and predominantly in the regions associated with 
olfactory bulb biogenesis and circadian regulation where the role of PK2-PKR2 signaling has 
been functionally characterized (Cheng et al., 2006).  
Studies using transgenic overexpression of the prokineticin receptors and knockout 
mice have provided much insight into the role of each prokineticin receptor in distinct 
physiological processes. Loss of function mutations in either PK2 or PKR2 have been shown 
to result in human Kallmann syndrome and hypogonadotropic hypogonadism with the 
primary pathological features being recapitulated in mouse models with either receptor 
knockouts or null mutations (Pitteloud et al., 2007; Abreu et al., 2008). PKR2 but not PKR1 
knockout mice show abnormal olfactory bulb development with hypoplasia and severe 
atrophy of the reproductive organs highlighting the importance of PKR2 signaling in both 
these physiological processes. PKR1 knockout mice on the other hand have impaired pain 
sensitization and nociceptive responses that are also evident in PK2 knockout mice indicating 
the involvement of a PK2-PKR1 signaling pathway in these events (Hu et al., 2006; Negri et 
al., 2006; Giannini et al., 2009). In the cardiovascular system where both receptors have 
distinct spatial expression patterns, overexpression of PKR2 in mouse hearts induces 
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hypertrophy and capillary vessel leakage without angiogenesis whereas the targeted 
overexpression of prokineticin receptor-1 (PKR1) induced neovascularization implicating 
different distinct signaling pathways for the two receptors in this system (Urayama et al., 
2008; Urayama et al., 2009). In contrast, PKR1 knockout results in dysfunctional cardiac and 
kidney development and is accompanied by mitochondrial defects and increased apoptosis in 
both tissues (Boulberdaa et al., 2011). The results from studies with the individual 
prokineticin receptor knockout mice further underscore the fact that differential expression 
and availability of the individual prokineticin ligands and receptors could account for their 
ability to regulate the above set of complex and diverse biological processes.  
Given that the prokineticins and their receptors were discovered only around a decade 
ago, much remains to be understood in terms of tissue-specific transcriptional regulatory 
networks that define the expression patterns of each receptor as well as the downstream 
signaling pathways coupled to them.  More recent studies are shedding light on some of these 
paradigms. For example, emerging evidence suggests that PKR2 potentially exists as a dimer 
in vivo with interactions between transmembrane domains being important for dimerization. 
(Marsango et al., 2010). A recent study also identified connective tissue growth factor 
(CTGF) as a direct downstream target of a PK1-PKR1 signaling in endometrial epithelial 
cells and decidua samples.  
Prokineticin-2 gene structure  
Prokineticin proteins are assembled from relatively simple mRNA elements made up 
of the signal peptide followed by the mature functional protein.  The gene and promoter 
structures are highly conserved in both humans and mice, indicative of their functional roles 
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in important physiological processes. Mammalian prokineticin genes contain four exons with 
the third exon being a target for alternative splicing in prokineticin-2. The first exon encodes 
a 19-residue signal peptide that targets the proteins for constitutive secretion. Exon-2 
contains six of the cysteine residues and Exon-4 encodes for four of the ten conserved 
cysteines. An alternative splice form of prokineticin-2 has been identified recently, which 
contains a 63 bp insertion between exon 2 and exon 4 resulting in a longer isoform of PK-2 
(PK2L) that has an additional 21 amino-acid residues (Kaser et al., 2003; Chen et al., 2005b). 
Figure 6: PK2 gene structure and alternate splicing forms 
 
In the mature PK2L isoform, the 21 amino acid insertion occurs between Lys47 and 
Val48 and consists of highly basic amino acids with 19 being either lysine or arginine. 
Further, exon-3 insertion encodes for two putative furin protease cleavage sites. Co-
expression of furin with PK-2L in vitro resulted in a shorter cleaved form of the protein 
(PK2β) that could still functionally activate prokineticin receptors (Chen et al., 2005b). 
Interestingly, the shorter PK2β fragment showed greater selectivity for PKR1 than PKR2 
whereas both PK1 and PK2 show no selectivity for either prokineticin receptor. The specific 
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function of the alternatively spliced isoform (PK2L) is yet to be determined in vivo although 
preliminary evidence suggests it might be differentially expressed from PK2 in some tissues 
such as the lung (Chen et al., 2005b).  No alternative splice forms have been detected for 
PK1 to date. Prokineticins are highly basic proteins with the pI of PK-2 determined to be 
around 8.85 while that of PK2L was 10.68 due to the lysine and arginine rich exon-3 
insertion. PK1 (EG-VEGF) was shown to bind with high affinity to heparin-sepharose, and it 
has been suggested that due to the highly basic nature of these secreted proteins, their 
bioavailability and activity may be further regulated by interactions with components of the 
extracellular matrix (LeCouter et al., 2003).  
The transcriptional regulatory elements for PK2 have been characterized in detail for 
with the human and mouse promoters being highly conserved between the two species 
(LeCouter et al., 2003; Zhang et al., 2007a). Multiple E-box elements (CACGTG) have been 
identified in both the mouse and human PK-2 promoter sequences (Cheng et al., 2002; Zhang 
et al., 2007a).  The E-box sequences are targets of a diverse set of transcription factors 
belonging to the E-box specific basic Helix-Loop-Helix (bHLH) family, which include 
CLOCK, BMAL1, Ngn1, MASH1 and HIF1α, all of which have been shown to regulate the 
expression of PK2 in distinct physiological processes. The expression in the suprachiasmatic 
nucleus was shown to be under the control of CLOCK and BMAL (Cheng et al., 2002; 
Cheng et al., 2005; Watanabe et al., 2007).  During olfactory bulb biogenesis where PK2 is 
abundant in the granule cell layer and periglomerular layers, its expression is regulated by the 
proneural transcription factors Neurogenin 1(Ngn1) and MASH1 which directly bind to E-
box elements in the PK-2 promoter. These results were also confirmed in vivo with Ngn1 and 
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MASH1 mutant mice which showed  significantly reduced PK-2 expression(Zhang et al., 
2007a). Two putative HIF1α binding sites were defined on the mouse promoter less than 300 
nucleotides upstream of the transcriptional start site at -115 and -248. Indeed, PK2 was 
shown to be highly induced by hypoxia both in vivo and in cell cultures (LeCouter et al., 
2003; Shojaei et al., 2007). Thus, the ability of PK-2 to regulate many distinct biological 
processes ranging from olfactory bulb development to angiogenesis and circadian function 
can be partly attributed to its sophisticated mechanisms of gene regulation by different 
members of the bHLH family of transcription factors.  
Figure 7: Transcriptional regulation of PK2 in distinct biological processes by bHLH 
transcription factors 
 
 
 
 
 
 
 
 
 
Prokineticin-2 protein structure  
Current insight into the structural elements of prokineticin-2 is largely based on the known 
NMR structure of MIT-1, the prototypical member of the AVIT family and the recently 
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published NMR structure of the amphibian prokineticin homolog Bv8 (Boisbouvier et al., 
1998).  The prokineticins have a very compact structure as a result of the five disulfide 
bridges formed between the 10 highly conserved cysteine residues buried in the core of the 
folded protein.  The N-terminal and C-terminal ends are exposed at the surface of the 
molecule and participate in receptor binding and activation.  The folded protein is believed to 
have an approximately ellipsoid shape with a net positive charge on one side and a 
hydrophobic face on the other (Fig. 8).  
Figure 8: PK2 protein structure depicting spatial distribution of charged amino acids 
and buried cysteine residues in the folded protein 
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Many charged amino acid residues are buried inside the core of the protein in 
proximity with the disulfide bridges whereas some of the hydrophobic residues are more 
exposed on the surface. The more recent and detailed NMR structure of the amphibian 
prokineticin homolog also identified two β-hairpins at the C and N terminus of the protein 
and a single turn of 310 helix at the N terminus (Kaser et al., 2003; Morales et al., 2010).  
The structural and functional elements of the protein required for signaling have also 
been characterized in detail using point mutation analysis and by generating chimeric 
prokineticins. The first six N-terminal amino acids (AVITGA) of both prokineticins and all 
of their invertebrate homologs are completely conserved and are critical for both receptor 
binding and activation. Addition or substitution mutations in any of the six amino acids 
results in an inactive protein. However, the N-terminal AVITG segment alone appears to be 
insufficient for activity as synthetic peptides of the first 6 or 12 amino acid residues alone 
does not have any significant functional activity even at high doses (Bullock et al., 2004). 
NMR studies also revealed that deletion of the AVITG region did not alter the overall 
structure and fold of the Bv8 homologue but results in a complete loss of activity. Further, 
the loss of activity in the N-terminal truncated AVIT-mutant could not be compensated for or 
complemented by the addition of synthetic AVITG-OH or AVITG-NH2 peptides in solution.  
Interestingly, the mutant lacking the AVITG motif also failed to antagonize the functional 
activity of the native protein suggesting that the N-terminus of the protein is probably 
required for both receptor binding and receptor activation. (Morales et al., 2010). The 
contribution of the C-terminal amino acids and the cysteine residues have also been 
investigated by mutation analysis and domain swapping experiments. Substitution of two of 
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the cysteine residues (cysteines 18 and 60) abolished prokineticin signaling in functional 
assays. Importantly, substitution of the cysteine rich C-terminal domains from other protein 
families such as the colipase and dickkopf proteins failed to elicit activation of the 
prokineticin receptors. However, the swapping of C-terminal domains of PK1 and PK2 with 
the C-terminal domains of each other preserved their functional activity (Bullock et al., 
2004). Thus, while the specific framework of the cysteine residues is critical to functional 
activity, there appears to be some tolerance to variability in the C-terminus based on the fact 
that PK-1 and PK-2 which are only about 50% identical in their amino acid sequences can 
still functionally substitute for each other at the C-terminal domains.  
Together, the data from genetic, biochemical and structural studies to date suggest 
that the binding of the prokineticins and activation of their receptors proceeds through a 
highly intricate process. The N-terminal AVITG motif is absolutely necessary for binding 
and functional activation of the prokineticin receptors. Similarly, the spatial distribution of 
the conserved cysteine residues at the core of the protein appear to be critical for activity 
while a small degree of tolerance to variations in the C-terminal domain might be plausible. 
The availability of the recently solved NMR solution structure of the Bv8 would facilitate a 
better understanding of the structure-activity relationships regulating the dynamics of 
prokineticin ligand-receptor interactions. For example, identifying the role of the conserved 
amino acid residues situated in the solvent-exposed loops of the protein would likely provide 
further insight into cooperative interactions involved in prokineticin ligand-receptor binding 
and functional activation (Morales et al., 2010) 
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Figure 8: PDB secondary structure for PK2 based on the NMR structure solved by 
Morales et al (2010). 
 
                         310 helix                                  β-sheets 
 
An important aspect of understanding the structure-function relationships involved in 
prokineticin signaling would be the development of agonists and antagonists to the G-protein 
coupled receptors PKR1 and PKR2. Elegant studies by Bullock et al. (2004) using 
prokineticins with N-terminal substitution mutants identified that specific mutations at the N-
terminus can result in mutant proteins with antagonist activity. Substitution of the N-terminal 
alanine with methionine (A1MPK1) or the addition of a methionine at the N-terminus 
(MetPK1) generates mutant proteins that antagonize the activity of PKR1 and PKR2 by both 
PK1 and PK-2. Further, the pre-incubation of the antagonists increased their potency by 
almost twofold. The peptide antagonists were also shown to be functional in vivo and in cell 
culture assays and have been useful in dissecting the functional roles of prokineticin receptor 
signaling in the brain(Cheng et al., 2002; Cottrell et al., 2004; Ng et al., 2005). Chemical 
antagonists of the prokineticin receptors have been recently developed based on triazine and 
pyrimidindione derivatives (Balboni et al., 2008; Giannini et al., 2009; Ralbovsky et al., 
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2009). The triazine-based compounds were found to be highly selective for PKR1 in 
functional assays with almost 70-fold less potency as a PKR2 antagonist. Newer generation 
of traizine antagonists have been tested in models of inflammatory pain and have been  found 
to be highly effective as anti-hyperalgesic drugs (Giannini et al., 2009)  
Downstream signaling pathways activated by prokineticins:  
The two prokineticin receptors belong to the neuropeptide Y (NPY) receptor class of 
GPCRs which promote intracellular calcium mobilization, cAMP accumulation and 
phosphoinositol turnover (Lin et al., 2002a; Masuda et al., 2002). The first study to clone and 
characterize the prokineticins demonstrated that the recombinant proteins caused calcium 
influx at nanomolar doses and that the calcium influx was essential for their prokinetic 
actions on gastrointestinal smooth muscle. Preliminary evidence that prokineticins signaled 
through GPCRs came from GTPγS displacement experiments by the same study (Li et al., 
2001). Since then, various groups have shown that the two prokineticin GPCRs couple to Gi, 
Gq and Gs proteins depending on the cell type to activate multiple signaling pathways (Chen 
et al., 2005b). In adrenal cortex-derived endothelial (ACE), PK1 (EG-VEGF) activates 
p44/42 MAPK in a dose- and time-dependent manner which could be blocked by pertussis 
toxin, implicating Gαi coupling. Activation of the MAPK pathway resulted in increased 
proliferation and migration of these cells in response to PK1. Further, PK1 treatment also 
activated Akt and endothelial endothelial nitric-oxide synthase (eNOS) in an Akt-dependent 
manner. Akt activation was also a crucial survival signal for these cells in response to 
prokineticin signaling (Lin et al., 2002b). In endometrial epithelial Ishikawa cells, PROK1 
induced the expression and secretion of  IL-8 and IL-11 via the calcineurin/NFAT signaling 
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pathway (Maldonado-Perez et al., 2009; Cook et al., 2010). The expression of connective 
tissue growth factor was induced by PK1 in these same cells and was dependent on Gq, 
phospholipase C (PLC), cSrc, epidermal growth factor receptor (EGFR), mitogen-activated 
protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathways based 
on inhibitor studies (Waddell et al., 2011).  In longitudinal muscle-myenteric plexus cultures, 
treatment with PK1 stimulated nitric oxide release, a potential mechanism by which PK1 
inhibits spontaneous giant contractions in the circular muscle of the mouse proximal colon 
(Hoogerwerf, 2006). PK1 also activates the Akt pathway and induces proliferation and 
survival of neuroblastoma cells. Interestingly, PK1-induced proliferation required the 
expression of both prokineticin receptors while PKR2 was essential in mediating cell 
survival. In enteric neural crest cells, similar signaling pathways including the MAPK and 
Akt signaling are both activated by PK1 to induce proliferation and differentiation (Ngan et 
al., 2007a; Ngan et al., 2007b).  Similar survival signaling pathways are activated by in 
multiple myeloma cells where PK1 caused the phosphorylation of MAPK, Akt and STAT3. 
PK1 also upregulated Sphingosine kinase (SphK) and the potent anti-apoptotic bcl-2 family 
member Mcl-1 in these cells demonstrating that multiple survival signaling pathways could 
be activated downstream of the prokineticin receptors (Li et al., 2010).  PK1 also has 
proliferative effects on bovine steroidogenic glomerulosa and fasciculata cells in a pertussis 
toxin-sensitive manner indicating Gi coupling to the prokineticin receptors in these cells.  
PK1 treatment resulted in phosphorylation and activation of ERK1/2, which could be 
responsible for its proliferative effect in these endocrine cells, where prokineticins are 
thought to act as autocrine mitogenic factors (Keramidas et al., 2008).  In the third trimester 
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placenta, PK1 is highly expressed and was defined as a novel mediator of the inflammatory 
response since it induced the expression of IL-8 and COX-2(Denison et al., 2008). In 
placental cell extracts PK1 activated ERK1/2, which was dependent on sequential 
phosphorylation of cSrc and the epidermal growth factor receptor (EGFR). In both placental 
endothelial cell (HPEC) and umbilical vein-derived macrovascular endothelial cells 
(HUVEC), PK1 also acts as a survival factor by activating Akt and MAPK signaling 
(Brouillet et al., 2010). In human peripheral blood monocytes, PK1 induces morphological 
changes and the down regulation of B7-1, CD-14, CC chemokine receptor 5 and CXC 
chemokine receptor 4 (Dorsch et al., 2005). Further, monocytes treated with PK1 had 
increased levels of IL-12 and TNFα and decreased IL-10 production in response to LPS 
stimulation. Other groups showed that monocytes but not macrophages or dendritic cells 
stimulated with PK1 produced the chemokines CCL4, CXCL1 and CXCL8 (Monnier et al., 
2008). 
Since both PK1 and PK2 activate each of the prokineticin receptors (PKR1 and 
PKR2) with similar potency and show no selectivity to either receptor, their downstream 
signal transduction pathways are likely to be similar. PK2 acts as a potent chemotactic factor 
for macrophages at doses in the subnanomolar range. PK2 also potentiated LPS-induced IL-1 
and IL-12 production and reduced IL-10 levels in these cells (Martucci et al., 2006). The 
effects of PK2 on macrophages were found to be pertussis toxin insensitive but were blocked 
instead by the phospholipase inhibitor U73122 indicating the involvement of Gq proteins 
downstream of the prokineticin receptors. Interestingly, studies with prokineticin receptor 
knockout mice demonstrate that all of the effects of PK2 on macrophages are mediated by 
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PKR1. In primary mouse splenocytes, a similar pathway involving PK2-PKR1 signaling was 
demonstrated in vitro and in vivo using receptor knockout mice. PK2 increased the 
production of IL-1beta and decreased IL-4 and IL-10 levels in cultured mouse splenocytes 
and these effects were abrogated in cultures from PKR1 knockout mice.  PK2 was also 
demonstrated to be a potent chemotactic factor for neutrophils most likely via PKR2 signal 
transduction since PKR1 was not detected in these cells. PK2 was highly expressed in 
neutrophils that infiltrated tumors and isolated PK2 from neutrophils was found to be fully 
active in vitro. Further, the expression of PK2 in isolated neutrophils was induced by 
granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) in these cells. All of the reported effects of PK1 and PK2 on 
hematopoiesis and mobilization of hematopoietic cells were found to be pertussis toxin 
sensitive implicating the involvement of Gi proteins in prokineticin GPCR signal transduction 
in haematopoietic cells. In cardiomyocytes, a PK2-PKR1 signaling pathway was elegantly 
described using receptor-specific siRNA. PK2 activated Akt in these cells to protect against 
oxidative stress and promote angiogenesis (Urayama et al., 2007). 
 In neuronal cells and brain slices, PK2 can influence cell excitability presumably via 
PKR2, which is the dominant prokineticin receptor expressed in the brain. Following the 
initial discovery that PK2 regulates circadian rhythms by acting as an output molecule from 
the suprachiasmatic nucleus (Cheng et al., 2002), several studies have characterized the 
functions of PK2 in SCN target structures. In subfornical organ neurons, PK2 induces a 
reversible, dose-dependent depolarization and regulates voltage-activated potassium (K
+
) 
channels (Cottrell et al., 2004). Later, these PK2-mediated effects were shown to be 
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modulated by the MAPK signaling pathway and sodium channels (Fry et al., 2008). In 
cultured dorsal nociceptive root ganglion (DRG) neurons, the amphibian PK2 homolog Bv8 
increased the inward currents caused by heat and the capsaicin receptor, transient receptor 
potential vanilloid 1 (TRPV1). This effect was found to proceed by a PKC-epsilon-dependent 
signaling pathway (Vellani et al., 2006).  Similarly, in rat trigeminal ganglion neurons 
involved in pain perception, treatment with PK2 reduced inward currents produced upon 
GABA(A) receptor activation. The inhibitory effect of PK2 on the GABA receptor could be 
blocked by the pan PKC inhibitor but not by the protein kinase A inhibitor H89 suggesting 
the involvement of one or more PKC isoforms.  
Collectively, the studies to date demonstrate that diverse signaling pathways can be 
activated downstream of the prokineticin receptors by both PK ligands. This is exemplified 
by the fact that the prokineticin receptors are able to signal using Gi, Gq and Gs proteins. The 
functional cellular consequences of prokineticin signaling can be broadly categorized into 
cell survival, differentiation, migration, and excitability depending on the specific cell type 
and physiological function. Akt and ERK1/2 seem to be the main cell survival pathways 
activated by prokineticins as in the case of cardiomyocytes, endothelial cells, neural crest 
cells and myeloid cells. The same signaling pathways are also involved during angiogenesis 
and the survival of cancer cells including neuroblastomas and multiple myeloma cells. The 
ERK1/2 and other MAPK signaling pathways in cell differentiation induced by prokineticins 
and NFAT was identified as a key transcription factor downstream of the prokineticin 
receptors and regulates cytokine production. Nitric oxide generated by eNOS mediates the 
prokinetic functions of PK1 and PK2 on smooth muscle cells. MAPK and PKC signaling 
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have both been implicated in mediating the effects of PK-2 on excitable cells such as neurons 
of the subfornical organ and nociceptive dorsal root ganglion cells. It must be noted that 
although a wealth of evidence now supports a role for prokineticins as mediators of cell 
survival, to date neither of the prokineticins have been implicated in proapoptotic or cell 
death signaling pathways in any cell type. 
Prokineticin-2 signaling in the CNS  
Within the central nervous system, prokineticin-2 signaling through PKR2 has been 
shown to be the dominant ligand and receptor signaling axis for the prokineticins with PK1 
being undetectable in most brain regions except in the nucleus tractus solitarus and lateral 
reticular nucleus of the hindbrain. The regional expression of PK2 and its two prokineticin 
receptors have been characterized in detail across the entire mouse brain by in situ 
hybridization (Cheng et al., 2006). The expression of PK-2 was also determined at high 
resolution using the GENSAT EGFP-PK2 transgenic mouse in which the expression of the 
EGFP reporter protein is driven by the PK2 promoter (Zhang et al., 2009). The brain was 
identified as the major site of PK2 expression when the prokineticins were first discovered 
(Li et al., 2001; Lin et al., 2002a; LeCouter et al., 2003). Subsequently, the major functions 
for PK2 signaling in the brain were elegantly demonstrated using knockout mice. Cheng et 
al. (2002) first identified PK2 as an output molecule from the SCN circadian clock and 
demonstrated that PK2 expression rhythmically oscillates in the SCN in response to light. 
PK2 also induced its own transcription in the SCN by PKR2 signaling through a positive 
feedback loop. The PKR2 receptor is expressed in various SCN output areas including the 
paraventricular hypothalamic nucleus (PVN), dorsal medial hypothalamic nucleus (DMH), 
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paraventricular thalamic nuclei (PVT). Mice lacking either PK2 or PKR2 were subsequently 
shown to have defective circadian rhythms by independent groups. Consistent with the 
expression pattern of PK2 in the SCN and the presence of its receptors in distal autonomic 
control centers of the brain, PK2 was shown to modulate the excitability of subsets of 
subfornical organ neurons in a MAPK-dependent manner, functionally validating a potential 
mechanism for regulation of autonomic functions. More recent studies also demonstrated the 
ability of PK2 to regulate neuronal excitability in area postrema (AP) neurons of the medulla 
to and thus modulate autonomic functions in the brain (Ingves and Ferguson, 2010). 
 
Table 2: Expression of PK2 and its receptors in different brain region    
   References: Cheng et al.,( 2006) & Zhang et al., (2009) 
Brain Region PK2 PKR1 PKR2 
Olfactory bulb High Moderate High 
Cortex Not detected Not detected High 
Hippocampus & septum Not detected Low High 
Basal ganglia Moderate Low High 
Amygdala Not detected Not detected High 
Thalamus Not detected Not detected High 
Hypothalamus Low Not detected High 
Mesencephalon Not detected Moderate High 
Brainstem Not detected Moderate High 
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Development and maintenance of the olfactory bulb has emerged as another crucial 
function for PK2 signaling in the brain that has now been confirmed by several independent 
research groups using both PK2 and PKR2 knockout mice (Ng et al., 2005; Matsumoto et al., 
2006; Prosser et al., 2007; Zhang et al., 2007a).  Secreted PK2 acts as a chemoattractant for 
neural progenitors that originate in the subventricular zone and continuously migrate into the 
olfactory bulb via the rostral migratory stream to generate new interneurons. PK2 knockout 
mice exhibit a significant reduction in both the size of the olfactory bulb and its architecture. 
Defective migration neuronal progenitors with their accumulation in the rostral migratory 
stream was also evident in these mice suggesting that incomplete development of the 
olfactory bulb originates from defective progenitor cell migration. The constitutive induction 
of PK2 in this region of the brain was found to be under the regulation of the proneural 
transcription factors Neurogenin 1 and MASH1,which bind at conserved E-box sites on the 
PK2 promoter to activate transcription (Zhang et al., 2007a). The effects of PK2 in the 
olfactory bulb and subventricular zone are most likely mediated by PKR2 signaling since 
PKR1 expression is essentially absent along this pathway. Further, PKR2 was found to be 
expressed by migrating neuroblasts and subventricular zone transient-amplifying progenitors 
in the adult mouse brain (Puverel et al., 2009). Along the same lines, PK2 expression was 
shown to be associated with areas of active neuronal migration and proliferation in the adult 
zebrafish brain during normal development and during post-injury telencephalon 
regeneration. (Ayari et al., 2010). 
Emerging evidence suggests that PK2 is likely to have other important functions at 
distinct regions in the adult mammalian brain. The constitutive expression of the prokineticin 
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receptor PKR2 at high density across the brain even in the absence of either of its ligands 
suggest that PK2 might be induced locally at specific regions in the brain. Preliminary 
studies have shown that Bv8, the amphibian homologue of the prokineticins can protect 
cerebellar granule neurons and cortical neurons in culture against excitotoxic injury and 
degeneration, although in vivo evidence is lacking. Bv8 activated the typical PK2 survival 
signaling pathways Akt and p44/42 MAPK in cultured neurons to protect against 
excitotoxicity in vitro. Prokineticin receptors were also found to be expressed on cultured 
astrocytes and microglial cells and PK2 signaling induced calcium mobilization and 
proliferation in primary astrocytes (Koyama et al., 2006). High levels of PKR1 were reported 
in glial cells suggesting that PKR1 might be the dominant prokineticin receptor in non-
neuronal cells in the CNS. The functional effects of PK2 on glial cells remain to be 
determined in detail and could be particularly relevant given the important functions of 
microglia and astrocytes in neurodegeneration and development.  
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CHAPTER II 
 
PROTEOLYTIC ACTIVATION OF PROAPOPTOTIC KINASE PKC IN 
DOPAMINERGIC NEURONS BY TNFα DEATH RECEPTOR SIGNALING AND 
NEUROINFLAMMATION 
A manuscript communicated to the journal Neurobiology of Disease 
 
Richard Gordon, Arthi Kanthasamy, Vellareddy Anantharam  and Anumantha G. 
Kanthasamy 
Abstract 
The mechanisms of progressive dopaminergic neuronal loss in Parkinson’s disease 
(PD) remain poorly understood largely due to the complex etiology and multifactorial nature 
of disease pathogenesis. Several lines of evidence from human studies and experimental 
models over the last decade have identified neuroinflammation as a potential 
pathophysiological mechanism contributing to the progression of the disease.  Tumor 
necrosis factor-α (TNF) has recently emerged as the primary neuroinflammatory mediator 
that can elicit dopaminergic cell death in PD. However, the signaling pathways by which 
TNF mediates dopaminergic cell death have not been elucidated. Herein, we report that TNF 
death receptor signaling in dopaminergic neuronal cells activates an isoform in the novel 
PKC family, PKC, by caspase-3 and caspase-8 dependent proteolytic cleavage via the 
extrinsic apoptotic pathway. Notably, TNFR1 neutralizing antibody or the soluble TNF 
receptor Etanercept almost completely blocked the TNFα-induced PKC proteolytic 
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activation suggesting the involvement of the canonical death receptor pathway in the kinase 
activation.  The proteolytic activation of PKC was accompanied by translocation of the 
kinase to the nucleus.  Inhibition of PKC signaling by siRNA or overexpression of a 
cleavage-resistant mutant protects against TNF-induced cell death. Further, primary 
dopaminergic neurons obtained from PKC knockout (-/-) mice are also protected against 
TNFα neurotoxicity. We also demonstrate proteolytic activation of PKC in the mouse 
substantia nigra in the neuroinflammatory LPS model. Collectively, these results identify 
proteolytic activation of PKC proapoptotic signaling as a crucial downstream effector of 
dopaminergic cell death induced by TNFα. These findings also provide a rational for 
therapeutically targeting PKC to mitigate progressive dopaminergic degeneration resulting 
from chronic neuroinflammatory processes. 
Introduction 
Parkinson’s disease (PD) is a debilitating neurodegenerative movement disorder 
affecting around 2% of the population over the age of 60 (Moore et al., 2005; Schapira, 
2009). The pathological hallmark of the disease is a selective loss of dopaminergic (DA) 
neurons in the substantia nigra of the midbrain resulting in a depletion of striatal dopamine 
that is clinically manifest as a range of motor and nonmotor deficits (Obeso et al., 2010). A 
prominent clinical feature of PD is a sustained neuroinflammatory response in the SNpc that 
is initiated early during dopaminergic degeneration, and still evident in postmortem PD 
patients with increased microgliosis, dystrophic astrocytes and lymphocyte infiltration 
(Hirsch and Hunot, 2009; Glass et al., 2010; Tansey and Goldberg, 2010). Compelling 
evidence over the last decade from animal models, in vitro studies and PD patients has 
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demonstrated that the protracted neuroinflammation that occurs in the SNpc can exacerbate 
the degeneration of vulnerable dopaminergic neurons, but the molecular mediators and 
mechanisms involved are still being established.   
Tumor necrosis factor-α (TNF) has recently emerged as an important 
neuroinflammatory mediator linked to dopaminergic degeneration in PD. Increased levels of 
TNF are present in the SNpc and the CSF of postmortem PD patients, and recently identified 
genetic polymorphisms in the TNFα gene locus have been linked to the development of PD 
(Boka et al., 1994; Mogi et al., 1994; Nagatsu et al., 2000; Nishimura et al., 2001; Wu et al., 
2007; Bialecka et al., 2008). Increased TNF is also well documented in rodent and nonhuman 
primate models of PD induced by neurotoxicants and in transgenic models (Mogi et al., 
1999; Barcia et al., 2005). Significantly, ablation of TNF signaling using knockout mice for 
TNFα or its receptors has been shown to attenuate MPTP-induced dopaminergic 
degeneration (Sriram et al., 2002; Ferger et al., 2004). Further, genetic or pharmacological 
inhibition of soluble TNF signaling with dominant negative mutants is protective against 6-
OHDA and LPS-induced dopaminergic degeneration in vivo (McCoy et al., 2006; McCoy et 
al., 2008). Conversely, the chronic expression of low levels of TNFα in the substantia nigra 
of rats using an adenoviral vector can induce progressive dopaminergic degeneration with 
delayed motor deficits (De Lella Ezcurra et al., 2010). Together, these independent studies 
strongly implicate TNF in the progressive loss of dopaminergic neurons in PD. However, the 
signaling mechanisms by which TNF can mediate dopaminergic degeneration have not been 
characterized.  
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Protein Kinase C (PKC), a member of the novel PKC isoform family, is highly 
expressed by dopaminergic neurons in the SNpc, in primary cultures and by dopaminergic 
cell lines (Zhang et al., 2007b).  Recent studies from our laboratory and others have shown 
that PKC is proteolytically activated by caspase-3 during dopaminergic cell death and that 
genetic or pharmacological targeting of PKC can protect against dopaminergic degeneration 
in PD models (Anantharam et al., 2002; Kaul et al., 2003; Zhang et al., 2007a; Hanrott et al., 
2008). In this paradigm, increased oxidative stress in dopaminergic neurons results in 
proteolytic activation of PKC by caspase-3 downstream of the intrinsic mitochondrial 
apoptotic pathway. The proteolytic cleavage of PKC by caspase-3 persistently activates the 
kinase as an effector of dopaminergic cell death.  
However, PKC activation by extrinsic neuroinflammatory mediators like TNF has 
not been studied and would be relevant to the progression of PD by neuroinflammatory 
mechanisms. Since TNF also activates caspase-3 by signaling through its death receptors, we 
tested if PKC is proteolytically activated during TNF-induced dopaminergic cell death and 
in the mouse substantia nigra (SN) by neuroinflammatory mechanisms in the LPS model of 
dopaminergic degeneration. Our findings herein demonstrate PKC as a key downstream 
target of TNFα death receptor signaling in dopaminergic neurons and identify a novel link 
between neuroinflammatory mechanisms and dopaminergic degeneration.   
 
Materials and methods 
Chemicals and reagents.  RPMI, neurobasal medium, B27 supplement, fetal bovine serum, 
L-glutamine, Sytox assay dye, IR-dye tagged secondary antibodies, penicillin, and 
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streptomycin and other cell culture reagents were purchased from Invitrogen (Gaithersburg, 
MD). Recombinant rat TNF, LPS (E. coli 0111:B4) and cytosine arabinoside were purchased 
from Sigma-Aldrich (St. Louis, MO). Recombinant murine TNF and the TNFR1 neutralizing 
antibody were from R&D Systems (Minneapolis, MN).  Etanercept (Enbrel) was purchased 
from Amgen Inc. (Thousand Oaks, CA).  Antibodies for rabbit PKC and caspase-8 were 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mouse TH antibody was purchased 
from Chemicon (Temecula, CA) and MAP-2 antibody from Cell Signaling Technologies 
(Beverly, MA). 
32
P-ATP was purchased from Perkin Elmer (Boston, MA) and the AMAXA 
Nucleofector kit from Lonza (Basel, Switzerland). Caspase assay substrates and inhibitors 
were purchased from MP Biomedicals (Solon, OH). The DNA fragmentation assay kit was 
purchased from Roche Applied Science and the Bradford protein assay kit was purchased 
from Bio-Rad Laboratories (Hercules, CA).   
Stereotaxic infusion of LPS into the mouse substantia nigra (SN). A single dose  LPS 
injection model that was previously described (Saijo et al., 2009) was used to induce delayed, 
progressive loss of dopaminergic neurons in the substantia nigra. Eight week old C57/BL/6 
mice (n = 6 per group) were anesthetized with a mixture of ketamine-xylazine (100mg/kg, 
10mg/kg) and carefully immobilized on a stereotaxic apparatus (Benchmark Angle One, 
Leica Microsystems). The skin above the skull was prepped with alcohol and an incision was 
made to expose the skull. A single burr hole was carefully drilled at the injection site for the 
right SN and ophthalmic gel was used protect the eyes. The stereotaxic coordinates for the 
injection site were anteroposterior (AP) -3.3 mm, mediolateral (ML) -1.2 mm, dorsoventral 
(DV) -4.6 mm from bregma (Franklin and Paxinos, 2008) A stainless steel cannula  attached 
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to a 5 μl Hamilton syringe was carefully inserted into the hole drilled at the injection site and 
a single dose of 5 µg LPS in a 1 µl volume was injected at the rate of 0.5 µl per minute. The 
needle was left in place for another 5 minutes to prevent retrograde flow of liquid along the 
needle track.  Control mice were injected in an identical manner with equal volumes of 
saline. After surgery, the skin was sutured and carefully held in place using sterile, non-
pyrogenic stainless steel clips (Autoclip Wound Closing System, Braintree Scientific, Inc). 
Mice were allowed to recover on a heating pad (Braintree Scientific, Inc) and were carefully 
monitored through recovery from anesthesia. All animal procedures were approved by the 
Iowa State University Institutional Animal Care and Use Committee (IACUC).  
Culture and treatment paradigm for rat dopaminergic N27 cells.  N27 cells were 
cultured as described previously (Clarkson et al., 1998; Kaul et al., 2003; Zhang et al., 
2007a).  Briefly, cells were cultured in RPMI
 
1640 medium containing 10% heat inactivated 
fetal bovine serum, 2 mM L-glutamine,
 
penicillin (100 units/ml), and streptomycin (100 
μg/ml).  Cells were maintained in a humidified atmosphere of 5% CO2 at 37°C.  For 
treatment with TNF, RPMI medium containing 2% fetal bovine serum was used. Cells were 
washed twice in 2% serum RPMI and then treated with the indicated doses of recombinant 
rat TNF in 2% serum medium.  
Primary mouse mesencephalic neuron cultures. Primary neurons were cultured from 
ventral mesencephalon tissue of gestational 14-day (E14) mouse embryos as described 
previously (McGuire et al., 2001; Zhang et al., 2007a) with some modifications. The ventral 
mesencephalon was dissected under a microscope and collected in ice cold DMEM F-12 
complete medium (DMEM-F12 supplemented with 10% heat-inactivated fetal bovine serum 
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(FBS), 50 U/mL penicillin, 50 μg/mL streptomycin, 2 mM L-glutamine, 100 μM non-
essential amino acids, and 2 mM sodium pyruvate). The tissue was then dissociated using 
trypsin-EDTA (0.25%) for 15 minutes at 37°C.  Trypsinization was stopped by adding an 
equal volume DMEM-F12 complete medium and dissociated tissue was washed in the same 
medium to remove residual trypsin. The DMEM-F12 medium was aspirated out and the 
tissue triturated in neurobasal medium containing the B-27 antioxidant supplement, 500 µM 
L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. After a single cell suspension 
was obtained, cells were passed through a 70 μm nylon mesh cell strainer to remove tissue 
debris and aggregates. Cells were counted using a Beckman Coulter ViCell XR automated 
cell counter and then plated at an equal density (0.8 x 10
6 
cells per well) in 24 well plates 
containing coverslips precoated with poly-D-lysine (100µg/ml). Cultures were maintained in 
neurobasal medium with B-27 antioxidant supplements and cytosine arabinoside (5 µM) was 
added to inhibit glial proliferation. Cultures were grown in a humidified CO2 incubator (5% 
CO2, 37°C) and the medium was changed every 2 days. Approximately 4 to 5-day-old 
cultures were used for treatment. The neuronal Cultures were verified to be around 98% free 
of glial cells at the time of treatment by using immunocytochemistry for MAP2, GFAP and 
iba1 as markers of neurons, astrocytes and microglia respectively. For TNF treatment, 
cultures were switched to serum-free neurobasal medium without antioxidant supplements 
and treated for 48 h. Recombinant murine TNF (30ng/ml) was added at the beginning of the 
treatment and re-added again 24 h later. At the end of the treatment, primary cultures were 
processed for TH immunocytochemistry and neurotransmitter uptake assays.  
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DNA fragmentation and Sytox assays. DNA fragmentation was quantified using the Cell 
Death Detection
 
ELISA Plus assay kit (Roche Applied Science) as described in our previous 
publications (Anantharam et al., 2002; Kaul et al., 2003; Zhang et al., 2007a). This highly 
sensitive and reliable
 
assay detects and quantifies early changes in apoptosis based on the 
amounts of histone-associated low
 
molecular weight DNA released into the cytoplasm of 
cells. Briefly, N27 cells were plated in 6-well plates at 0.8 x 10
6 
cells/well and treated the 
next day with TNF for 16 h. Cells were collected using a cell scraper and centrifuged at 400 
× g for 5 min. The cells were gently lysed using the lysis buffer provided with the kit.  The 
lysate then was spun down again at 200 x g for 10 min to pellet the nuclear fraction and the 
supernatant was collected and used to measure DNA fragmentation according to the 
manufacturer's instructions for the ELISA protocol. The absorbance at 405 nm was measured 
against an ABTS
 
solution as a blank (reference wavelength ~490 nm) using a Synergy-2 
Multi-Mode Microplate Reader (BioTek Instruments, Inc). The raw absorbance values were 
normalized to the amount of protein present in the lysates. The Sytox cytotoxicity assay was 
performed using the Sytox green dye (Molecular Probes). The assay is based on the principle 
that live cells with intact plasma membranes exclude the dye that selectively enter cells with 
a compromised membrane and emits bright green fluorescence on binding to DNA (Sherer et 
al., 2002). N27 cells were grown in 24 well plates and 1 µM of the Sytox dye was added at 
the time of treatment. Cells were treated for 16 h with TNF and pretreated with Etanercept or 
the caspase-8 peptide inhibitor (IETD-FMK). The increase in green fluorescence as a result 
of TNF cytotoxicity was measured using a fluorescence microplate reader (Spectramax 
Gemini, Molecular Devices) at an excitation of 485 nm and 538 nm emission. Phase contrast 
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and fluorescence images of matching fields were taken on the same cells to qualitatively 
visualize the toxicity in N27 cells. Images were captures using a NIKON TE2000 microscope 
equipped with a SPOT digital camera (Diagnostic Inc) 
Caspase-3 enzymatic activity assays. Enzymatic assays for caspase-3 activity were 
performed as described previously (Anantharam et al., 2002; Kaul et al., 2003) using  acetyl-
DEVD- amino-4-trifluoromethylcoumarin (Ac-DEVD-AFC, 25 μm) as the fluorometric 
substrate for the reaction. The fluorescence signals generated upon cleavage of the AFC 
peptide substrate by caspase-3 was measured at 510 nm with an excitation of 400nm using a 
Synergy-2 Multi-Mode microplate reader. Protein concentrations were determined using the 
Bradford assay and used to normalize caspase activity.  
Confocal immunofluorescence microscopy for PKC translocation. N27 cells were plated 
on poly-D-lysine (100 µg/ml) coated coverslips in 24 well plates at 0.2 x 10
6 
cells per well. 
The next day, the cells were treated with 30ng/ml of TNF for 6 h in 2% serum RPMI 
medium. Cells were fixed in 4% paraformaldehyde for 20 min and washed 5 times in PBS. 
The cells were blocked and permeabilized with blocking buffer (5% goat serum, 0.2% Triton 
X, and 0.05% Tween-20 in PBS) for 1 h and then incubated overnight at 4°C with a rabbit 
polyclonal PKC antibody (1:1000) that recognizes a C-terminal epitope present in both the 
native and the proteolytically cleaved protein. The cells were then washed 5 times in PBS 
and then incubated with secondary antibody (1:2000, Alexa 488 goat anti-rabbit) for 1 h at 
room temperature. Negative controls for non-specific staining that contained secondary 
antibody alone were used on parallel wells to ensure specificity of the fluorescent signals 
obtained. The cells were then washed 5 times in PBS and the nucleus was labeled using the 
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TOPRO 3 dye. The cells were then washed 3 more times in PBS and coverslips were 
mounted using the ProLong Gold antifade reagent (Molecular Probes). Confocal images were 
acquired with a Nikon EZ-C1 confocal system using the 488nm and 633 nm lasers to 
visualize PKC and TOPRO 3 respectively.  
Western blotting. Lysates from N27 cells and brain tissue were prepared using a modified 
RIPA buffer and normalized for equal amounts of protein using the BCA protein assay 
(Pierce Biotechnology). Gel loading dye was added to the lysates and stored in aliquots at -
80°C. Equal amounts of protein (30 to 50 µg) were loaded for each sample and separated on 
either 12% or 15% SDS-PAGE gels depending on the molecular weight of the target protein. 
After separation, the proteins were transferred to nitrocellulose membranes and non-specific 
binding sites were blocked by incubating the membranes in fluorescent Western blocking 
buffer (Rockland Immunochemicals) for 1 h and then probed with primary antibodies 
overnight at 4°C. Primary antibodies used were rabbit polyclonal PKC (1:500), mouse 
monoclonal TH (1:2000), rabbit polyclonal caspase-8 (1:200) and rabbit monoclonal cleaved 
caspase-3 (1:1000). Beta Actin (1:5000) was used as the loading control. After incubation, 
membranes were washed three times with PBS containing 0.05% Tween (PBST) and IR-dye 
tagged secondary antibodies (1:5000 Molecular Probes) were added and the membranes 
visualized on the Odyssey infra-red imaging system.  
PKC immunoprecipitation-kinase assays. The PKCδ enzymatic kinase activity assay was 
performed as described previously (Anantharam et al., 2002; Kaul et al., 2005; Zhang et al., 
2007a). Briefly, N27 cells or substantia nigra tissues were washed in ice cold PBS and then 
resuspended a mild RIPA lysis buffer containing protease and phosphatase inhibitor cocktail 
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(Pierce Biotechnology). The lysates were placed on ice for 20 min, sonicated gently and 
centrifuged at 13,000 rpm for 45 min. The supernatant was collected and protein 
concentration was determined using the Bradford assay (Bradford, 1976). All samples were 
made up to a concentration of 2 µg/ml and 500 µg of total  protein in a 250 µl volume was 
immunoprecipitated overnight at 4°C using 5 μg of the PKCδ antibody. The next day, the 
protein A-agarose beads (Sigma-Aldrich) was added and the samples incubated for 1 h at 
room temperature. The protein A-bound antibody complexes were then washed three times in 
2X kinase assay buffer (40 mM Tris, pH 7.4, 20 mM MgCl2, 20 μM ATP, and 2.5 mM 
CaCl2), and then resuspended in 40 μl of the same buffer. The kinase reaction was started by 
adding 40 μl of the reaction buffer containing 0.4 mg of histone H1, 50 μg/ml 
phosphatidylserine, 4 μM dioleoylglycerol, and 10 μCi of [γ-32P] ATP at 3000 Ci/mM to the 
immunoprecipitated samples. The samples were incubated for 10 min at 30°C. The kinase 
reaction was stopped by adding 2X SDS loading buffer and boiling the samples for 5 min. 
The proteins were separated on a 12% SDS-PAGE gel and the phosphorylated histone H1 
bands were scanned using a Fujifilm FLA 5000 imager. Image analysis and band 
quantification was performed using the Fujifilm Multigauge software package.  
Transfection of PKC siRNA and cleavage-resistant (PKCD327A-CRM) mutant. Design 
and synthesis of PKC siRNA is described in our previous publications (Yang et al., 2004; 
Zhang et al., 2007a). N27 cells were transfected with 40 to 50nM of either PKC or scramble 
siRNA duplexes using the AMAXA Nucleofector kit according to the manufacturer’s 
instructions. Transfected cells were counted using a Vi-Cell XR automated cell counter and 
seeded at equal density (0.5 x 10
6 
cells/well) into 6-well plates. The cells were treated 24 h 
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after transfection to allow for optimal knockdown of gene expression, which was verified by 
Western blotting (Fig. 6B). At the end of the treatment, cells were collected and used for the 
DNA fragmentation assay as described above. For studies with the PKC cleavage-resistant 
mutant (PKCD327A-CRM), stable N27 cell lines overexpressing either the mutant PKCD327A 
protein or the -galactosidase (Lac Z) protein as the vector control were prepared as 
described in our publications (Latchoumycandane et al., 2005). Both cell lines were cultured 
in the presence of blasticidin for 3 passages before treatment. Stable expression of the PKC 
CRM-mutant and the Lac Z vector control at the time of treatment were confirmed by 
staining for the V5-epitope (Fig. 6D). Cells were plated at equal density (0.7 x 10
6 
cells per 
well) in 6 well plates and allowed to grow overnight.  The next day, cells were treated with 
30ng/ml of TNF for 16 h and processed for the DNA fragmentation assay. 
Dopamine and GABA uptake assays. Uptake assays for tritiated dopamine and GABA on 
primary EVM cultures was performed according to previously published protocols (Liu et al., 
2000a; Gao et al., 2002; McCoy et al., 2006). After treatment, the primary neuron cultures 
from PKC wild type (+/+) and knockout (-/-) mice were washed three times with 0.5 ml of 
warm Krebs–Ringer buffer (16 mM sodium phosphate, 120 mM NaCl, 4.7 mM KCl, 1.8 mM 
CaCl2, 1.2 mM MgSO4, 1.3 mM EDTA, and 5.6 mM glucose; pH 7.4). The cultures were 
then incubated with either 5 μM [3H]-Dopamine (30 Ci/mmol) and 10 μM [3H]-GABA (90 
Ci/mmol) in Krebs-Ringer buffer at 37°C for 20 min. The cells were then washed three times 
with ice cold Krebs-Ringer buffer and collected in 1 ml of 1N NaOH. Scintillation fluid was 
added to a total volume of 5 ml and the radioactivity counts were measured using a Tri-Carb 
Liquid Scintillation counter (Packard). In parallel wells, the nonspecific uptake of Dopamine 
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and GABA was determined by incubating with 10µM mazindol and 2 mM -alanine 
respectively. The nonspecific uptake values were subtracted to obtain the data for high 
affinity neurotransmitter uptake.  
TH-positive cell counts and immunofluorescence. After TNF treatment, primary neuron 
cultures from PKC wild type (+/+) and PKC knockout (-/-) mice were fixed in 4% 
paraformaldehyde and permeabilized with PBS containing 2% BSA, 0.2% Triton X-100 and 
0.05% Tween-20. Blocking buffer (PBS with 2% BSA) was added for 1 h at room 
temperature and primary antibodies for TH (1:1000) and MAP2 (1:1000) were diluted in 
blocking buffer and incubated overnight at 4°C. The next day, cells were washed in PBS 4 
times and incubated with appropriate Alexa-dye conjugated secondary antibodies for 1 h at 
room temperature. After several washes, the samples were counterstained with Hoechst to 
label the nucleus and coverslips were mounted using the Prolong Antifade (Molecular 
Probes) mounting medium. Images were acquired using a Nikon inverted fluorescence 
microscope (Model TE-2000U) equipped with a SPOT digital camera system (Diagnostic 
Instruments, Sterling Heights, MI). Image analysis was performed using the Metamorph 
software package (Universal imaging Systems, PA).  
Data analysis.  Data analysis was performed using Prism 4.0 software package (GraphPad 
Software, San Diego, CA). The data was first analyzed using one-way ANOVA and then 
Bonferroni's post-test was performed to compare all treatment groups. Differences of p<0.05 
were considered statistically significant. The Student's t-test was used when differences 
between two groups were being compared.  
 
67 
 
 
Results 
TNF is toxic to rat N27 dopaminergic neuronal Cells. 
In order to test if TNF could induce dopaminergic cell death and determine the 
mechanism of toxicity, we treated rat dopaminergic N27 cells with recombinant TNF and 
determined the kinetics of cell death using the DNA fragmentation assay and increases in 
Sytox fluorescence. Exposure to TNF (30ng/ml) for 16 h significantly increased Sytox 
fluorescence and caused a threefold increase in DNA fragmentation compared to untreated 
controls (Fig. 1). Pretreatment with the TNF neutralizing drug Etanercept or a caspase-8 
inhibitor (IETD-FMK) almost completely blocked TNF-induced apoptosis, indicating that 
canonical TNF death receptor signaling through activation of caspase-8 could be a potential 
mechanism for dopaminergic neurotoxicity caused by sustained exposure to TNF. In pilot 
experiments, we tested various doses of TNFα and treatment times and the 30 ng/ml dose 
was chosen for mechanistic studies with cell culture models although doses as low as 
10ng/ml could induce toxicity. (Data not shown)  
Caspase-8 and caspase-3 are activated during TNF-induced cell death in dopaminergic 
cells. 
To further establish the mechanism of TNF toxicity on dopaminergic cells and the 
signaling pathways involved, we studied caspase activation downstream of TNFα signaling. 
High levels of the pro-caspase 8 protein were detected in N27 cells and TNF treatment 
induced dose dependent activation of caspase-8 at 3 h with increased accumulation of the 
active p20 fragment (Fig. 2A). Further, the activation of caspase-8 was attenuated by 
pretreatment with the TNFα inhibitor Etanercept (Fig. 2B). Since caspase-3 is an important 
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effector caspase downstream of TNFα death receptor signaling and is known to be activated 
in PD models and in the human PD brain (Hartmann et al., 2000; Zhao et al., 2001) , we 
studied caspase-3 activity in TNF-treated N27 cells. We found that TNF treatment for 6 h 
caused activation of caspase-3 which could be blocked by pretreatment with Etanercept and 
the caspase-8 inhibitor IETD-FMK (Fig. 2B, 2C). These results indicate that caspase-3 is 
activated in a caspase-8 dependent manner downstream of TNF death receptor signaling in 
N27 dopaminergic cells and could be an important mechanism linking the extrinsic 
neuroinflammatory insults to dopaminergic degeneration.  
TNFα induces proteolytic activation of Protein Kinase C in N27 dopaminergic 
neuronal cells  
PKC has been shown to be an oxidative stress-sensitive kinase that is highly 
expressed in dopaminergic neurons. During oxidative stress-induced apoptosis in 
dopaminergic neurons and other cell types, PKC has been shown to be activated by caspase-
3 mediated proteolytic cleavage at its hinge region resulting in persistent activation of the 
kinase and amplification of apoptotic signals. However, PKC activation by the extrinsic 
apoptotic pathway in dopaminergic neurons or its role in neuroinflammation-induced 
dopaminergic neurotoxicity has not been examined. We tested if PKC can be activated by 
caspase-3 during TNF-induced death of dopaminergic neuronal cells and function as a 
downstream apoptotic effector. Interestingly, TNF treatment caused a time and dose-
dependent proteolytic activation of PKC that was detectable 3 h after treatment and 
increased strongly at 6 h  (Fig. 3A). Dose response studies at the 6 h time point showed that 
doses as low as 10ng/ml of TNF could induce detectable proteolytic activation of PKC, 
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which increased substantially with 30ng/ml TNF. Higher doses of TNF (60ng/ml) did not 
significantly increase PKC cleavage further (Fig. 3B). Since caspase-8 and caspase-3 were 
activated by TNF in these cells, we tested if PKC proteolytic activation was dependent on 
this signaling pathway by using the specific caspase inhibitors DEVD-FMK and IETD-FMK. 
Pretreatment with the caspase-8 and caspase-3 peptide inhibitors  suppressed TNF-induced 
proteolytic activation of protein kinase C (Fig. 3C). Collectively, these results demonstrate 
for the first time that the pro-apoptotic kinase PKC is activated by caspase-8 and caspase-3 
dependent proteolytic cleavage during TNF-induced apoptosis in dopaminergic neuronal 
cells.  
Proteolytic activation of PKC by TNF signaling persistently activates the kinase in N27 
dopaminergic neuronal cells 
Unlike many other proteins for which proteolytic cleavage can result in loss of 
function or inactivation, the proteolytic cleavage of PKC by caspase-3 during oxidative 
stress-induced dopaminergic cell death has been shown to persistently activate this kinase 
(Anantharam et al., 2002; Kanthasamy et al., 2003; Kaul et al., 2003; Zhang et al., 2007a). 
We used immunoprecipitation-kinase assays and Western blotting to verify if TNFα-induced 
proteolytic activation of PKC leads to sustained activation of the kinase in dopaminergic 
N27 cells. As shown in Fig. 4A treatment with TNF for 6 h significantly increased 
proteolytic cleavage of PKC, which was blocked by pretreatment with Etanercept or a 
TNFR1 (TNFRSF1) receptor-neutralizing antibody. PKC IP-kinase assays performed on the 
same lysates showed a robust increase in PKC kinase activity in TNF-treated samples, 
which could be attenuated by pretreatment with Etanercept or by TNFR1 (TNFRSF1) 
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receptor neutralization. Together, these findings demonstrate that PKC is proteolytically 
activated in N27 dopaminergic neuronal cells by a TNFR1-dependent signaling pathway, 
resulting in sustained activation of the kinase during TNF-induced cell death.  
PKC translocates to the nucleus during TNFα-induced apoptosis.  
Rapid and dynamic translocation to distinct subcellular locations following activation 
is a characteristic feature of PKC in different cell types and typically delineates the unique 
functional role of this kinase in a particular system (Gomel et al., 2007).  PKC has been 
shown to translocate to the plasma membrane, the endoplasmic reticulum, the mitochondria 
and the nucleus in a cell- and stimulus-specific manner. Unique substrate proteins have been 
identified as candidates for PKC phosphorylation in these subcellular locations that 
participate in a range of cellular functions from apoptosis to cell migration and activation of 
immune cells (Steinberg, 2004). Particularly, nuclear translocation of PKC has been shown 
to occur following proteolytic activation by apoptotic stimuli.  A nuclear localization signal 
(NLS) is present on the C-terminus of the catalytic domain that is released upon proteolytic 
cleavage by caspase-3. To further characterize the functional role of PKC in dopaminergic 
cell death induced by TNF, we used immunocytochemistry and confocal microscopy to study 
the subcellular localization of PKC following TNF treatment. N27 cells were treated with 
TNF for 6 h, the time point at which the highest level of cleaved PKC was detected, and 
confocal immunofluorescence was used to visualize the subcellular localization of PKC. We 
detected prominent nuclear localization of PKC after 6 h of TNF treatment, while in 
untreated controls PKC was almost completely localized in the cytoplasm (Fig.5A). 
Interestingly, we also observed punctuate staining of PKC at distinct locations around the 
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perinuclear region in TNF-treated cells (labeled with red arrows) in addition to the overall 
increase in nuclear localization. The nuclear translocation of PKC points to a pro-apoptotic 
function for this kinase during TNF death receptor signaling in these cells. The distinct 
pattern of perinuclear accumulation, however, appears to be unique to TNF signaling in these 
cells and does not occur during treatment with other neurotoxicants we have studied 
previously that induce apoptosis by the intrinsic cell death pathway.  
Overexpression of a cleavage-resistant mutant (PKCD327A-CRM) or siRNA knockdown 
of PKC protects against TNFα dopaminergic cell death.  
The proteolytic activation of PKC by caspase-3 and its translocation to the nucleus 
indicate an important function for this kinase in effecting apoptosis induced by TNF in 
dopaminergic N27 cells. To validate a pro-apoptotic role for PKC signaling in this system, 
we used siRNA suppression of PKC and a caspase-3 cleavage-resistant mutant of PKC 
(PKCD327A-CRM). N27 cells were transfected with siRNA to PKC or scramble siRNA and 
incubated for 24 h to allow for maximum suppression of PKC protein levels, which we 
validated by Western blotting (Fig. 6B). The transfected cells were then treated with TNF for 
16 h and processed for the DNA fragmentation assay. In N27 cells transfected with scramble 
siRNA, TNF caused a significant increase in DNA fragmentation while the PKC siRNA 
transfected cells were protected from cell death (Fig. 6A). These results confirm that PKC is 
required for TNF-induced apoptosis in dopaminergic cells and that genetic or 
pharmacological modulation of PKC may be effective in attenuating TNF-induced 
neurotoxicity.  To determine the relevance of PKC proteolytic cleavage during pro-
apoptotic TNF signaling, we used N27 cells over expressing a mutant PKC  protein that is 
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resistant to proteolytic cleavage (PKCD327A-CRM) by caspase-3 due to a point mutation at 
the cleavage site. Stable N27 cells that expressed either the cleavage-resistant PKC mutant 
or the LacZ protein were established as described previously (Latchoumycandane et al., 
2005). The cells were treated with TNF for 16 h and processed for DNA fragmentation. As 
shown in Fig.6C, TNF treatment caused a 2.5-fold increase in DNA fragmentation in LacZ 
cells, while cells expressing the PKCD327A-CRM mutant were protected from TNF toxicity, 
indicating that proteolytic cleavage of PKC is crucial for TNF-induced cell death. 
Collectively, these results demonstrate that PKC functions as a proapoptotic kinase during 
TNF-induced dopaminergic neurotoxicity and that proteolytic cleavage of PKC by caspase-
3 downstream of TNF signaling is required for cell death.  
Primary dopaminergic neurons obtained from PKCδ knockout (-/-) mice are protected 
from TNFα neurotoxicity  
In order to extend our results from the mechanistic studies with dopaminergic N27 
cells to a more relevant system, we used primary mouse ventral mesencephalic dopaminergic 
neuron cultures to study the role of PKC in mediating TNF-induced dopaminergic 
neurodegeneration.  We established primary EVM neuronal (>95% glial-free) cultures from 
PKC wild type (+/+) and knockout (-/-) mice and treated them with recombinant TNF in 
supplement-free neurobasal medium, as described in the Methods section. Dopaminergic 
neurotoxicity was assessed by dopamine uptake assays and by TH-positive cell counting. As 
shown (Fig.7A,B), TNF exposure caused a 40-50% decrease in dopamine uptake and TH-
positive cell counts in cultures from PKC WT (+/+) mice, consistent with previous reports 
of dopaminergic neurotoxicity induced by TNF in similar model systems (McGuire et al., 
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2001; McCoy et al., 2006). Significantly, in primary neuron cultures obtained from PKC 
knockout (-/-) mice, TNF induced only about a 20% reduction in dopamine uptake and TH-
positive neuron counts, indicating that these cultures were resistant to TNF toxicity. With TH 
as a marker for dopaminergic neurons and MAP-2 as a pan-neuronal marker, we utilized 
double labeling immunofluorescence to visualize the effects of TNF exposure on the 
dopaminergic and other neuron populations in primary EVM cultures. Untreated cultures 
from both PKC wild type (+/+) and knockout (-/-) mice had similar numbers of 
dopaminergic neurons and displayed extensive branched neurites and normal cell bodies 
(Fig. 7D, top panel). In TNF-treated cultures, fewer TH-positive neurons with smaller cell 
bodies and a clear loss of neurites was evident in cultures from PKC wild type (+/+) mice. 
In contrast, dopaminergic neurons in cultures from PKC knockout (-/-) mice displayed 
visible branched neurites and more numerous cell bodies with normal morphology (Fig. 7D, 
lower panel) demonstrating significant protection against TNF-toxicity in these cultures. 
These results are consistent with the established function of PKC as a common apoptotic 
effector in different cell types (Humphries et al., 2006). We also used GABA uptake assays 
on cultures treated with TNF under the same conditions to determine if TNF neurotoxicity 
extended to other neuronal populations relevant to PD such as the GABA neurons. In 
agreement with findings from previous studies (McCoy et al., 2006), TNF treatment did not 
induce a significant reduction in GABA uptake under our treatment conditions, even when 
higher doses (60ng/ml) were used (Fig. 7C).  
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PKC is activated by proteolytic cleavage in the mouse SNpc in the LPS 
neuroinflammatory model of Parkinson’s disease. 
Next we sought to extend the significance of our results obtained with the N27 cell 
culture model and primary neuron cultures to an in vivo model of dopaminergic degeneration 
relevant to neuroinflammation. Elevated levels of TNFα and neuroinflammation are well 
documented in the established MPTP and 6-OHDA models of PD. In fact, the use of 
dominant negative TNFα has been shown to be neuroprotective against 6-OHDA-mediated 
dopaminergic neurotoxicity (McCoy et al., 2006). However, previous studies from our 
laboratory and others have demonstrated proteolytic activation of PKC downstream of the 
intrinsic mitochondrial apoptotic pathway initiated by oxidative stress (Kanthasamy et al., 
2003; Kaul et al., 2003; Zhang et al., 2007a; Hanrott et al., 2008). Since this could potentially 
confound our studies, which were study the proteolytic activation of PKC by extrinsic 
neuroinflammatory mechanisms, we avoided the use of the MPTP or 6-OHDA models of 
dopaminergic degeneration. Instead, we selected the widely used stereotaxic LPS injection 
model of neuroinflammation-induced dopaminergic degeneration for our experiments  
(Herrera et al., 2000; Liu et al., 2000b; McCoy et al., 2006; Saijo et al., 2009). In this model, 
a single injection of LPS into the rodent substrantia nigra elicits a sustained, localized 
neuroinflammatory response that results in a delayed and selective loss of dopaminergic 
neurons in the SNpc. The dopaminergic degeneration usually starts within days of the LPS 
injection and is complete around two weeks (Liu et al., 2000b). Significantly, dopaminergic 
degeneration is evident up to a year later and appears to be permanent in this model (Herrera 
et al., 2000).  C57bl6 mice were stereotaxically injected with a single dose of 5 µg LPS into 
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the substantia nigra and sacrificed 14 days later, the time at which significant dopaminergic 
degeneration occurs in this model(Saijo et al., 2009). The SN tissue was dissected and probed 
for proteolytic activation of PKC using Western blotting and IP-kinase assays as described 
in our previous publications (Zhang et al., 2007a). As shown in Fig. 8B, mice that received 
saline injections did not show proteolytic activation of PKC in the SN, while in LPS-
injected mice, strong proteolytic activation of PKC was evident at 14 days. The PKC 
Western blots were reprobed for tyrosine hydroxylase to confirm accurate dissection of the 
substantia nigra region. As expected, the LPS-injected mice had decreased TH protein levels 
(Fig. 8B), indicative of the increased loss of dopaminergic neurons. We also used PKC 
immunoprecipitation-kinase assays with a histone substrate on nigral tissue samples from 
LPS- and saline-injected mice. In nigral tissues from LPS-injected mice; we detected 
substantially higher PKC kinase activity compared to saline injected controls (Fig. 8A), 
demonstrating that the proteolytic cleavage of PKC resulted in activation of the kinase in 
vivo. Equal protein loading and accurate dissection of the nigral region was confirmed by 
Western blotting for -actin and TH respectively. Together, these results demonstrate for the 
first time that protein kinase C can be activated by proteolytic cleavage in the substantia 
nigra during dopaminergic degeneration caused by LPS induced neurotoxicity 
Discussion 
In this study, we identify PKC as a novel signaling mediator of TNFα-induced 
neurotoxicity in dopaminergic neurons and demonstrate that proteolytic activation of PKC 
regulates dopaminergic degeneration induced by TNF. We also demonstrate for the first time, 
the proteolytic activation of PKC in the mouse substantia nigra by neuroinflammatory 
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mechanisms during LPS-induced dopaminergic degeneration. Previous reports from our 
laboratory and other independent research groups have shown that proteolytic activation of 
PKC in dopaminergic neurons is a common effector of apoptosis v induced by diverse 
neurotoxic stimuli that converge on the intrinsic mitochondrial apoptotic pathway primarily 
through intracellular oxidative stress mechanisms (Anantharam et al., 2002; Kaul et al., 2003; 
Yang et al., 2004; Latchoumycandane et al., 2005; Kanthasamy et al., 2006; Zhang et al., 
2007a; Hanrott et al., 2008; Sun et al., 2008; Cunningham et al., 2009). However, proteolytic 
activation of PKC by extrinsic apoptotic effectors has not been studied and would be 
relevant to the progressive loss of dopaminergic neurons resulting from chronic 
neuroinflammatory processes involving TNFα and other potentially neurotoxic mediators 
(Block et al., 2007; Whitton, 2007). Based on the substantial literature supporting a 
degenerative role for the TNFα during dopaminergic cell death in PD models, we 
hypothesized that PKC can be proteolytically activated downstream of canonical TNF death 
receptor signaling by caspase-3 in dopaminergic neurons. Since proteolytic cleavage of 
PKC typically results in persistent activation of the kinase as an apoptotic effector, we 
reasoned that blocking proapoptotic PKC signaling could protect against TNF toxicity.  
The results from our mechanistic studies using N27 rat dopaminergic cells demonstrate for 
the first time that soluble TNF induces a time- and dose-dependent proteolytic cleavage of 
PKC (Fig.  3A,B) by a caspase-8 and caspase-3 signaling pathway (Fig. 3C), indicative of 
canonical TNF death receptor signaling via caspase-8. Using the anti-TNF drug Etanercept 
and neutralizing antibodies to the TNFR1 (p55) death receptor, we show that proteolytic 
cleavage of PKC by soluble TNF is dependent on TNFR1 signaling and is accompanied by 
77 
 
 
a substantial increase in PKC kinase activity (Fig. 4A, B), typical of proteolytic activation. 
The subcellular localization of PKC following activation has been shown to be an important 
factor determining the pro or anti-apoptotic functions of this kinase in different model 
systems (DeVries-Seimon et al., 2007; Gomel et al., 2007). In particular, numerous studies 
have demonstrated that nuclear translocation of PKC is required for induction of apoptosis 
by diverse stimuli and is driven by a bipartite nuclear localization sequence at it’s C-terminus 
(DeVries-Seimon et al., 2007; Reyland, 2007; Humphries et al., 2008). On the other hand, 
proteins belonging to the TNF superfamily such as BAFF (B-cell-activating factor belonging 
to the TNF family) have been shown to prevent nuclear accumulation of PKC and thus 
prolong cell survival in B-cells (Mecklenbrauker et al., 2004). Our confocal 
immunofluorescence studies reveal a distinct localization of PKC to the nucleus 6 h  after 
TNF treatment, the time point at which maximum proteolytic cleavage of PKC was evident 
(Fig. 3A). Interestingly, while intense PKC staining is evident throughout the nucleus in 
TNF-treated cells, there is also a distinct pattern of accumulation PKC at specific sites 
around the peri-nuclear region and within the nucleus (shown as an inverse gray scale image 
in Fig. 5B). In our experience, this pattern of PKC nuclear localization is unique to TNF 
treatment and is not evident during nuclear translocation induced by other neurotoxicants 
such as MPTP, 6-OHDA or hydrogen peroxide in these cells. It is likely that PKC has 
unique substrates in and around the nucleus and functions differently during cell death 
induced by extracellular signals such as TNF. The substrates of PKC and the functional 
significance of these findings are currently under investigation in our laboratory. The kinetics 
of PKC proteolytic activation and it’s translocation to the nucleus in dopaminergic cells is 
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consistent with a proapoptotic role for PKC downstream of TNFα signaling in 
dopaminergic cell death. Indeed, suppressing total PKC protein levels using siRNA or 
blocking proteolytic activation using a PKC cleavage-resistant mutant (PKCD327A-CRM)  
affords robust protection against TNF toxicity in N27 cells (Fig. 6A,B). The results from our 
mechanistic experiments are further supported by our studies in primary mouse EVM 
neuronal cultures treated with soluble TNF, a more relevant model system for dopaminergic 
degeneration compared to immortalized cell lines. While TNF toxicity on primary 
dopaminergic neurons was mild compared to other neurotoxicants such as MPP
+ 
(Zhang et 
al., 2007a), we observed a substantial reduction in TH neuron numbers (Fig. 7A) and 
functional impairment using dopamine uptake studies (Fig. 7B) in cultures from PKC wild 
type (+/+) mice, consistent with previous reports (McGuire et al., 2001; McCoy et al., 2006). 
In contrast, dopaminergic neurons in EVM cultures obtained from PKC knockout (-/-) mice 
were protected against TNF toxicity, indicating that PKC signaling is essential for 
dopaminergic degeneration by the extrinsic cell death cascade triggered by TNF.  
Evidence from previous studies (McGuire et al., 2001; McCoy et al., 2006) and our 
own results here (Fig. 4A,B), indicate that TNF can induce dopaminergic neurotoxicity by a 
direct mechanism of action, possibly via the TNFR1 (TNFRSF1) death receptor, which has 
been shown to be highly expressed on these cells. However, several lines of evidence suggest 
that TNF can also contribute to dopaminergic degeneration indirectly by potentiating 
microglial activation and release of ROS or other neurotoxic mediators, that increase local 
oxidative stress levels in the SNpc (Sriram et al., 2006; Block et al., 2007; De Lella Ezcurra 
et al., 2010). Since TNF levels in the SNpc are elevated both in animal models and human 
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PD patients and given the concomitant microglial activation that is evident, it is likely that 
potentiation of microglial neurotoxic responses by TNF occurs in vivo, although it may not 
be the primary mechanism of dopaminergic neurotoxicity as shown by McCoy et al. (2006) 
using mixed neuron-glial cultures. With the plethora of important functions ascribed to TNF 
in the normal brain and given the pleotropic nature of this important cytokine, it is likely that 
neurotoxic TNF signaling is tightly regulated in the nigrostriatal system, and that TNF by 
itself may be insufficient to directly elicit dopaminergic degeneration in vivo, as shown by 
Castano et al. (2002). Rather, a chronic increase in TNF levels in the nigrostriatal system 
may drive the progressive loss of compromised, vulnerable dopaminergic neurons in the pro-
oxidant environment of the SNpc, both by TNF apoptotic signaling and by potentiation of 
microglial neurotoxic responses, including ROS and RNS (McGuire et al., 2001; McCoy et 
al., 2006; Block et al., 2007; Qin et al., 2007; De Lella Ezcurra et al., 2010). Nonetheless, our 
data demonstrating that PKC is proteolytically activated in the SNpc in the purely 
neuroinflammatory LPS model (Fig.8A,B) of PD implicates proapoptotic PKC signaling as 
a common downstream effector of dopaminergic cell death triggered by convergent 
neuroinflammatory mechanisms involving TNF and other neurotoxic mediators in vivo.  
Despite extensive research into the etiology of PD for several decades, a cogent basis 
for the selective vulnerability and substantial loss of SNpc dopaminergic neurons still 
remains elusive. The emerging consensus that PD results from complex interactions between 
environmental, genetic and cellular processes that induce dopaminergic cell death over time, 
(Sulzer, 2007; Obeso et al., 2010), highlights the multifactorial nature of the disease and 
underscores the importance of identifying therapeutic targets that are relevant across these 
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multiple mechanisms of disease pathogenesis. While oxidative stress, mitochondrial 
dysfunction and proteasomal impairment have been identified as causative factors that can 
trigger dopaminergic degeneration, reactive microgliosis and dysregulated 
neuroinflammation can sustain this process and result in progressive neurotoxicity (Block et 
al., 2007; Whitton, 2007; Glass et al., 2010). A wealth of evidence already supports a role for 
proteolytic activation and proapoptotic PKC signaling during dopaminergic cell death in PD 
models via proteasomal impairment, mitochondrial dysfunction and oxidative stress 
mechanisms. Further, pharmacological targeting of PKC with kinase or peptide inhibitors 
has shown efficacy in both in vitro and in vivo models of PD. (Kanthasamy et al., 2006; 
Zhang et al., 2007a). Our results from this study, provide exciting new evidence for PKC 
proapoptotic signaling during dopaminergic cell death induced by TNF and in LPS-induced 
dopaminergic degeneration in vivo by neuroinflammatory mechanisms. Together with 
previous studies, our results here suggest that proteolytic activation of PKC could be a 
common downstream target of multiple mediators of dopaminergic degeneration by both 
extrinsic and intrinsic cell death mechanisms, making it an attractive therapeutic target 
during the progressive phase of PD.  
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Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  TNF toxicity to N27 dopaminergic cells. (A) DNA fragmentation assay. N27 
dopaminergic cells were treated with TNF (30ng/ml) for 16 h or pretreated for 30 min with 
either Etanercept (5µg/ml) or the caspase-8 peptide inhibitor IETD-fmk (25µM), and 
processed for DNA fragmentation. Experiments were performed in triplicate; the raw values 
B 
A  
C 
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were normalized using protein concentration and expressed as percent control. TNF 
treatment significantly increased DNA fragmentation in N27 cells, which was attenuated by 
Etanercept or caspase-8 inhibition. (B) Visualization of TNF toxicity by Sytox fluorescence. 
N27 cells treated with TNF (30ng/ml), or pretreated with Etanercept (5µg/ml) were 
processed for Sytox green imaging after 16 h. Phase contrast and fluorescence images were 
acquired on the same fields from live cells after 20 min of incubation with the Sytox dye. 
Increased green fluorescence is evident with TNF treatment, indicative of cytotoxicity. (C) 
Quantitative estimation of Sytox fluorescence. Sytox fluorescence was quantified by 
measuring the fluorescence intensity using a plate reader. Data represent the group mean + 
SEM of six to eight individual readings.  Asterisks (***p<0.001 and **p<0.01) indicate 
significant differences between control cells and TNF treatments, or between TNF-treated 
cells and those pretreated with Etanercept or IETD-fmk. 
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Figure 2.  Activation of caspase-8 and caspase-3 in N27 cells by TNF treatment. (A) 
Western blot for active caspase-8. Lysates from N27 cells treated with different doses of 
TNF (10 to 30ng/ml) for 3 h were probed using a rabbit polyclonal antibody to caspase-8 that 
detects both procaspase-8 and the active form of the enzyme. TNF treatment induced a dose-
dependent increase of the active caspase-8 (p20) fragment. (B) Etanercept blocks TNF-
induced caspase-8 activation. Pretreatment with Etanercept (5µg/ml) for 30 minutes 
suppressed the activation of caspase-8 induced by TNF (30ng/ml) treatment in N27 cells. (C, 
D) Caspase-3 activity assay and western blot. Enzymatic assays for caspase-3 activity were 
performed using a fluorogenic peptide substrate (Ac-DEVD-AFC) on lysates from N27 cells 
treated with TNF (30ng/ml) for 6 h or pretreated with either Etanercept (5µg/ml) or the 
caspase-8 inhibitor IETD-fmk (25µM). Raw values were normalized using protein 
concentrations and expressed as percent control. TNF treatment induced significant 
activation of caspase-3 which was blocked by Etanercept and the caspase-8 inhibitor. 
Caspase-3 activation was also confirmed by western blotting (D). Data represent the group 
mean + SEM of six to eight individual readings. Asterisks (***p<0.001) indicates significant 
differences between controls and TNF-treated cells or TNF treated cells and pretreatment 
groups with Etanercept and IETD-fmk.  
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Figure 3.  TNF activates PKC by proteolytic cleavage downstream of  caspase-3 and 
caspase-8. (A) Time course of PKC activation. N27 cells were treated with recombinant 
TNF (30ng/ml) for 3 h  and 6 h and lysates were probed by Western blotting with an 
antibody to the C-terminus that detects both the native protein (78 kDa) and the 
proteolytically cleaved catalytic fragment (38 kDa). Actin was used as the loading control. 
TNF treatment caused a time-dependent increase in PKC cleavage which peaked at 6 h. (B) 
Dose-dependent proteolytic activation of PKC  by TNF treatment. N27 cells were treated 
with increasing doses of TNF (0 to 60ng/ml) for 6 h and lysates were probed for PKC 
protein levels by Western blotting. TNF induced a dose dependent increase in PKC 
cleavage stating at 10ng/ml. (C) Caspase-3 and caspase-8 dependent proteolytic cleavage of 
PKC. N27 cells were treated with 30ng/ml of TNF alone for 6 h or in the presence of 
peptide inhibitors (25µM) of caspase-8 (Ac-IETD-fmk) and caspase-3 (Ac-DEVD-fmk). 
Cells were collected and lysates were probed for PKC proteolytic cleavage by Western 
blotting. Proteolytic activation of PKC by TNF treatment was attenuated by inhibition of 
caspase-3 and caspase-8.  
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Figure 4.  Proteolytic cleavage of PKC downstream of TNF signaling persistently 
activates the kinase in dopaminergic N27 cells and is dependent on TNF-R1 (p55) 
signaling. (A) Western blot of proteolytic activation of PKC in TNF-treated N27 cells. N27 
cells were treated with TNF (30ng/ml) for 6 h or pretreated with either a TNFR1 neutralizing 
antibody (p55-nAb, 20 µg/ml) or Etanercept (5µg/ml) for 30 minutes and lysates were 
probed for PKC proteolytic cleavage by Western blotting. TNF induced strong proteolytic 
cleavage of PKC which could be blocked by neutralizing TNFR1 receptor signaling. (B) 
Immunoprecipitation-kinase assay for PKC activation. IP-kinase assays were performed on 
the same cell lysates used for Western blots. PKC was immunoprecipitated from 500µg of 
total protein from each sample and used for the in vitro kinase activity assay with a histone 
substrate and radiolabeled [γ-32P] ATP. PKC activity was quantified using densitometric 
analysis of the 
32
P-histone band intensity and expressed as percent of control samples. As 
seen, the proteolytic cleavage of PKC induced by TNF treatment (A) is accompanied by a 
concomitant increase in kinase activity and is dependent on signaling through the p55 
TNFR1 receptor (B). A representative kinase assay gel is shown. Data represent the group 
mean + SEM of densitometric values obtained from three independent experiments. Asterisks 
(***p<0.001, ** p<0.01) indicate significant differences between control and TNF-treatment 
groups or between TNF treatment and pretreatment groups with Etanercept or TNFR1 
neutralizing antibody (TNFR1-nAb).  
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Figure 5.  PKC translocates to the nucleus during TNF treatment. (A) Confocal 
imaging of PKC localization. (A )N27 cells were treated with TNF for 6 h and processed 
for immunocytochemistry using a rabbit polyclonal PKC antibody to the C-terminus of the 
protein that detects the native and proteolytically cleaved form. An Alexa-488 dye-tagged 
secondary antibody was used to visualize PKC (green) and the nucleus was stained using 
the TOPRO-3 dye (blue). In untreated controls (top panel), PKC was almost completely 
localized to the cytosol with no evident nuclear localization as seen in the merged images and 
the XY-plane spatial intensity plots of the green and blue channels. In TNF-treated cells 
(lower panel), a distinct localization of PKC to the nucleus and the peri-nuclear region is 
readily apparent. (B) Inverse grey scale image of PKC immunofluorescence staining in 
TNF-treated cells showing PKC accumulation at distinct spatial locations at the perinuclear 
region (red arrows).  
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Figure 6.  siRNA knockdown of PKC or overexpression of the PKC proteolytic 
cleavage-resistant mutant (PKCD327A-CRM) protects against TNF toxicity. (A) DNA 
fragmentation assay in siRNA transfected cells. N27 cells transfected with either siRNA to 
PKC or scrambled control siRNA were treated with TNF for 16 h and processed for the 
DNA fragmentation assay to quantify cell death. Suppression of the PKC protein level was 
confirmed by Western blotting (B). TNF-induced DNA fragmentation was significantly 
reduced in PKC siRNA transfected cells confirming the pro-apoptotic role of this kinase. 
(C) DNA fragmentation assay in N27 cells over expressing the cleavage-resistant PKC 
mutant protein (PKCD327A-CRM). N27 stably expressing the cleavage-resistant PKC 
mutant or the β-galactosidase (LacZ) control gene were treated with TNF for 16 h  and 
processed for the DNA fragmentation assay to quantify cell death. Expression of the mutant 
PKC protein was confirmed by imaging the V5 tag by immunocytochemistry (D). DNA 
fragmentation induced by TNF was reduced in N27 cells expressing the caspase-3 cleavage-
resistant mutant protein, indicating the proteolytic cleavage is a necessary event for TNF 
toxicity in these cells. Data represent the group mean + SEM of at least six individual 
readings.  Asterisks (***p<0.001) indicate significant differences between TNF-treated 
groups in scramble siRNA or lacZ expressing cells and PKC siRNA or cleavage-resistant 
mutant expressing cells respectively.  
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Figure 7.  Primary dopaminergic neurons in EVM cultures from PKC knockout mice 
are protected against TNF toxicity. Primary mouse EVM neuronal cultures (>95% free of 
glial cells) were treated with recombinant TNF (30ng/ml) in supplement-free neurobasal 
medium. TNF was re-added 24 h  later for a total treatment time of 48 h. PKC wild type 
(PKC +/+) and knockout (PKC -/-) EVM cultures were treated in parallel under identical 
conditions. (A-C) TH-positive neuron counts and neurotransmitter uptake assays. 
Dopaminergic neurons were identified by tyrosine hydroxylase labeling and the number of 
TH-positive neurons from 8 random fields per well were counted at 20X magnification for 
each treatment group. Data from 3 independent experiments were combined and expressed as 
percent control (A). The uptake of tritiated [3H] dopamine was determined in TNF-treated 
cultures from PKC WT and knockout mice. The values for non-specific uptake of dopamine 
obtained in the presence of mazindol were subtracted as background and the data expressed 
as percent control (B). Combined data from three independent experiments is shown. GABA 
uptake was also determined in wild type cultures to verify if TNF was toxic to other cell 
populations under these treatment conditions. (C). Dopamine uptake and TH-positive neuron 
counts were significantly reduced with TNF treatment in cultures obtained from PKC 
wildtype (+/+) mice while cultures from PKC knockout (-/-) mice were resistant to TNF 
toxicity.  No significant changes in GABA uptake were observed. Data represent the group 
mean + SEM of three experiments.  Asterisks (***p<0.001, **p<0.01 and *p<0.05) indicate 
significant differences between control and TNF-treated groups in PKC wild type cultures, 
and also between TNF treatments from PKC wildtype (+/+) and PKC knockout (-/-) 
cultures. (D) Immunocytochemistry for TH-positive neurons. Dopaminergic neurons were 
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identified by tyrosine hydroxylase staining (green) and MAP-2 (red) was used as a pan-
neuronal marker. Images were acquired at 20X magnification. Representative fields are 
shown for each treatment. Untreated cultures from both WT and knockout mice (top panel) 
displayed normal morphology and had similar numbers of dopaminergic neurons.  In TNF-
treated groups (lower panel), extensive loss of neurites and degeneration of dopaminergic 
neurons is evident in cultures from PKC wildtype (+/+) mice while cultures from PKC 
knockout (-/-) mice have visible branched neurites (red arrows), more numerous cell bodies 
and are resistant to degeneration induced by TNF, consistent with the established role of this 
kinase in apoptosis.  
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Figure 8.  Proteolytic activation of PKC in the mouse substantia nigra  during LPS-
induced dopaminergic degeneration. (A) PKC kinase activity in mouse substantia nigra 
tissue.  C57BL/6 mice were stereotaxically injected with a single dose of LPS (5 µg) in the 
SN to elicit dopaminergic degeneration. Mice were sacrificed after 14 days and PKC IP-
kinase assays were performed on nigral tissue lysates. The kinase activity was quantified by 
densitometric analysis of the 32P-Histone bands. Western blots of tyrosine hydroxylase and -
actin were performed on the same lysates to verify accurate dissection of the nigral tissue and 
protein loading respectively. Significantly higher PKC kinase activity was evident in nigral 
tissues obtained from LPS-injected mice compared to saline controls. Experiments were 
repeated three times and representative blots are shown (B) Proteolytic cleavage of PKC in 
mouse substantia nigra tissue. To determine if the increased PKC kinase activity was a 
result of proteolytic activation, Western blots were performed on nigral tissue lysates 
obtained from mice injected with either LPS or saline as control. Increased proteolytic 
cleavage of PKC was evident in LPS-injected mice and was essentially absent in the saline-
injected group. Blots were also probed for tyrosine hydroxylase and -actin to confirm 
accurate dissection of the nigral tissue and equal protein loading. Experiments were repeated 
3 times and representative blots are shown. Data represent the group mean + SEM.  Asterisks 
(**p<0.01) indicate significant differences between saline and LPS-injected mice.  
 
 
 
 
107 
 
 
CHAPTER III 
 
PROTEIN KINASE C IS INDUCED IN ACTIVATED MICROGLIA AND 
REGULATES MICROGLIAL NEUROTOXICITY AND DOPAMINERGIC 
DEGENERATION IN PARKINSON’S DISEASE MODELS 
 
A manuscript communicated to The Journal of Neuroscience 
Richard Gordon,  Anamitra Ghosh, Colleen Hogan, Arthi Kanthasamy, Vellareddy 
Anantharam & Anumantha G. Kanthasamy 
 
Abstract 
Several lines of evidence suggest that chronic microglial activation and 
neuroinflammation can contribute to the progressive degeneration of dopaminergic neurons 
initiated by oxidative stress and other neurotoxic mechanisms in Parkinson’s disease (PD). In 
this study we identify that protein kinase C (PKC), a member of the novel PKC family, is 
highly induced in activated microglia and regulates microglial proinflammatory responses. 
PKC mRNA and protein expression is increased in activated primary microglia and BV-2 
cells with a concomitant increase in kinase activity. PKC showed distinct intracellular 
localization in activated microglia that appears to be stimulus-specific. Further, primary 
microglia isolated from PKC knockout mice have reduced cytokine and chemokine 
production, nitric oxide generation and intracellular ROS responses compared to microglia 
from wild-type mice. PKC knockout mice show a dramatic recovery from LPS-induced 
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systemic inflammation and sickness behavior along with reduced levels of TNFα and other 
proinflammatory cytokines in the substantia nigra, demonstrating a crucial role for PKC in 
regulating neuroinflammatory responses. In the MPTP model of PD, PKC knockout mice 
had reduced microglial activation and oxidative stress levels in the substantia nigra. 
Significantly, PKC knockout mice showed robust protection against MPTP-induced 
nigrostriatal dopaminergic degeneration and motor deficits. Taken together, our findings 
identify PKC as a novel regulator of microglial activation and neuroinflammatory 
processes, and demonstrate that therapeutic targeting of PKC could be useful to mitigate 
progressive nigrostriatal dopaminergic degeneration in PD.  
 
Introduction 
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder 
affecting around 2% of the population over the age of 60 (Moore et al., 2005; Schapira, 
2009). The pathological hallmark of PD is a selective loss of dopaminergic (DA) neurons in 
the substantia nigra of the midbrain resulting in a depletion of striatal dopamine that is 
clinically manifest as a range of motor and nonmotor symptoms (Obeso et al., 2010). 
Sustained microglial activation and neuroinflammation in the SNpc is evident in PD patients 
and animal models of the disease, being initiated early during dopaminergic degeneration and 
still apparent in postmortem PD patients (Block et al., 2007; Hirsch and Hunot, 2009; Glass 
et al., 2010; Tansey and Goldberg, 2010). Compelling evidence from human, animal and 
epidemiological studies now support a role for neuroinflammatory mechanisms in the 
pathogenesis and progression of Parkinson’s disease with both the innate and adaptive arms 
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of the immune system being involved.  (Wu et al., 2002; Benner et al., 2004; Ghosh et al., 
2007a; Brochard et al., 2009; Appel et al., 2010; Tansey and Goldberg, 2010). However, 
little is known about the process by which microglial cells escape regulatory control and 
become persistently activated in the disease state and contribute to the slow progressive 
degeneration of dopaminergic neurons. Microglial NADPH oxidase has been shown to be 
involved in generation of free radicals in the substantia nigra and can exacerbate 
dopaminergic degeneration by augmenting local oxidative stress levels (Wu et al., 2002; Wu 
et al., 2003). Similarly, NFB activation in microglia has been shown to be a critical 
regulator of the microglial neurotoxic response by mediating proinflammatory cytokine 
levels and the regulation of iNOS activity in the substantia nigra (Ghosh et al., 2007a). 
However the intracellular signaling pathways involved in regulating sustained microglial 
activation during dopaminergic degeneration remain to be established and could provide 
potential targets to slow the progression of the disease.  
Protein kinase C (PKC), a member of the novel PKC isoform family, is highly 
expressed by dopaminergic neurons in the SNpc, primary neurons and by dopaminergic cell 
lines (Zhang et al., 2007b).  Recent studies from our laboratory and others have shown that 
PKC is proteolytically activated by caspase-3 during dopaminergic cell death and that 
genetic or pharmacological targeting of PKC can protect against dopaminergic degeneration 
in PD models (Anantharam et al., 2002; Kaul et al., 2003; Zhang et al., 2007a; Hanrott et al., 
2008). However, PKC has also been shown to regulate inflammatory responses and immune 
signaling in peripheral immune cells including neutrophils, B cells and macrophages 
(Tepperman et al., 2000; Bey et al., 2004; Mecklenbrauker et al., 2004; Carpenter and 
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Alexander, 2008; Kilpatrick et al., 2010). Therefore, we hypothesized that PKC could be 
involved in the microglial activation and thereby regulate the neuroinflammatory response. 
We tested our hypothesis using microglia isolated from PKC knockout mice and in vivo 
using the systemic LPS model and the classic MPTP mouse model of PD.  
Our findings herein identify a novel function for native full-length PKC signaling in 
microglial cells. We demonstrate that PKC is highly induced in activated microglia and 
regulates the microglial proinflammatory response and nigrostriatal dopaminergic 
degeneration in vivo. Given that critical components of the microglial activation machinery, 
including NFB, NADPH and iNOS, are known substrates of PKC, our findings have 
profound implications for targeting the microglial neuroinflammatory response to mitigate 
progressive nigrostriatal dopaminergic degeneration in PD.   
 
Materials and methods 
Chemicals and Reagents  
DMEM/F-12, RPMI, fetal bovine serum, L-glutamine, IR-dye tagged secondary 
antibodies, Hoechst nuclear stain, penicillin, and streptomycin and other cell culture reagents 
were purchased from Invitrogen (Gaithersburg, MD). Recombinant TNFα was purchased 
from Peprotech (Rocky Hill, NJ), LPS (E. coli 0111:B4) was purchased from Sigma and 
recombinant human alpha synuclein was purchased from rPeptide Inc (Bogart, GA). 
Aggregation of alpha synuclein was performed according to previously published procedures 
(Zhang et al., 2005) by incubating the purified recombinant protein at room temperature with 
agitation for 7 days. The formation of alpha synuclein aggregates was verified by 
111 
 
 
transmission electron microscopy (Supplementary Figure1). Antibodies for rabbit PKC, 
GRP-78 and NOS2 were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mouse TH 
antibody was purchased from Chemicon (Temecula, CA) and rabbit Iba1 antibody was from 
Wako Chemicals (Richmond, VA). 
32
P-ATP was purchased from Perkin Elmer (Boston, 
MA) and the histone substrate from Sigma.  The Bradford protein assay kit was purchased 
from Bio-Rad Laboratories (Hercules, CA).   
Animal studies  
The generation and maintenance of PKC delta knockout mice is described in our 
previous publications (Zhang et al., 2007b). Mice were genotyped as per previously 
published protocols (Miyamoto et al., 2002). Wild-type C57Bl/6 mice and PKCδ knockout 
mice were housed under standard conditions of constant temperature (22 ± 1°C), humidity 
(relative, 30%), and a 12 h light/dark cycle with free access to food and water ad libitum. Six 
to eight week old mice were used for all studies. The well-characterized acute MPTP mouse 
model of PD (Wu et al., 2003; Przedborski et al., 2004; Kim et al., 2007; Hu et al., 2008) was 
primarily used for neuroinflammation and neuroprotection studies. The mice from the MPTP 
treatment group received 4 i.p. injections of MPTP-HCl (18 mg/kg free base) dissolved in 
saline at 2-h intervals and control mice received saline injections. The mice were sacrificed 1 
to 7 days after the last injection. The nigral neuroinflammatory response was also studied 
using the systemic LPS injection model (Qin et al., 2007) that has been shown to induce 
chronic neuroinflammation and progressive dopaminergic degeneration in mice. A single 
injection of LPS (5 mg/kg, i.p.) was delivered to PKCδ wild-type and knockout mice. 
Control groups received equivalent injections of saline. Mice were sacrificed 24 to 48 h later. 
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All animal procedures were approved by the Iowa State University Institutional Animal Care 
and Use Committee (IACUC).  
Primary microglial cultures and treatments 
Primary microglial cultures were prepared from C57BL/6 postnatal day 1 (P1) mouse 
pups. The mouse brains were harvested, meninges removed, and then placed in  Dulbecco’s 
modified Eagle’s medium/F-12 nutrient media (DMEM-F12,GIBCO Cat # 11320) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 50 U/mL penicillin, 50 
μg/mL streptomycin, 2 mM L-glutamine, 100 μM non-essential amino acids, and 2 mM 
sodium pyruvate (Invitrogen). The brain tissue was then incubated in 0.25% trypsin for 30 
min with gentle agitation. The trypsin reaction was stopped by adding an equal volume of 
DMEM/F12 complete medium and the brain tissue was washed 3 times. The tissue was then 
triturated gently to prepare a single cell suspension and then passed through a 70 μm nylon 
mesh cell strainer to remove tissue debris and aggregates. The cell suspension then was made 
up in DMEM/F12 complete medium and seeded into T-75 flasks. The cells were placed in 
humidified CO2 incubator at 37°C, the medium was changed after 4 to 5 days and the mixed 
glial cells were grown to confluence. Microglial cells were separated from confluent mixed 
glial cultures by differential adherence and magnetic separation to >97% purity as described 
in our recent publication (Gordon et al., 2011). Microglia were allowed to recover for at least 
48 hours after plating. Primary microglia were treated in DMEM/F12 complete medium 
containing 2% FBS. 
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Lentiviral transduction of primary microglia and shRNA knockdown of PKCδ 
Lentiviral transduction and knockdown of PKCδ in primary microglia was performed 
according to previously published reports (Takahashi et al., 2005) with some modifications. 
Pre-validated lentiviral particles expressing PKCδ-specific shRNA was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA) (catalog # sc-36246-V) along with non-specific 
control shRNA lentiviral particles (catalog # sc-108080). Titers of the viral particles were 
around 10
6
 multiplicity of infection. Purified microglial cells were seeded at 3 x 10
5
 cells/ml 
into 24-well plates and allowed to attach overnight. The next day, lentiviral particles and 5 
μg/ml of polybrene (Millipore Inc.) were added to the culture and centrifuged for 60 min at 
30°C. The plates were further incubated for 3 h at 37°C before removing the supernatant 
containing the viral particles and replacing with complete DMEM/F12 medium containing 
10% FBS. The efficiency of transduction was around 90% as determined by GFP expression 
48 h later and all treatments were performed at this time point. Lentiviral shRNA knockdown 
of the PKCδ protein in primary microglia was confirmed by Western blotting using a rabbit 
polyclonal antibody.  
Immunohistochemistry and Immunofluorescence studies 
Mice were deeply anesthetized with ketamine/xylazine mixture and then perfused 
transcardially with freshly prepared 4% PFA. Brains were removed, postfixed in PFA for 48 
h and 20 micron sections were cut using a freezing microtome (Leica Microsystems). Section 
from the substantia nigra and other regions of interest were processed for 
immunohistochemistry. Antigen retrieval was performed by heating the free-floating sections 
in citrate buffer (10mM sodium citrate, pH 8.5) for 30 minutes at 90°C. Sections were then 
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washed several times in PBS and blocked with PBS containing 2% BSA, 0.2% TritonX-100 
and 0.05% tween-20 for 2 h at room temperature. Sections were then incubated with 
antibodies directed against PKCδ (rabbit polyclonal, 1:500) and TH (mouse monoclonal, 
1:2000) overnight at 4°C and washed several times in PBS. The sections were incubated with 
Alexa dye-conjugated secondary antibodies for 1 h at room temperature and added then 
stained with Hoechst dye. Sections were mounted on slides using prolong antifade gold 
mounting medium (Invitrogen) according to the manufacturer’s instructions. Samples were 
visualized using a Nikon inverted fluorescence microscope (TE-2000U) and images were 
captured using a spot digital camera (Diagnostic Instruments Inc, Sterling Heights, MI) 
PKCδ immunofluorescence in primary microglia was performed according to previously 
published protocols with some modifications. Briefly, microglial cells were grown on poly-
D-lysine coated coverslips and treated 48 h later. At the end of treatments, cells were fixed 
with 4% paraformaldehyde, washed in PBS and incubated in blocking buffer (PBS 
containing 2% BSA, 0.5% TritonX and 0.05% Tween) for 1 h at room temperature. The 
coverslips were then incubated overnight at 4°C with respective primary antibodies diluted in 
PBS containing 2% BSA. Samples were then washed several times in PBS and incubated 
with Alexa dye-conjugated secondary antibodies. The nucleus was labeled with Hoechst stain 
(10 μg/ml) and coverslips were mounted with Fluoromount medium (Sigma Aldrich) on 
glass slides for visualization.  
qRT-PCR for gene expression analysis 
RNA isolation from primary microglial cells and brain tissue samples was performed 
using the Absolutely RNA Miniprep Kit and 1 μg of total RNA was used for reverse 
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transcription with the AffinityScript qPCR cDNA synthesis system (Agilent Technologies) 
according to the manufacturer’s instructions. Quantitative SYBR Green real-time PCR assays 
for PKCδ and proinflammatory cytokine gene expression analysis was performed using the 
RT² SYBR Green Master Mix with prevalidated qPCR primers (SA biosciences qPCR assay 
system) Catalog numbers of the primers were PKCδ - PPM03810E, IL1β - PPM03109E, 
IL12 - PPM03020E, TNFα - PPM03113F and iNOS - PPM02928B. The mouse 18SrRNA 
gene (catalog number - PPM57735E) was used as the housekeeping gene for normalization. 
For each primer, the amount of template which provided the maximum efficiency without 
inhibition of the PCR reaction was determined during initial optimization experiments. For 
all experiments, dissociation curves were run according to the manufacturer’s instructions 
and melting curve analysis was performed to ensure a single peak was obtained at the right 
melting temperature without non-specific amplicons. The fold change in gene expression was 
determined by the ΔΔCt method using the threshold cycle (Ct) value for the housekeeping 
gene and for the respective target gene of interest for each sample. 
Western blotting 
Brain tissue and microglial cell lysates were prepared using a modified RIPA buffer 
and normalized for equal amounts of protein using the BCA protein assay kit (Pierce 
Biotechnology). Equal amounts of protein (30 to 50 µg) were loaded for each sample and 
separated on either 12% or 15% SDS-PAGE gels depending on the molecular weight of the 
target protein. After separation, proteins were transferred to a nitrocellulose membrane and 
the nonspecific binding sites were blocked for 1 h using a blocking buffer specifically 
formulated for fluorescent Western blotting (Rockland Immunochemicals) and then probed 
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with the respective primary antibodies overnight at 4°C.  After incubation the membranes 
were washed 3 times with PBS containing 0.05% Tween and IR-dye tagged secondary 
antibodies (1:5000 Molecular Probes) were added and the membranes visualized on the 
Odyssey infrared imaging system. Primary antibodies used were rabbit polyclonal PKC 
(1:500), mouse monoclonal TH (1:2000), rabbit polyclonal iba1 (1:200), mouse monoclonal 
gp91 PHOX (1:2000) and rabbit iNOS (1:250). Beta Actin and Tubulin (1:5000) were used 
as loading controls.  
PKC immunoprecipitation-kinase assays 
PKCδ IP kinase activity assays were performed as described previously (Anantharam 
et al., 2002; Kaul et al., 2005; Zhang et al., 2007a) with some modifications. Briefly, primary 
microglia or BV-2 cells were collected after treatments, washed in ice cold PBS and 
resuspended in a mild RIPA lysis buffer containing protease and phosphatase inhibitor 
cocktail (Pierce Biotechnology).The lysates were then centrifuged at 13,000 rpm for 45 min. 
The supernatant was collected and protein concentration determined using the Bradford assay 
(Bradford, 1976). Protein concentration was normalized and 500 µg of total protein in a 250 
µl reaction volume was immunoprecipitated overnight at 4°C using 5 μg of PKCδ antibody. 
The next day, protein-A agarose beads (Sigma-Aldrich) were added and the samples 
incubated for 1 h at room temperature. The protein A-bound antibody complexes were 
collected and  washed 3 times in 2X kinase assay buffer (40 mM Tris, pH 7.4, 20 mM 
MgCl2, 20 μM ATP, and 2.5 mM CaCl2), and then resuspended in the same buffer. The 
kinase reaction was started by adding 40 μl of the reaction buffer containing 0.4 mg of 
histone H1, 50 μg/ml phosphatidylserine, 4 μM dioleoylglycerol, and 10 μCi of [γ-32P] ATP 
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at 3000 Ci/mM to the immunoprecipitated samples. The samples were then incubated for 10 
min at 30°C and the kinase reaction stopped by adding 2X SDS loading buffer and boiling 
for 5 min. Proteins were separated on a 15% SDS-PAGE gel and phosphorylated histone 
bands were imaged on a Fujifilm FLA 5000 imager. Image analysis and band quantification 
was performed using the Fujifilm Multigauge software package.  
Microglial nitric oxide detection  
Nitric oxide production by primary microglia was measured indirectly by quantification of 
nitrite in the supernatant using the Griess reagent (Sigma Aldrich). Magnetically separated 
microglia were plated in poly-D-lysine coated 96-well plates at 10
5
 cells per well. Cells were 
treated with 100 ng/mL LPS for 24 h and 100 μL of supernatant was collected from each well 
and an equal volume of the Griess reagent was added. The samples were incubated on a plate 
shaker at room temperature for 15 min until a stable color was obtained. The absorbance at 
540 nm was measured using a Synergy 2 multi-mode microplate reader (BioTek Instruments) 
and the nitrite concentration determined from a sodium nitrite standard curve. 
Multiplex cytokine and chemokine Luminex immunoassays 
Primary microglia were obtained from PKCδ wild-type and knockout mice on the 
same day and seeded in poly-D-lysine coated 96-well plates at 0.5 x 10
5
 cells per well. The 
cells were treated for 24 h with 100 ng/mL LPS, 30 ng/ml TNF or 300 nM aggregated alpha 
synuclein. After treatment, 50 µL of supernatant from each well was collected and frozen at -
80°C. The levels of cytokines and chemokines in the supernatants were determined using the 
Luminex bead-based immunoassay platform (Vignali, 2000) using pre-validated multiplex 
118 
 
 
kits (Milliplex mouse cytokine and chemokine panels – Millipore Corporation) according to 
the manufacturer’s instructions 
Intracellular reactive oxygen species (iROS) detection 
Intracellular reactive oxygen species (iROS) were determined using the fluorescent 
probe 2’,7’-dichlorodi-hydrofluorescein diacetate (DCFH-DA) (Calbiochem), according to 
previously published reports (Zhang et al., 2005; Qian et al., 2007). Magnetically separated 
microglia from PKCδ wild-type and knockout mice were plated at 105 cells per well in 96-
well plates and allowed to attach overnight. Before treatment, cells were washed in HBSS 
and incubated with 40 µM DCFH-DA in HBSS containing 2% FBS for 30 min. Cells were 
then treated with 100 ng/mL LPS, 30 ng/mL of recombinant mouse TNF alpha or 300 nM 
aggregated alpha synuclein.  for 6 h. The fluorescence intensity was determined using a 
Synergy-2 multi-mode microplate reader at an excitation of 485/20 nm and an emission of 
530/25 nm. The fluorescence value from the control cultures was subtracted as background 
and the increase in fluorescence with treatments was expressed as increased iROS as 
previously described (Zhang et al., 2005; Qian et al., 2007). 
Tyrosine hydroxylase (TH) immunostaining and stereological counting of TH positive 
neurons   
TH- diaminobenzidine (DAB) immunostaining was performed on striatal and 
substantia nigral sections as described previously (Ghosh et al., 2010). Briefly, PKCδ wild-
type and knockout mice were injected with MPTP or saline and sacrificed 7 days after 
treatment. The mice were perfused with 4% paraformaldehyde (PFA) and brains were post-
fixed with PFA for 48 h before storage in 30% sucrose. Frozen blocks were prepared from 
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the fixed brains and were cut using a cryostat into 30 µm coronal sections. Sections were 
probes with an anti-TH antibody (Calbiochem; rabbit anti-mouse, 1:1600) overnight at 4C 
and then incubated with biotinylated anti-rabbit secondary antibody. The sections were then 
treated with Avidin peroxidase (Vectastatin ABC Elite kit). The DAB reagent provided with 
the kit was used for producing the brown colored stain. The total number of TH-positive 
neurons in SNpc was counted by unbiased stereology using the Stereo Investigator software 
(MicroBrightField, Inc., Williston, VT) and the optical fractionator method as described in 
our previous publications (Ghosh et al., 2007b; Ghosh et al., 2010) 
HPLC analysis of striatal dopamine and its metabolite levels   
The amount of striatal dopamine (DA) and its metabolites (DOPAC and HVA) was 
quantified by high-performance liquid chromatography (HPLC) with electrochemical 
detection as described previously (Zhang et al., 2007 and Ghosh et al., 2010). Briefly, 7 days 
after the last MPTP injection, PKCδ wild-type and knockout mice were sacrificed and striata 
were collected, weighed and stored at -80C. Neurotransmitters from striatal tissues were 
extracted in a 0.1 M perchloric acid solution containing 0.05% Na2EDTA and 0.1% Na2S2O5) 
and isoproterenol (used as an internal standard). Extracts were filtered in 0.22 µm spin tubes, 
and 20 µl of the sample was loaded for analysis.  Dopamine, DOPAC and HVA were 
separated isocratically in a reversed-phase column using a flow rate of 0.7 ml/min. An HPLC 
system (ESA Inc., Bedford, MA, USA) with an automatic sampler equipped with a 
refrigerated temperature control (model 542; ESA Inc.) was used for all experiments. The 
electrochemical detection system consisted of a Coulochem model 5100A with a 
microanalysis cell (model 5014A) and a guard cell (model 5020) (ESA Inc.). Standard 
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catecholamine stock solutions of 1 mg/ml were prepared in perchloric acid solution and 
further diluted to a final working concentration of 50 pg/µl prior to injection. All data 
acquisition and analysis were performed using the EZStart HPLC Software (ESA Inc.).  
Behavioral studies and locomotor activity measurements  
Five days after MPTP treatment, wild-type and knockout mice were tested for 
behavioral parameters and locomotor activity. An automated instrument (AccuScan, model 
RXYZCM-16, Columbus, OH, USA) was used to monitor the locomotor activity of mice. 
The activity chamber was 40×40×30.5 cm in dimensions, made of clear Plexiglas and 
covered with a Plexiglas lid with ventilation holes. Infrared monitoring sensors were located 
every 2.54 cm along the perimeter (16 infrared beams along each side) and 2.5 cm above the 
floor. Two additional sets of 16 sensors were located 8.0 cm above the floor on opposite 
sides. Prior to any behavioral studies, mice were placed inside the infrared monitor for 5 min 
daily for 3 consecutive days to train them. The various locomotor activity parameters were 
determined simultaneously over a 10 min testing session and were presented as horizontal 
movement, vertical movement, total distance travelled (cm), total movement time, and 
rearing activity. Data was collected and analyzed by a VersaMax Analyzer (AccuScan, 
model CDA-8, Columbus, OH).     For Rotarod performance analysis, a 20 rpm speed setting 
was used to monitor the foot movement of mice as described in our previous publication 
(Ghosh et al., 2010). A total of 6 trials per mouse was performed and mice were given a 7-10 
min rest interval between trials.   
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Data analysis  
Data analysis was performed using the Prism 4.0 software package (GraphPad Software, San 
Diego, CA). The data was first analyzed using one-way ANOVA and then Bonferroni's post-
test was performed to compare all treatment groups. Differences of p<0.05 were considered 
statistically significant. The Student's t-test was used when differences between two groups 
were being compared. 
 
Results 
Protein Kinase Cδ is highly induced during microglial activation 
Sustained nigral neuroinflammation and reactive microgliosis are evident in 
Parkinson's disease (PD) patients and all animal models of the disease and believed to 
contribute to disease pathogenesis by driving progressive dopaminergic neuron loss. Previous 
studies from our laboratory and other independent research groups have shown that 
proteolytic activation of PKC occurs in  dopaminergic neurons and that therapeutic 
targeting of PKC can provide neuroprotection in the mouse MPTP model of PD 
(Anantharam et al., 2002; Kanthasamy et al., 2003; Kaul et al., 2003; Zhang et al., 2007a; 
Hanrott et al., 2008; Sun et al., 2008; Cunningham et al., 2009). Since reactive microgliosis is 
apparent in PD patients and animal models of the disease, we tested if PKC could play a 
role in microglial activation. Using an antibody directed against the C-terminus of the protein 
we initially determined if PKC proteolytic activation occurs in primary microglia and BV-2 
cells using various activation stimuli relevant to PD. Surprisingly, we did not detect 
proteolytic cleavage of PKC during microglial activation in any of the treatments. Instead, 
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to our surprise, we found that the native full length PKC protein is highly induced with 
sustained microglial activation (Fig.1). In primary microglia, the full length PKC protein 
was upregulated following microglial activation with LPS and aggregated alpha synuclein 
(Fig. 1A). In BV-2 microglial cells, a commonly used microglial cell line, we observed 
significant induction of PKC following stimulation with LPS and TNFα. Further, active 
MMP-3, a protease released from degenerating dopaminergic neurons which activates 
microglia (Kim et al., 2005; Kim et al., 2007), also induced significant induction of PKC 
protein levels in BV-2 cells (Fig. 1C). To validate our Western blot results for PKC 
induction at the gene level, we did qRT-PCR experiments for changes in PKC gene 
expression levels in primary microglia stimulated with LPS, TNF and aggregated alpha 
synuclein for 24 h.  We observed significant increases (threefold to sixfold) in PKC gene 
expression in activated microglia. In primary microglial cells, TNFα caused the highest 
increase in PKC mRNA levels followed by LPS and aggregated alpha synuclein. Together, 
these results demonstrate for the first time that the PKC gene and protein levels are both 
increased in activated microglial cells. To validate our preliminary findings from primary 
microglia in vivo, we used two well characterized mouse models relevant to 
neuroinflammation and PD: the classic MPTP model (Czlonkowska et al., 1996; Du et al., 
2001; Wu et al., 2003; Przedborski et al., 2004) and the more recent single dose systemic 
LPS model (Cunningham et al., 2005; Qin et al., 2007). In both the acute MPTP model and 
the systemic LPS model, a strong microglial activation response is observed 24 to 48 h after 
treatment (Wu et al., 2003; Qin et al., 2007) in the mouse substantia nigra. Therefore, we 
determined the changes in PKC gene expression levels by qRT-PCR at the 24 h time point 
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in nigral tissue obtained from MPTP and LPS-injected mice. In agreement with our in vitro 
results we observed around a ninefold increase with the MPTP model and around fivefold 
increase with LPS treatment in PKC mRNA levels in the mouse substantia nigra (Fig. 1E). 
Collectively these results demonstrate that PKC is induced during microglial activation and 
could play an important role in regulating the microglial neuroinflammatory response. 
PKC kinase activity is increased in activated microglia 
Having confirmed that the full length PKC protein was being induced during 
sustained microglial activation, we determined if there was a concomitant increase in PKC 
kinase activity. Since PKC is member of the novel PKC family (PKCs :, ε,ε, ζ) it does not 
require calcium for activation, although lipid cofactors such as DAG are necessary for 
maximum kinase activity. Further, we did not detect a proteolytically cleaved PKC 
fragment in activated microglia suggesting that classical full length PKC activation 
mechanisms involving multiple priming phosphorylations at the activation loop may be 
involved (Steinberg, 2004). We used PKC immunoprecipitation-kinase assays with a 
histone substrate and 
32
P-ATP to measure the kinase activity of PKC in primary microglia 
and BV-2 cells activated with LPS, TNFα and aggregated alpha synuclein. In unstimulated 
primary microglial cells we observed only low levels of basal PKC kinase activity, however 
upon stimulation with LPS, TNFα or aggregated alpha synuclein there was a sharp increase 
in PKC kinase activity (Fig. 2A). The increase in PKC kinase activity followed a similar 
trend as the mRNA levels (Fig. 1D) with TNF having the highest levels of PKC kinase 
activity followed by LPS and aggregated alpha synuclein. The recombinant PKC protein 
was used as a positive control. We obtained similar results with BV-2 microglial cells under 
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the same treatment conditions (Fig. 2B). Together these results demonstrate that the PKC 
protein is induced during microglial activation along with a concomitant increase in its 
kinase activity. In contrast to the proteolytic activation mechanism of PKC by caspase-3 
cleavage during dopaminergic cell death, it appears that in microglia, PKC activation is 
likely to occur through a series of priming phosphorylations at its activation loop, turn motif 
and hydrophobic motif as reported in other immune cells. The specific mechanisms of PKC 
activation in microglia and its potential substrates are currently under investigation in our 
laboratory. Interestingly, the induction and activation of PKC in primary microglia by 
diverse activation stimuli such as LPS, TNFα and aggregated alpha synuclein suggests that 
PKC signaling could be a common pathway regulating microglial activation. 
PKC localization in activated primary microglia 
Having confirmed that PKC is both induced and activated in cultured microglia we 
studied the subcellular localization of this kinase during microglial activation to better 
understand its function and identify potential substrates. Several reports have characterized 
the dynamic spatial and temporal distribution of PKC in various cell types and shown that 
the subcellular localization of PKC determines its survival or apoptotic functions 
(Mecklenbrauker et al., 2004; Gomel et al., 2007; Humphries et al., 2008). In cardiomyocytes 
for example, native PKC translocates from the nucleus to the perinuclear region and to the 
cytoskeleton. Nuclear and mitochondrial localization of PKC is well established during 
proapoptotic signaling in most cell types. On the other hand, membrane translocation and 
nuclear shuttling of PKC has been reported during immune cell activation. While the 
expression of various PKC isoforms has been reported previously in microglia and 
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astrocytes, the localization dynamics of PKC during microglial activation has not been 
determined. We used immunocytochemistry to determine the subcellular localization of 
PKC in primary microglia stimulated with LPS, TNFα and aggregated alpha synuclein. The 
chaperone protein GRP-78 was used to label the ER, and the nucleus was labeled with 
Hoechst. In unstimulated primary microglia, PKC was largely localized to the cytosol with 
some diffuse staining evident in the nucleus. Stimulation of primary microglia with LPS 
caused an intense and dramatic localization of PKC to the nucleus and the endoplasmic 
reticulum network (Fig.3) as seen by colocalization with both Hoechst and GRP-78. When 
compared to other treatments, LPS also induced the most dynamic change in microglial 
morphology with increased hypertrophy and processes. TNF alpha treated microglia showed 
distinct morphology with increased spiny processes but PKC remained largely in the cytosol 
with only diffuse staining in the nucleus similar to controls. The increased PKC expression 
level with TNF treatment was also evident as brighter PKC fluorescence in TNF treated 
cells. In primary microglia treated with aggregated alpha synuclein, PKC was largely 
localized to the cytoplasm, and a distinct exclusion of PKC from the nucleus was evident as 
seen by almost no colocalization with the Hoechst stain. Again, increased PKC expression 
was apparent as brighter PKC fluorescence staining in alpha synuclein-treated cells. The 
dynamic localization of PKC in primary microglia activated by distinct pathways indicates 
that PKC could have different substrates and subcellular functions in each case. PKC has 
been shown to act in the NFkB pathway possibly as an IkB kinase in other cell types 
(Rahman et al., 2001; Minhajuddin et al., 2009). The NADPH oxidase system is another 
relevant target for PKC phosphorylation in these cells and has been shown to be critical for 
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microglial neurotoxicity and oxidative stress in PD models (Wu et al., 2002; Gao et al., 2003; 
Wu et al., 2003). The p47 PHOX subunit of the NADPH oxidase complex in particular is a 
bona fide substrate for PKC and could be a common target for regulation of the microglial 
activation response by diverse stimuli.   
Knockdown of PKC by shRNA attenuates LPS-induced nitric oxide production and 
pro-inflammatory cytokine release 
Since PKC was highly induced during microglial activation along with a 
concomitant increase in its kinase activity, we reasoned that the suppression of PKC protein 
levels could be used to determine its role in regulating the microglial response. We used a 
lentiviral shRNA system to specifically suppress PKC protein levels in primary microglia 
cells and studied the microglial activation response with LPS stimulation. Successful 
lentiviral infection of primary microglia was confirmed by the visualization of green 
fluorescent protein co-expressed with the shRNA (Fig. 4A). In pilot experiments we obtained 
optimal shRNA suppression of PKC protein levels around 72 h after lentiviral infection as 
determined by Western blotting (Fig. 4B) and primary microglia were treated at this time 
point for 24 h with 100 ng/ml of LPS. LPS-induced nitric oxide production was significantly 
reduced (p <0.001) in primary microglia transfected with PKC shRNA (Fig. 4C). We also 
determined the levels of typical proinflammatory cytokines released from primary microglia 
as a measure of the activation response.  In microglia transfected with PKC shRNA, the 
LPS-induced release of IL-6 and TNFα were both significantly reduced compared to 
microglia transfected with non-specific shRNA (Fig.4D). Together these results suggest that 
PKC can regulate the proinflammatory responses of microglia induced by LPS. 
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Interestingly, in the same supernatants the levels of LPS-induced IL-12 were not significantly 
different between in PKC shRNA transfected microglia suggesting PKC can selectively 
regulate specific cytokine pathways during LPS-stimulation.   
Microglia from PKC knockout mice have reduced cytokine and chemokine production 
To establish the role of PKC in regulating the microglial activation response, we 
used primary microglia isolated from PKC knockout (-/-) mice.  Primary microglia obtained 
from wild-type and knockout mice were separated on the same day from mixed glial cultures, 
seeded at equal density and treated in parallel with LPS, TNF and aggregated alpha synuclein 
for 24 h. The levels of various cytokine and chemokines in the supernatant were determined 
using a multiplex bead-based Luminex assay system (Millipore Bioplex).  In LPS-treated 
microglial cells, the levels of several cytokines were significantly reduced in microglia from 
PKC knockout (PKC -/-) mice including IL-6,  IL-1α and IL-12 p70 (Fig. 5A). The 
production of several chemokines was also reduced in PKC knockout mouse microglia 
including MIP1α, KC (CXCL-1), MIP-2, IP-10, KC and LIX (Fig. 5B). The levels of several 
other cytokines and chemokines in the same supernatant remained unchanged between wild-
type and PKC knockout microglia suggesting a selective regulation of specific cytokine and 
chemokine pathways by PKC. We also measured cytokine responses in primary microglia 
treated with TNFα and aggregated alpha synuclein. In TNFα treated primary microglia, the 
levels of IL-6, IP-10, KC, RANTES, MCP-1, MIP-2 and g-CSF were significantly reduced 
(Fig. 6A) . Interestingly, the levels of MIP1α and MIP1 were increased in PKC knockout 
mouse microglia in contrast to LPS-treatment where MIPα was reduced and MIP1 did not 
change significantly. We presume this is likely due to the different signaling pathways by 
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which LPS and TNF activate microglial cells (TLR-4 versus TNF receptors), and a 
differential involvement of PKC in these pathways as evidenced by the distinct spatial 
localization of PKC following LPS and TNF treatments (Fig. 3B). In primary microglia 
treated with low dose aggregated alpha synuclein, we did not observe major changes with 
cytokine production similar to previous reports (Zhang et al., 2005).  TNFα, MCP-1 and IP-
10 were slightly elevated with alpha synuclein treatment in microglia from wild-type mice 
and were significantly reduced in microglia from the PKC knockout mice (Fig. 6C). Other 
cytokines did not increase appreciably with alpha synuclein treatment. Collectively, these 
results point to a profound and selective regulation of microglial cytokine and chemokine 
regulation by PKC signaling. These results also support a role for PKC as a common 
downstream kinase regulating microglial activation by different distinct stimuli  
Microglia from PKC knockout mice have reduced nitric oxide production and 
intracellular ROS generation 
Nitric oxide production and intracellular ROS (iROS) generation are important 
aspects of the microglial activation response and are particularly relevant in PD models 
where deregulated microglial activation is believed to exacerbate dopaminergic degeneration 
by augmenting oxidative stress (Block et al., 2007). We compared the nitric oxide production 
and intracellular ROS generation in microglia isolated from wild-type and PKC knockout 
mice. Nitric oxide production was measured indirectly using the Griess assay. LPS treatment 
for 24 h induced a sharp increase in nitrite levels (~ 35 µM) in wild-type (PKC +/+) 
microglia, while in microglia from knockout mice (PKC -/-) there was only a modest 
increase in nitrite levels (~ 10 µM) with LPS treatment. Significant differences (p < 0.001) 
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were obtained between LPS-treated microglia from wild-type and PKC knockout mice (Fig. 
7A). Both TNF (30 ng/ml) and aggregated alpha synuclein (300 nM) did not increase basal 
levels of nitric oxide production in primary microglia up to 48 h compared to untreated 
controls (data not shown). The original study by Zhang et al. (2005) using aggregated alpha 
synuclein did not report significant increases in nitrite production even at the highest doses 
tested. We also tested the intracellular ROS generation response in primary microglia 
obtained from PKC wild-type and knockout mice. Both LPS and TNFα increased 
intracellular ROS levels in primary microglia from wild-type mice at 6 h,, whereas primary 
microglia from PKC knockout mice that were seeded at the same density and treated in 
parallel had significantly lower levels (p < 0.01) of intracellular ROS (Fig. 7B,C). Together, 
these results further support an important role for PKC signaling in the regulation of 
different aspects of the microglial proinflammatory response beyond cytokine production. 
Based on its known substrates in immune cells it is possible that PKC could be a key 
upstream component of important immune-regulatory signaling pathways such as NFB or 
the NADPH oxidase complex, both of which are known to be substrates for PKC 
phosphorylation in other cell types. The iNOS enzyme is also a known target for PKC 
regulation (Ginnan et al., 2006) either directly or via the NFB signaling pathway.  
PKC knockout mice are resistant to LPS-induced sickness behavior and motor deficits   
To validate our results obtained with isolated primary microglia in animal models of 
PD, we used both the systemic LPS model (Qin et al., 2007) and the well established MPTP 
model of dopaminergic degeneration (Wu et al., 2003; Przedborski et al., 2004). In the LPS 
model of PD, a single dose of LPS-injected systemically in mice caused sustained 
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neuroinflammation in the brain and progressive dopaminergic degeneration almost a year 
later. Other groups have also used multiple dosing regimens for LPS to induce dopaminergic 
degeneration at earlier time points (Lee et al., 2008). A wealth of evidence now implicates a 
role for chronic neuroinflammation in the progression of PD and more recently that systemic 
inflammation can be an important factor as well. We injected PKC wild-type (+/+) and 
PKC knockout mice (-/-) with a single dose of LPS (5 mg/kg) and compared the behavioral 
and neuroinflammatory responses. To our surprise, the PKC knockout mice injected with 
LPS showed a dramatic recovery from endotoxic shock. While the wild-type mice showed 
typical signs of endotoxic shock at around 48 h with hunched posture and minimal 
movement, the PKC knockout mice started to recover at around 24 h after injection and had 
almost normal behavioral responses at 48 h. To confirm these surprising observations, we 
performed extensive behavioral and locomotor analyses on LPS-injected mice. Age-matched 
PKC wild-type and knockout mice were injected with a single dose of 5 mg/kg LPS (ip) and 
behavioral activity was assessed using the VersaMax Analyzer and by rotarod performance 
tests 48 hours later. As shown in the versaplot of locomotor activity (Fig. 8A), LPS-injected 
wild-type (PKC +/+) mice exhibited very little movement and overall locomotor activity 
while the knockout mice (PKC -/-) had almost normal behavioral responses and locomotor 
activity. We also quantified the horizontal and vertical activity in these mice using the 
VersaMax Analyzer and obtained the same results. The recovery of the PKC knockout mice 
from endotoxic shock was also readily apparent in the classic rotarod performance test (Fig. 
8D). While LPS-injected wild-type mice spent almost no time on the rotarod, the LPS-
injected PKC knockout mice spent almost as much time as the saline-injected group. 
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Although the cellular and molecular mechanisms for this phenomenon are not immediately 
apparent, these dramatic results support a crucial role for PKC in regulating the systemic 
inflammatory response to LPS. Studies are currently ongoing in our laboratory to investigate 
the potential mechanisms involved.  
PKC knockout mice have reduced nigral proinflammatory responses in the following 
LPS-induced neuroinflammation  
After our behavioral studies, which demonstrated that PKC knockout mice were 
resistant to LPS-induced endotoxic shock and systemic inflammation, we tested the 
neuroinflammatory responses of these mice in relevance to PD by studying the 
proinflammatory cytokine responses and microglial activation status in the substantia nigra 
of these mice. In the original study by Qin et al. (2007), the authors found that the levels of 
TNFα were chronically elevated in the brain and that the TNF signaling pathway was 
responsible for transfer of the systemic inflammation into the brain (Qin et al., 2007). Using 
qRT-PCR we determined the changes in gene expression levels of the proinflammatory 
cytokines TNFα, IL1 and IL-12 in substantia nigra tissue of LPS-injected PKC wild-type 
and knockout mice. The gene expression studies were performed 48 h after the LPS injection, 
the time point by which the PKC knockout mice had recovered from LPS-induced sickness 
behavior. Consistent with the results from the previous report with this model we observed 
highly elevated levels of TNFα mRNA in (20- to 60-fold over saline controls) in nigral tissue 
obtained from wild-type C57 black mice (Fig. 8A). However the PKC knockout mice had 
only about a threefold increase in TNFα mRNA at 48 h over the saline-injected control  
group. We obtained similar results with IL-12 as well. IL-1 expression was only slightly 
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increased in LPS-injected wild-type mice but the fold change was significantly less in LPS-
injected knockout mice (Fig. 8A). The almost normal levels of TNFα in the PKC knockout 
mice is particularly relevant based on the studies of Qin et al (2007) with this model where 
sustained elevated TNF levels were detected for up to 10 months after the single LPS 
injection. A wealth of other independent studies also supports a pathogenic role for TNF in 
the degenerative process in both inflammatory and neurotoxic models of PD. In particular the 
neuroprotection demonstrated with dominant negative TNF in animal models of PD suggests 
that this pleotropic cytokine could be crucial to the degenerative process in the substantia 
nigra by neuroinflammatory mechanisms. (Sriram et al., 2002; Ferger et al., 2004; McCoy et 
al., 2006; Sriram et al., 2006; McCoy et al., 2008). Our data here showing that TNF levels are 
significantly reduced in PKC knockout mice injected with LPS suggests that PKC could be 
regulating TNFα production possibly through the NFB pathway. We also tested the levels 
of Iba1 and iNOS as markers of the neuroinflammatory response in the SN tissue following 
LPS injection. Both iNOS and Iba1 were increased at 48 h post LPS injection in PKC wild-
type mice. In PKC knockout mice no induction of Iba1 or iNOS was apparent suggesting 
that the inflammatory response was substantially reduced following LPS stimulation (Fig. 8 
B,C) in these mice in concordance with the behavioral studies and the rapid recovery of these 
mice from LPS-induced endotoxemia (Fig. 7).  
PKC knockout mice have reduced cytokine responses, microglial activation and 
oxidative stress markers in the MPTP model of PD 
To validate our hypothesis that PKC can regulate microglial activation and the 
neuroinflammatory response, we utilized the well established MPTP mouse model in which 
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microglial activation and neuroinflammation is well documented (Wu et al., 2002; Wu et al., 
2003; Benner et al., 2004; Przedborski et al., 2004; Hu et al., 2008; Brochard et al., 2009; 
Chung et al., 2010). Based on our results from the primary microglia studies in which PKC 
knockout microglia (PKC -/-) had reduced cytokine and chemokine levels, nitric oxide 
generation and lower levels of intracellular ROS, we reasoned that the microglial 
neuroinflammatory response would be reduced in the MPTP model of PD. The dramatic 
recovery of the PKC knockout mice from LPS treatment and the reduced 
neuroinflammatory responses in the substantia nigra also support this hypothesis. Both wild-
type and PKC knockout mice were treated according to the acute MPTP model (4 doses of 
18 mg/kg MPTP at 2 h intervals) and the neuroinflammatory responses were studied 24 h 
later the time point at which robust neuroinflammation was evident (Czlonkowska et al., 
1996; Du et al., 2001; Wu et al., 2003; Przedborski et al., 2004). MPTP intoxication induced 
the mRNA levels of TNFα, IL-1 and iNOS as expected in the wild-type mice. In the PKC 
knockout mice however the MPTP-induced cytokine production was significantly reduced 
(Fig.10A) similar to the results obtained with the LPS-injected mice (Fig.9A). The microglial 
NADPH oxidase complex has been shown to be critical for microglial neurotoxicity and 
oxidative stress in the substantia nigra in the MPTP model.  The gp91-phox subunit of the 
NADPH complex has been shown to be induced in microglia during the nigral 
neuroinflammatory reaction following MPTP intoxication in this model (Wu et al., 2003). 
We compared the levels of gp-91 phox between wild-type and PKC knockout mice injected 
with MPTP 24 h after treatment by Western blotting with nigral lysates. In wild-type mice 
injected with MPTP there was a strong induction of gp-91 phox as expected, however, in the 
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PKC knockout mice there was no detectable induction of gp91 phox (Fig. 10B).  We also 
probed for microglial activation using the microglial marker Iba1. In MPTP-treated wild-type 
mice, we observed a typical robust microglial activation response in the substantia nigra as 
evidenced by the increased density and ramified morphology of the microglial cells (Fig. 
10C, lower panel). In PKCδ knockout mice, however, reduced microglial activation 
morphology and microglial cell density was apparent suggesting that PKCδ could be crucial 
to microglial activation following MPTP-induced dopaminergic damage. Together, these 
results suggest that the microglial neuroinflammatory response is attenuated in PKC 
knockout mice. Sustained microglial ROS generation is believed to be a major mechanism 
contributing to the progressive degeneration of dopaminergic neurons in PD. Since the gp-91 
phox and iNOS are the primary sources of microglial ROS in the MPTP model and were both 
reduced in PKC knockout mice, we reasoned that the oxidative stress markers in the 
substantia nigra of these mice would be attenuated following MPTP treatment and that PKCδ 
knockout mice could be protected against MPTP-induced dopaminergic degeneration. 
Together these results suggest that the microglial neuroinflammatory response and the 
resulting oxidative stress induced by MPTP treatment are attenuated in the PKC knockout 
mice, indicating that PKC could be a crucial upstream regulator of these responses in vivo.   
PKC knockout mice are protected against MPTP-induced nigrostriatal dopaminergic 
degeneration  
Previous studies from our laboratory have demonstrated that PKC is highly 
expressed in dopaminergic neurons and can be proteolytically activated by caspase-3 
cleavage during oxidative stress-induced apoptosis (Anantharam et al., 2002; Kanthasamy et 
135 
 
 
al., 2003; Kaul et al., 2003; Zhang et al., 2007b). Importantly, the pharmacological inhibition 
of PKC using the chemical inhibitor rottlerin is neuroprotective in the MPTP model of PD. 
Our exciting new results in this study suggest that PKC can regulate the microglial 
neuroinflammatory response in vitro and in vivo. Since microglial neuroinflammation and 
oxidative stress have been shown to exacerbate dopaminergic degeneration in the 
nigrostriatal system, we determined if the PKC knockout mice are protected against 
nigrostriatal dopaminergic degeneration in the MPTP model. Age-matched wild-type and 
PKC knockout mice were treated with MPTP and nigrostriatal dopaminergic degeneration 
was assessed 7 days later. Striatal dopamine levels and its metabolites DOPAC and HVA 
were quantified by HPLC. As expected, MPTP intoxication caused a severe loss of dopamine 
and its metabolites in the wild-type C57 black mice at 7 days to about 25% of the saline-
treated controls. In PKC knockout mice however, dopamine and its metabolites were 
reduced only by about 40-50% compared to saline-injected control mice (Fig 7 A, B, C). 
Statistically significant differences were observed between the PKC +/+ and PKC -/- mice 
injected with MPTP for dopamine (p < 0.001), DOPAC and HVA (p < 0.05). We also used 
TH-DAB immunostaining and stereological counting to accurately estimate the loss of 
dopaminergic neurons and striatal fiber density in the nigrostriatal system of in wild-type and 
PKC knockout mice. Both striatal TH fiber density (Fig. 11B) and the number of TH-
positive immunostained dopaminergic neurons in the substantia nigra (Fig. 11C) were higher 
in PKC knockout mice treated with MPTP compared to wild-type mice demonstrating 
robust protection of the nigrostriatal system in PKC knockouts. Together, these results 
confirm that PKC signaling can participate in dopaminergic degeneration by acting as a 
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proapoptotic kinase in dopaminergic neurons as we have shown previously, and also by 
regulating microglial activation and proinflammatory responses as we have shown here for 
the first time.  
PKC knockout mice are protected against MPTP-induced motor deficits 
Motor impairments arising from nigrostriatal degeneration and dopamine depletion 
are a hallmark of PD in humans and can be recapitulated in the mouse MPTP model.  We 
used the VersaMax Analyzer and rotarod performance tests to assess the motor deficits in the 
wild-type and PKC knockout mice 7 days after MPTP treatment, the time point at which the 
nigrostriatal lesion is apparent. We quantified several behavioral parameters including total 
rest time, horizontal activity, vertical activity, total distance traveled, total movement time 
and the number of stereotypy movements over a 10 min interval in saline- and MPTP-treated 
wild-type and PKC knockout mice. The total rest time (Fig. 12C) was significantly 
increased in MPTP-treated PKC wild-type mice but not in PKC knockout mice. 
Significant improvement in motor and behavioral function was obvious in the PKC 
knockout mice treated with MPTP compared to the wild-type as seen with the  quantified 
horizontal activity, vertical activity, total distance traveled, total movement time and the 
number of stereotypy movements (Fig.12 C – G). The improved motor functions was also 
apparent with the rotarod performance test where MPTP-treated knockout mice were almost 
as competent on the rotarod as the saline controls with no statistical differences in the amount 
of time spent between the two groups. In contrast the MPTP-injected wild-type mice had the 
lowest amount of time recorded on the rotarod indicative of significant motor impairments 
arising from nigrostriatal degeneration. Together, these results confirm that the PKC 
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knockout mice are protected against MPTP-induced nigrostriatal dopaminergic degeneration 
and that the robust neuroprotection observed translates into improved motor and behavioral 
functions.  
 
Discussion 
Reactive microgliosis is well documented in human PD patients and all animal 
models of the disease. Although mechanistic studies over the last decade in animal models of 
the disease support a proinflammatory and neurotoxic role for chronically activated microglia 
in dopaminergic degeneration, the signaling pathways regulating microglial activation have 
not yet been established.  Microglial NADPH oxidase has been shown to be a major source 
of ROS in the substantia nigra that can contribute to the loss of dopaminergic neurons (Wu et 
al., 2002; Wu et al., 2003; Qin et al., 2005). Similarly, the NFB pathway has been shown to 
be an important regulator of the microglial proinflammatory response in the substantia nigra 
with the selective inhibition of NFB being neuroprotective in the MPTP model (Ghosh et 
al., 2007a). The NFB signaling pathway could be particularly relevant since it can regulate 
both the microglial pro-inflammatory response by modulating key cytokines such as TNFα 
and by regulating the levels of the oxidative stress generating components including subunits 
of the NADPH oxidase complex and iNOS. However, the intracellular signaling pathways 
that regulate the potentially neurotoxic proinflammatory responses of microglia in PD remain 
to be elucidated.  
Our results in this study identify the PKC signaling pathway as  a novel regulator of 
the microglial activation response both in vitro and in two animal models of PD that are 
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relevant to neuroinflammation. Importantly, our studies show that the PKC gene and protein 
levels are induced during microglial activation by distinct mechanisms and stimuli including 
TNF receptors (TNFα), TLR-4 (LPS) and phagocytosis (aggregated α synuclein).  We also 
observed induction of PKC protein levels in BV-2 microglial cells by activated MMP-3, 
which could potentially activate microglia through protease activated receptors as suggested 
by previous reports (Kim et al., 2005; Kim et al., 2007). The significance of these findings is 
twofold. First, they suggest that PKC induction could be a common downstream signaling 
component involved in activation of microglial cells by distinct mechanisms and activation 
stimuli. The distinct subcellular localization pattern of PKC in primary microglia during 
activation by LPS, TNF and aggregated alpha synuclein supports this view. Secondly, our 
results suggest that the amount of PKC in the microglial cells could set the threshold and 
magnitude of the activation response. The increased mRNA and protein levels of PKC in 
activated microglia support this view, as do our results with shRNA knockdown of PKC 
expression levels in primary microglia and our results with PKC knockout mouse microglia. 
Further, our kinase assay results demonstrate that the increased PKC protein expression 
correlate with increased PKC kinase activity in microglial cells suggesting that the 
increased protein levels may be required to sustain the PKC signaling and maintain the 
activation state of the microglia. A recent study (Burguillos et al., 2011) reported proteolytic 
cleavage of PKCδ by caspase-3 in BV2 cells overexpressing PKCδ when activated  with 
LPS. In our studies, we did not observe a proteolytically activated form of PKCδ in non-
transfected BV2 cells or primary microglia stimulated with LPS, TNFα or aggregated α-
synuclein but only an increase in the native protein which we found was expressed at low 
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levels in unstimulated microglia as reported by Burguillos et al. (2011). We posit that the 
proteolytic activation of PKCδ is likely an artifact of the overexpression system in the BV2 
cells and does not occur under physiological conditions.  
Our results with the multiplexed cytokine assays further support the involvement of 
PKC signaling in the microglial activation response by distinct mechanisms since 
significant changes were observed in the production of various cytokines and chemokines 
between microglia from PKC wild-type and knockout mice using three different activation 
stimuli (LPS, TNFα and aggregated alpha synuclein). More importantly, the levels of many 
cytokines and chemokines did not change between wild-type and PKC knockout mouse 
microglia indicating a selective and stimulus-specific regulation of the microglial cytokine 
response rather than an overall reduction in cytokine production or release. Significantly, our 
results showing reduced nitric oxide production and intracellular ROS generation in 
microglia isolated from PKC knockout mice demonstrate that PKC can regulate the 
microglial ROS generation machinery, which is particularly important in nigrostriatal 
dopaminergic degeneration and the progression of PD. Given that the p47 subunit of NADPH 
oxidase, the NFB signaling pathway and iNOS are either direct substrates of PKC 
phosphorylation or are subject to regulation by PKC in other immune cells during 
proinflammatory events, it is likely that one or more these pathways is a  downstream target 
of PKC signaling during microglial activation. Current studies in our laboratory are focused 
on identifying the downstream signaling pathways of PKC and its mechanism of activation 
in microglial cells.  
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 The systemic LPS model was recently developed and has been used by several groups 
to investigate the mechanisms of chronic inflammation on dopaminergic degeneration (Qin et 
al., 2007; Lee et al., 2008). A hallmark of this model is the sustained elevation of TNFα 
levels in the brain that is evident even 10 months after a single systemic LPS injection (Qin 
et al., 2007). Our data demonstrates that in PKCδ knockout mice treated with LPS, the level 
of TNFα in the substantia nigra is not significantly higher than saline controls but is highly 
elevated (40- to 60-fold over saline controls) in wild-type mice similar to results obtained by 
shown by Qin et al. (2007). These findings are particularly relevant in the context of recent 
reports implicating a role for TNFα  signaling in the progressive loss of dopaminergic 
neurons (Sriram et al., 2002; McCoy et al., 2006; De Lella Ezcurra et al., 2010), and suggest 
that PKC could be important in regulating both the systemic and  CNS inflammatory 
responses.  The reduced levels of Iba1 and iNOS in the substantia nigra of LPS-injected 
PKC knockouts compared to wild-type mice also support this view. Chronically activated 
microglia in the substantia nigra have been shown to produce proinflammatory mediators that 
can exacerbate dopaminergic degeneration by augmenting oxidative stress levels. Microglia 
NADPH oxidase is the primary source of free radicals in the nigrostriatal system and has 
been extensively investigated in animal models of PD. Further, therapeutic targeting the 
microglial response using anti-inflammatory strategies has shown efficacy in different animal 
models of the disease. Our results with the MPTP model demonstrate that the microglial 
inflammatory response and oxidative stress levels in the substantia nigra are reduced in 
PKC knockout mice. Significantly, both TNFα mRNA levels and the induction of the gp91-
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phox subunit of the NADPH complex are attenuated in the knockout mice during the 
inflammatory response following MPTP treatment.  
Our neuroprotection studies with the MPTP model demonstrate that the reduced 
microglial proinflammatory response in the PKC knockout can contribute to the protection 
of the nigrostriatal system from MPTP-induced damage. The preservation of the 
dopaminergic system in the PKC knockout mice also translates into improved behavioral 
and motor function. The robust neuroprotection seen in the PKC knockout mice is most 
likely a result of two independent functions of this kinase. One as a mediator of the 
microglial proinflammatory response by full length PKC proinflammatory signaling as we 
have shown here, and also by functioning as a proapoptotic kinase following proteolytic 
activation in dopaminergic neurons as shown previously (Anantharam et al., 2002; Kaul et 
al., 2003; Zhang et al., 2007a). Therefore the robust protection of the nigrostriatal system in 
the PKC knockout mice could be a combined effect resulting from ablation of PKC 
proinflammatory signaling in microglia and a resistance against oxidative stress-induced 
apoptosis in dopaminergic neurons.  The reduced microglial inflammatory response in the 
PKC knockout mice results in lower levels of oxidative stress and proinflammatory 
mediators in the nigrostriatal system, and is likely to be a major factor contributing to the 
neuroprotection of the dopaminergic neurons in these mice. Conversely, the resistance to 
oxidative stress-mediated apoptosis in dopaminergic neurons is likely to result in less 
activation of the microglia thus mitigating the self-propelled cycle of dopaminergic 
degeneration and microglial activation, which is thought to drive sustained reactive 
microgliosis and neurotoxicity in the substantia nigra (Block et al., 2007).  
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A therapeutic rationale for targeting PKC is immediately apparent from these 
studies. Small molecule kinase inhibitors could potentially mitigate both the microglial 
proinflammatory responses and also directly protect against oxidative stress-mediated 
degeneration in dopaminergic neurons (Zhang et al., 2007a). The multifactorial etiology of 
disease pathogenesis and the complex genetic, environmental and cellular interactions which 
contribute to dopaminergic degeneration in PD make therapeutic intervention an enormous 
challenge (Sulzer, 2007; Obeso et al., 2010).  Therefore, identifying therapeutic targets that 
are relevant across multiple modalities of disease pathogenesis will be necessary to 
effectively block disease progression. While oxidative stress, mitochondrial dysfunction and 
proteasomal impairment are causative factors that can trigger dopaminergic degeneration, 
reactive microgliosis and deregulated neuroinflammation can sustain this process and result 
in progressive neurotoxicity (Block et al., 2007; Whitton, 2007; Glass et al., 2010).  Our 
novel findings presented here provide a rational for targeting PKC signaling to attenuate the 
microglial neuroinflammatory response and mitigate the progressive degeneration of 
dopaminergic neurons. In addition to the known pro-apoptotic functions of PKC during 
dopaminergic degeneration by oxidative stress, mitochondrial dysfunction and proteasomal 
impairment, our results here identify PKC signaling in microglia as a potential therapeutic 
target to block microglial neurotoxicity and progressive dopaminergic neuron loss.  
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Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Induction of PKCδ gene and protein expression during microglial activation. 
A, Increased PKCδ protein expression in primary microglia. Purified primary microglia were 
treated with LPS (100 ng/ml) and 300 nM aggregated alpha synuclein (α Syn) for 24 h and 
PKCδ protein levels were probed by Western blotting using an antibody against the C-
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terminus of the protein that detects both the native and cleaved fragments. B, Increased 
PKCδ gene expression in primary microglia and in the mouse substantia nigra. SYBR-green 
real time quantitative PCR analysis for PKCδ gene expression in isolated primary microglial 
cells treated with LPS (100 ng/ml), TNFα (30 ng/ml) and aggregated alpha-synuclein (300 
nM) for 24 h (left panel). The normalized fold increase in PKCδ gene expression over the 
control group was calculated by the ΔΔCt method. Increased PKCδ gene expression in the 
substantia nigra of mice treated with MPTP (4 x 18 mg/kg ip) and LPS (5 mg/kg, ip) for 24 h 
(right panel), the time point at which robust microglial activation and neuroinflammation is 
evident. Data represent the mean ± SEM from three experiments, (*** p <0.001, ** p <0.01 
and * p <0.05). C, Increased PKCδ protein expression in activated BV-2 microglial cells. 
Immortalized BV-2 microglial cells were activated with LPS (1 μg/ml) and TNFα (30 ng/ml) 
for 24 h and the PKCδ protein levels were determined by Western blotting. β-actin was used 
as the loading control (left panel).BV-2 cells were also treated with 250 ng/ml of pro and 
active MMP-3 enzyme  for 24 h. The inactive proenzyme was activated using the 
organomercurial activator aminophenylmercuric acetate (APMA) in vitro. Increased PKCδ 
expression was observed with LPS, TNFα and active MMP-3 treatment in BV-2 cells. 
APMA alone did not increase PKCδ expression levels compared to untreated controls. 
Representative blots are shown and experiments were repeated at least three times. 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. PKCδ kinase activity is increased during microglial activation. A, PKCδ kinase 
activity assay in primary microglia. The kinase activity of PKCδ was determined using a 
32
P-Histone 
32
P-Histone 
A 
B 
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standard immunoprecipitation-kinase assay. Primary microglial cells were treated with LPS 
(100 ng/ml), TNFα (30 ng/ml) and aggregated alpha synuclein (300 nM) for 24 h. The PKCδ 
protein was immunoprecipitated from 500 µg of total protein from each sample and 
processed for the in vitro kinase activity assay using a histone substrate and radiolabeled [γ-
32
P] ATP. The kinase activity was quantified by densitometric analysis of the 
32
P-histone 
band intensity and expressed as percent control. The pure recombinant PKCδ protein was 
used as a positive control for the kinase assay. B, PKCδ kinase activity assay in BV-2 
microglial cells. BV-2 cells were treated with LPS (1 μg/ml), TNFα (30 ng/ml) and 
aggregated alpha synuclein (300 nM) for 24 h and samples were processed for the PKCδ IP-
kinase assay. In both BV-2 cells and primary microglia, the kinase activity of PKCδ is highly 
increased following microglial activation. Representative kinase assay gels are shown. Data 
represent the group mean ± SEM of densitometric values obtained from three independent 
experiments. Asterisks (***p<0.001, ** p<0.01 and * p<0.05) indicate significant differences 
between control and treatment groups 
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Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Dynamics of PKCδ localization during microglial activation. Isolated primary 
microglia were treated with LPS (100 ng/ml), TNFα (30 ng/ml) and aggregated alpha 
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synuclein (300 nM) for 24 h. Cells were fixed in 4% PFA and processed for 
immunofluorescence staining using a rabbit polyclonal antibody to PKCδ (Red, Alexa-555). 
The endoplasmic reticulum was labeled using the ER marker Grp-78 (Green, Alexa 488). 
The nucleus was labeled with Hoechst stain (blue). In control cells, diffused cytosolic 
staining of PKCδ is evident. LPS activated microglia showed the most dramatic changes in 
morphology and PKCδ localization with distinctive staining and accumulation in the nucleus 
and the ER network as seen in the merged images. In microglia activated with TNFα and 
aggregated alpha synuclein PKCδ staining was more distinct compared to controls but was 
largely excluded from the nucleus and showed more cytosolic accumulation. Experiments 
were repeated more than three times and representative images are shown.  
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Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Lentiviral sh-RNA knockdown of PKCδ attenuates LPS-induced microglial 
activation. A, Isolated primary microglia were transfected with lentiviral vectors expressing 
either PKCδ sh-RNA or non-specific (NS) sh-RNA as controls. The transfections efficiency 
was determined by visualizing the GFP-tag co-expressed by the viral vectors and knockdown 
A 
C 
B 
161 
 
 
of the PKCδ native protein level was confirmed by Western blotting. B, Knockdown of 
PKCδ attenuates LPS-induced microglial nitric oxide production. Primary microglia 
transfected with either non-specific or PKC-delta sh-RNA and were treated with LPS (100 
ng/ml) for 24 h. Nitric oxide levels in the supernatant were determined using the greiss 
reagent. Primary microglial transfected with PKCδ sh-RNA showed reduced nitrite levels in 
the supernatant compared to microglia transfected with non-specific sh-RNA. C, Effect of 
PKCδ knockdown on LPS-induced pro-inflammatory cytokine production in primary 
microglia. Primary microglia transfected with either non-specific or PKCδ sh-RNA and were 
treated with LPS (100 ng/ml) for 24 h and pro-inflammatory cytokines were quantified using 
the luminex immunoassay system. Knockdown of PKCδ attenuated LPS-induced IL-6 and 
TNFα production but not IL-12 levels in the same supernatants. Experiments were repeated 
three times. Data represent the group mean ± SEM from one representative experiment. 
Asterisks (***p<0.001) indicate significant differences between non-specific sh-RNA and 
PKCδ sh-RNA transfected groups stimulated with LPS; "ns" denotes no significant 
difference.  
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Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Primary microglia from PKCδ knockout mice have attenuated cytokine and 
chemokine production in response to LPS stimulation. Primary microglia were isolated 
from PKCδ wild-type (+/+) and knockout (-/-) mice and seeded in equal numbers on poly-D-
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lysine coated plates. The cells were treated with LPS (100 ng/ml) for 24 h and cytokine 
levels in the supernatant were quantified using the Luminex immunoassay system. Primary 
microglia isolated from PKCδ knockout (-/-) mice showed significantly reduced levels of IL-
1α, IL-6, IL-12p70, MIP-1α, KC (CXCL1), MIP-2, IP-10, LIF and LIX (CXCL5) upon LPS 
stimulation compared to microglia isolated from PKCδ wild-type (+/+) mice. Data represent 
the group mean ± SEM from three experiments. Asterisks (***p<0.001 and ** p<0.01) 
indicate significant differences between LPS-treated groups from PKC delta (+/+) and PKCδ 
(-/-) microglial cells (solid black bars).  
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Figure 6. 
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Figure 6: Primary microglia from PKCδ knockout mice have attenuated cytokine and 
chemokine production in response to TNFα and aggregated alpha synuclein activation. 
A, Primary microglia were isolated from PKCδ wild-type (+/+) and knockout (-/-) mice and 
seeded in equal numbers onto poly-D-lysine coated plates. The cells were treated with TNFα 
(30 ng/ml) for 24 h and cytokine levels in the supernatant were quantified using the Luminex 
immunoassay system. Primary microglia isolated from PKCδ knockout (-/-) mice showed 
significantly reduced levels of IL-6, IP-10, KC (CXCL1), RANTES (CCL5), g-CSF, MIP-2 
and MCP-1 following TNFα stimulation compared to microglia isolated from PKCδ wild-
type (+/+) mice. The levels of MIP-1α and MIP-1β however were significantly increased in 
the same supernatants. B, In primary microglia activated with aggregated alpha synuclein 
(300 nM for 24 h) only TNFα, IP-10 and MCP-1 were detected and the levels of all three 
were significantly reduced in PKCδ knockout mice.  Data represent the group mean ± SEM 
from three to four experiments. Asterisks (***p<0.001, ** p<0.01 and p<0.05) indicate 
significant differences between LPS-treated groups from PKC delta (+/+) and PKCδ (-/-) 
microglial cells.  
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Figure 7 
 
 
 
 
 
 
 
 
Figure 7. Primary microglia from PKCδ knockout mice have reduced nitric oxide and 
ROS generation responses. A, Nitric oxide assay. Primary microglia were isolated from 
PKCδ wild-type (+/+) and knockout (-/-) mice and treated with LPS (100 ng/ml) for 24 h. 
Nitric oxide production was determined the Greiss reagent and a sodium nitrite standard 
curve. Microglia isolated from PKCδ knockout mice showed reduced nitric oxide production 
compared to wild-type microglial cells. B, Reduced intracellular ROS generation in 
microglia from PKC knockout (-/-) mice. Primary microglia from PKCδ wild-type (+/+) and 
knockout (-/-) mice were treated with LPS (100 ng/ml, left panel) and TNFα (30 ng/ml, right 
panel) for 6 h and intracellular ROS generation was quantified using the fluorescent DCFDA 
dye. Microglia isolated from PKCδ knockout mice had attenuated intracellular ROS levels 
compared to those isolated from PKCδ wildtype (+/+) mice. Data represent the group mean ± 
SEM.Asterisks (***p<0.001 and ** p<0.01) indicate significant differences between LPS-
treated groups or TNFα-treated groups from PKCδ (+/+) and PKCδ (-/-) microglial cells.  
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Figure 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Rapid recovery of PKCδ knockout mice (-/-) from LPS-induced endotoxemia 
and sickness behavior. A, Locomotor activity and movement tracks (VersaPlot) of saline- 
and LPS-injected mice. Age-matched PKCδ wild-type (+/+) and knockout (-/-) mice were 
injected with a single dose of LPS (5 mg/kg, i.p.) or equivalent volumes of saline and the 
A B 
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behavioral activity was assessed 48 h later using the VersaMax Analyzer. The VersaPlot of 
the movement tracks demonstrates that LPS-injected PKCδ knockout (-/-) mice show almost 
normal locomotor activity similar to saline-injected controls (lower panel) as compared to 
PKCδ wild-type (+/+) mice (top panel). B, Total horizontal movements and C, Total vertical 
activity of saline and LPS-injected mice quantified using the VersaMax Analyzer 48 h after 
treatment showing significantly improved activity in PKCδ knockouts (-/-) compared to wild-
type littermates injected with LPS. D, Rotarod performance analysis. The time spent on the 
rotarod was quantified 48 h after LPS (5 mg/kg) treatment. LPS-injected PKCδ knockout 
mice show improved performance on the rotarod compared to wild-type littermates. Data 
represent the group mean ± SEM from three to four experiments. Asterisks (***p<0.001 and 
** p<0.01) indicate significant differences between LPS-treated groups from PKC delta wild-
type (+/+) and PKCδ knockout (-/-) mice. ## denotes p<0.001 compared to saline injected 
mice. 
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Figure 9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. PKCδ knockout mice have reduced nigral proinflammatory cytokine 
production and microglial inflammatory markers following systemic LPS treatment. A, 
real-time SYBR green qRT-PCR for pro-inflammatory cytokines. Age-matched PKC delta 
wild-type (+/+) and knockout (-/-) mice were injected with 5 mg/kg LPS (ip) and 
proinflammatory cytokine gene expression was determined by real-time qRT-PCR 48 h later, 
the time point at which PKCδ knockout mice recovered form LPS toxicity based on 
behavioral studies. The levels of TNFα, IL-12 and IL-1β were highly expressed following 
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LPS stimulation in PKCδ wild-type mice but were significantly reduced in PKCδ knockout 
mice. Data represent the group mean ± SEM from three experiments. Asterisks (*p<0.05 and 
** p<0.01) indicate significant differences between LPS-treated groups from PKC delta wild-
type (+/+) and PKCδ knockout (-/-) mice. B, Western blot for Iba1 and iNOS. Nigral tissue 
was dissected from LPS-injected PKCδ wild-type (+/+) and knockout (-/-) mice 48 h after 
treatment and lysates were probed for the microglial activation marker Iba1 and for iNOS by 
Western blotting. PKCδ wild-type (-/-) mice had increased levels of Iba1 (left panel) and 
iNOS (right panel) following LPS treatment as expected and both markers were reduced in 
PKCδ knockout mice (-/-) suggesting that PKCδ has a critical role in regulating the 
microglial neuroinflammatory response in vivo following LPS stimulation. Representative 
blots are shown and experiments were repeated twice. 
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Figure 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. PKCδ knockout mice have reduced nigral proinflammatory cytokine 
production, microglial activation and gp91PHOX levels following MPTP-induced 
neuroinflammation. A, Real-time SYBR green qRT-PCR for pro-inflammatory cytokines in 
the mouse substantia nigra. Age-matched PKCδ wild-type (+/+) and knockout (-/-) mice 
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were injected with 4 doses of MPTP (18 mg/kg) or saline at 2 h intervals. Nigral tissues were 
dissected 24 h after the last injection and mRNA levels for TNFα, IL1β and iNOS were 
determined by real-time SYBR green qRT-PCR. The 18S rRNA gene was used as the 
internal normalizing control and the data expressed as fold change over saline-treated 
controls. Asterisks (*p<0.05, ** p<0.01 and ***p< 0.001) indicate significant differences 
between LPS-treated groups from PKCδ wild-type (+/+) and PKCδ knockout (-/-) mice 
injected with MPTP. B, Western blot for gp-91 PHOX. Nigral tissues from PKCδ wild-type 
(+/+) and knockout (-/-) mice were dissected 24 h after the last injection of either saline (S) 
or MPTP (M). Lysates were probed by Western blotting for gp91-PHOX, the membrane-
bound subunit of the NADPH-oxidase complex, using a mouse monoclonal antibody. β-actin 
was used as a loading control. MPTP treatment caused a robust increase in gp91 PHOX 
protein levels in wild-type mice as expected but not i PKCδ knockout mice. Reduced basal 
levels of NADPH oxidase were also evident in PKCδ knockout (-/-) mice. Representative 
blots are shown and experiments were repeated three times. C, Iba1-immmunohistochemistry 
in nigral brain sections. Substantia nigra section from PKCδ wild-type (+/+) and knockout (-
/-) mice were stained for the microglial activation marker Iba1 using a rabbit polyclonal 
antibody (1:500 dilution). Sections were then incubated with an Alexa-488 (green) 
conjugated secondary antibody. Images were captured using a Nikon TE-2000 fluorescence 
microscope at 20X magnification. The substantia nigra zone is outlined in red. Scale bar is 50 
μm. Representative images are shown.  
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Figure 11. 
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Figure 11. PKCδ knockout mice are protected against MPTP-induced nigrostriatal 
dopaminergic degeneration.  A, HPLC analysis of striatal dopamine and its metabolites. 
PKC delta wild-type and knockout mice were treated with 4 doses of MPTP (18 mg/kg) or 
saline at 2 h intervals and were sacrificed 7 days after the last injection. The levels of striatal 
dopamine and its metabolites DOPAC and HVA were determined by HPLC. Data represent 
the mean ± SEM of six mice per group. Asterisks (***p< 0.001) indicate significant 
differences between saline and MPTP-treated wild-type mice; # p<0.01 and * p<0.05 denotes 
significant differences between PKCδ wild-type and knockout mice treated with MPTP. B, 
TH-DAB immunohistochemistry in substantia nigra and striatial sections. Mice were 
perfused 7 days after MPTP dosing and sections were processed for TH-DAB 
immunostaining. Images were captured at 2X and 20X (Inserts) magnifications for SNpc 
sections. Striatal sections were imaged at 2X magnification. PKCδ knockout mice were 
significantly protected against TH-neuron and terminal degeneration compared to wild-type 
littermates. Representative images are shown and experiments were repeated three times. C, 
Stereological analysis of TH-positive neurons in the substantia nigra of PKC wild-type and 
knockout mice following MPTP treatment.  
 
 
 
 
 
 
175 
 
 
Figure 12 
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Figure 12. PKCδ knockout mice are protected against MPTP-induced behavioral and 
locomotor deficits. A, Versaplot movement track of mice. Locomotor and behavioral 
parameters were analyzed 5 days after MPTP treatment in PKCδ wild-type and knockout 
mice. Locomotor activity was measured using a VersaMax Analyzer. The movement track 
(Versaplot) of the mice collected over 10 minutes was plotted. Red dots denote vertical 
movements. B-F, quantification of locomotor and behavioral parameters using the VersaMax 
Analyzer. Saline or MPTP-treated mice were placed in the VersaMax Analyzer for 10 
minutes and various locomotor activity parameters were measured simultaneously. PKCδ 
knockout mice showed significantly improved vertical activity (B), horizontal activity (C), 
total distance travelled (D), number of stereotypy movements (E) and total movement time 
(F). G, Rotarod performance analysis. Rotarod analysis was performed 5 days after MPTP 
treatment and the amount of time spent on the rotarod was measured in PKCδ wild-type and 
knockout mice. Data represent the mean ± SEM of more than six mice per group. Asterisks 
(***p< 0.001 and ** p<0.01) denote significant differences between MPTP-treated wild-type 
(WT) and PKCδ knockout (KO) mice; # denotes a significant difference (p<0.01) between 
wild-type controls and MPTP-treated groups. 
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Manuscript Supplementary Figures 
Figure 1.   Electron microscopy imaging of alpha synuclein aggregates 
 
 
 
 
 
 
 
 
 
 
Figure 2.   Knockdown of PKCδ expression by siRNA attenuates LPS-induced TNFα 
levels 
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CHAPTER IV 
 
A SIMPLE MAGNETIC SEPARATION METHOD FOR HIGH-YIELD ISOLATION 
OF PURE PRIMARY MICROGLIA 
 
A paper published in the Journal of Neuroscience Methods  
Richard Gordon, Colleen E. Hogan, Matthew L. Neal, Vellareddy Anantharam, Anumantha 
G. Kanthasamy and Arthi Kanthasamy 
Abstract 
Microglial cells play a dynamic role in the brain beyond their established function of 
immune surveillance. Activated microglia play a key role in neural development, 
neuroinflammation, neural repair and neurotoxicity.  They are particularly important in 
several neurodegenerative diseases in which sustained microglial activation contributes to the 
progression of neurodegenerative processes. Consequently, understanding microglial 
function in CNS health and disease has become an area of active research in recent years. 
However, a significant obstacle to progress in this field has been the inherent difficulties in 
obtaining large amounts of primary microglial cells to routinely perform mechanistic studies 
and characterize the signaling pathways regulating the dynamics of microglial activation. 
Herein, we describe a novel column-free magnetic separation protocol for high-yield 
isolation of primary microglia from mouse postnatal mixed glial cultures. The procedure is 
based on optimized culture conditions that enable high microglial cell densities in the 
confluent mixed glial cultures followed by highly efficient recovery of pure microglia by 
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magnetic separation. The novel column-free magnetic separation system utilizes tetrameric 
antibody complexes (TAC) with dual specificity for the CD11b-PE labeled microglia and 
dextran magnetic nanoparticles. An FcR blocker (anti-CD16/32) is added to enhance the 
purity of the microglial separation by preventing non-specific labeling of other cell types. 
This procedure yields on average > 3 x 10
6 
microglial cells per mouse pup, with a remarkable 
purity of 97% and recovery of around 87% of microglia from the mixed glial population. 
Importantly, the microglia obtained by this method are fully functional and respond like cells 
obtained by conventional isolation techniques.  
 
Introduction 
The functional responses of microglia in the normal and diseased brain have become 
intensively investigated since their discovery as key players in the central nervous system 
(CNS). Besides their established functions of immune surveillance and phagocytic clearance 
in the brain, activated microglia have been shown to participate in neuronal survival by 
providing neurotrophic support and in maintaining neuron homeostasis during development  
(Bessis et al., 2007; Marin-Teva et al., 2004; Streit, 2002). They also have been implicated in 
facilitating neurogenesis and neural repair by directing the migration of neuronal progenitors 
to the sites of brain injury (Aarum et al., 2003; Walton et al., 2006). However, in chronic 
neurodegenerative diseases such as Alzheimer’s or Parkinson’s disease, there is compelling 
experimental evidence that microglial activation becomes deregulated and that the sustained 
reactive microgliosis that occurs can be neurotoxic and exacerbate neurodegeneration (Block 
et al., 2007).  Under disease conditions, the persistently activated microglia can augment 
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neurodegenerative processes by promoting oxidative stress, as well as by producing 
proinflammatory mediators including cytokines and chemokines (Aschner et al., 1999; Glass 
et al., 2010) 
Although much progress has been made at the cellular level in terms of defining the 
functional role of microglia as active players in CNS development, health and disease, far 
less is known about the subcellular processes, extracellular interactions and intracellular 
signaling pathways that regulate the dynamics of microglial activation. Particularly, the 
process by which microglia become chronically activated in neurodegenerative diseases and 
evade intrinsic mechanisms of regulatory control is largely unknown (Block et al., 2007; 
Glass et al., 2010). Understanding these phenomena would have immense therapeutic 
implications since reactive microgliosis is evident in most neurodegenerative diseases. The 
study of microglial cell biology, however, has been hindered due to inherent difficulties with 
obtaining large enough yields of primary microglial cells to routinely perform experimental 
techniques to elucidate signaling pathways, such as Western blotting, cell fractionation or 
proteomic studies. Unlike astrocytes, isolated primary microglia do not proliferate well 
unless specific growth factors are added. Immortalized cell lines, such as the BV-2 and N9 
cells, have been widely used to study microglial responses. However, the highly dynamic and 
intricate process of microglial activation is poorly reproduced by such cell lines as they do 
not display the quintessential morphology changes seen with activation. Also, these cell lines 
have a far more limited cytokine and chemokine profile in comparison with primary 
microglia. In vitro experiments with isolated primary microglia are therefore of immense 
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utility in deciphering the signaling pathways and complex interactions regulating microglial 
activation and provide the most relevant model system for mechanistic studies.  
Various protocols have been developed for microglial isolation. The differential 
adherence method is one of the most popular protocols. Mixed glial cultures are obtained 
from newborn rodent brains and allowed to grow to confluency. The microglial cells are then 
separated from the adherent astrocyte layer by agitation on a rotary shaker (Floden and 
Combs, 2007). The resulting microglial cell population, though highly pure, is low in number 
since most of the microglia that grow below the astrocyte layer are not recovered.  Mild 
trypsinization has been reported as an alternative to the differential adherence method, and 
allows for a higher yield of pure microglial cells (Saura et al., 2003). Again, primary mixed 
glial cultures are obtained from newborn rodent brains and grown to confluency. An optimal 
concentration of trypsin, Ca
2+
, and EDTA has been determined and used to selectively detach 
the astrocyte layer, leaving the microglial cells attached. Mild trypsinization allows for a 
higher yield of microglia with purities comparable to the differential adherence method, 
though the amount of microglial cells obtained is still insufficient when considering possible 
experimental designs. Column-based magnetic separation is one of the newer techniques for 
isolation of primary microglia (Marek et al., 2008). Confluent mixed cultures are trypsinized 
and incubated with CD11b magnetic microbeads that specifically label microglial cells. The 
labeled cells then are run through a magnetic column where the microglial cells are 
selectively retained, while unlabeled cells pass through and are removed. After several 
washes, a purified fraction of microglial cells can be eluted. The microglia yield from 
column-based magnetic separation, however, is no higher than that obtained with mild 
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trypsinization. With the advent of highly specific monoclonal antibodies that label unique 
cell populations, magnetic cell separation technology has progressed to become an 
indispensable tool for cell separation in the field of immunology, and has been widely used to 
separate and analyze almost every immune cell type (Grutzkau and Radbruch, 2010).   
In this study, we report a new column-free magnetic separation method for high-yield 
isolation of primary microglia from postnatal mixed glial cultures, which is both simple and 
efficient. This procedure requires no special columns and can be carried out in routinely used 
round bottom polystyrene tubes. Unlike previously reported magnetic separation methods 
that utilize CD11b microbeads, our procedure utilizes bispecific tetrameric antibody 
complexes (TAC) and dextran-coated magnetic nanoparticles to label and purify microglial 
cells based on their selective expression of the CD11b epitope. Further, an anti-CD16/32 
(Fcγ III/II receptor) antibody is added to the labeling reagent as an FcR blocker to enhance 
the purity of the microglial separation by preventing non-specific labeling of other cell types 
in the mixed glial population. This system provides a rapid and efficient separation of 
microglia with extremely high recoveries (87.98 ± 2.6%) and purity levels in excess of 97%, 
which is sufficient for most types of studies. The magnetically separated microglia show 
typical morphological and functional responses with various activation stimuli for all aspects 
of the microglial response that were tested, including nitric oxide production, cytokine 
release and intracellular ROS generation. Notably, this method affords a yield and recovery 
of primary microglial cells that is high enough to perform common biochemical experiments 
involving Western blotting, PCR, and proteomics without sacrificing unreasonable numbers 
of postnatal mouse pups.  
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Materials and methods 
Preparation of mixed glia cultures 
Primary cultures were prepared from C57bl6 postnatal day P0 to P1 mouse pups. 
Mouse brains were harvested, meninges removed and then placed in ice-cold Dulbecco’s 
modified Eagle’s medium/F-12 nutrient mixture (DMEM-F12,GIBCO Cat # 11320) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 50 U/mL penicillin, 50 
μg/mL streptomycin, 2 mM L-glutamine, 100 μM non-essential amino acids, and 2 mM 
sodium pyruvate (Invitrogen). The tissue then was incubated in 0.25% trypsin (Sigma) in a 
37°C water bath for 30 min with gentle agitation. Trypsinization was stopped by adding an 
equal volume of DMEM-F12 complete media, and the brain tissue was washed three times in 
the same medium. A single cell suspension of the brain tissue was prepared by gentle 
trituration and passed through a 70 μm nylon mesh cell strainer to remove tissue debris and 
aggregates. The cell suspension then was made up in DMEM-F12 complete medium and 
seeded such that one mouse brain was plated into 2 T-75 flasks, each containing a total 
volume of 12 mL. Cells were placed in a humidified CO2 incubator at 37°C and allowed to 
attach. The medium was changed after 4 to 5 days and the mixed glial cells were allowed to 
grow to confluence. Microglial separations were performed on days 14 to 16, at which time 
the microglial cell density in the mixed glial cultures is high (Saura et al., 2003). 
Differential adherence isolation of microglia from mixed glial cultures 
Confluent 14- to 16-day old mixed glial cultures were placed on an orbital shaker (Stovall 
Belly Dancer) at 120 rpm for 2.5 h to induce the detachment of the microglial cells. 
Immediately following agitation, the supernatant containing the microglia was collected and 
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centrifuged at 300 x g for 5 min and resuspended in 2 mL of fresh DMEM-F12 complete 
medium. The primary microglia were counted using a Beckman Coulter Vi-Cell XR 
automated cell counter and plated according to the cell number required for experiments.  
Column-free magnetic separation for isolating microglia from mixed glia 
Column-free magnetic separation was performed on 14- to 16-day old confluent 
mixed glial cultures using the EasySep mouse CD11b positive selection kit purchased from 
STEMCELL Technologies (Catalog # 18770). The principle of the column-free magnetic 
separation method is presented in Fig. 1. Cells were trypsinized with 3 mL of 0.25% trypsin 
per T-75 flask. The flasks were agitated on a rotary shaker for 20 min and the trypsin reaction 
was stopped by adding 6 mL of DMEM-F12 complete media. Any remaining adherent cells 
were scraped off using a cell scraper. The harvested cell suspension was then gently 
triturated to break down cell aggregates, and then passed through a 70 μm cell strainer to get 
a uniform single cell suspension. Obtaining a uniform single cell suspension, free from 
aggregates, is critical to achieve a high yield and purity with magnetic separation. The cells 
were centrifuged at 200 x g for 6 min and counted on a Beckman Coulter ViCell XR 
automated cell counter. The mixed glial cells were resuspended at a density of up to 1x10
8
 
cells/mL in the recommended separation medium (PBS containing 2% FBS and 1 mM 
EDTA, with no calcium or magnesium) and transferred to a Falcon 5 mL polystyrene round-
bottom tube (BD Biosciences, Catalog #352058). The labeling reagent containing the 
CD11b-Phycoerythrin (CD11b-PE) monoclonal antibody and the FcR blocker (anti-
CD16/32) was added at 50 μL/mL. The cell suspension was mixed gently and incubated at 
room temperature for 15 min. The PE-Selection Cocktail (containing the bispecific tetrameric 
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antibody complexes directed against phycoerythrin and dextran) was then added at 70 
μL/mL. The cell suspension was mixed well and allowed to incubate at room temperature for 
15 min. The dextran-coated EasySep Magnetic Nanoparticles were gently mixed to obtain a 
uniform suspension and added at 50 μL/mL, mixed well, and allowed to incubate at room 
temperature for 10 min. The cell suspension was then made up to a total volume of 2.5 mL 
with separation medium. The cells were gently mixed to obtain uniform dispersion and the 
tube was placed into the EasySep Magnet obtained with the kit and set aside for 7 min. In 
one continuous motion, the EasySep Magnet was inverted to pour off the unlabeled cells. The 
magnetically labeled microglial cells remained inside the tube, held by the magnetic field of 
the magnet. The magnet and tube were left in the inverted position for 2-3 s, and then 
carefully returned to an upright position. The tube was then removed from the magnet and 
the magnetically retained cell suspension was made up to a volume of 2.5 mL with separation 
medium. The cell suspension was mixed by gentle pipetting up and down 2-3 times, and the 
tube was placed back into the magnet. The wash step was repeated 3 times to obtain purity 
levels of >97%. After the final wash, the purified microglial cells (positive fraction) were 
resuspended in DMEM/F12 complete media and counted using the Beckman Coulter Vi-Cell 
automated cell counter prior to seeding for experiments. The unlabeled cells obtained from 
the second and third pour-off steps were collected as the negative fraction.  
Flow cytometry 
The proportion of microglia in different cell populations was estimated by direct 
labeling with CD11b-PE followed by flow cytometric analysis. Cells were counted using a 
Vi-Cell XR automated cell counter and 1x10
6 
cells/mL were resuspended in 100 µL of flow 
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cytometry buffer (PBS with calcium and magnesium containing 0.01% sodium azide). Cells 
were labeled using the mouse CD11b-PE labeling reagent (STEMCELL Technologies) 
according to the manufacturer’s instructions. After labeling, the cells were washed twice in 
flow cytometry buffer and resuspended at a final volume of 1 mL and stored on ice until 
analysis. Flow cytometry was performed on a BD FACSCanto flow cytometer at Iowa State 
University’s centralized flow cytometry facility, and data analysis was performed using the 
instrument's software package.  
Immunofluorescence 
Immunofluorescence microscopy also was used to validate the purity levels of the 
microglial separations determined by flow cytometry. The positive and negative fractions 
obtained after separation, as well as the total mixed glial cell population obtained prior to 
magnetic separation, were seeded on poly-D-lysine- coated coverslips in a 24-well plate at a 
density of 200,000 cells per well. Cells were fixed with 4% paraformaldehyde for 30 min and 
washed five times with PBS. The cells were blocked and permeabilized for 1 h in blocking 
buffer (PBS containing 2% BSA, 0.5% TritonX and 0.05% Tween 20) and incubated with 
primary antibodies at 4°C overnight in PBS with 2% BSA. Primary antibodies used were 
goat polyclonal to Iba1 (Abcam) for microglia and rabbit polyclonal GFAP (Santa Cruz 
Biotechnology) for astrocytes, both at a concentration of 1:1000. After 3 washes in PBS, 
species-specific secondary antibodies (Alexa Fluor, Molecular Probes) were added at room 
temperature for 1 h. Images were captured using a Nikon Eclipse TE-2000 fluorescence 
microscope.  
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Western blotting 
For Western blot analysis, magnetically separated microglia cells were plated at a 
density of 4 x 10
6 
cells per flask in poly-D-lysine coated T-25 flasks. Cells were stimulated 
with 100 ng/mL LPS or 200 nM aggregated alpha synuclein (rPeptide Inc.) for 24 h. After 
treatment, cells were collected by trypsinization and cell scraping. Cell pellets were lysed 
using RIPA buffer (Pierce Biotechnology) and 30 μg of protein was loaded per sample. 
Proteins were separated on 12% polyacrylamide gels and transferred to a nitrocellulose 
membrane (BioRad) overnight. Membranes were incubated in fluorescent Western blocking 
buffer (Rockland Immunochemicals) for 45 min and then probed with primary antibodies for 
gp91phox (BD Transduction) at a dilution of 1:1,000, iNOS/NOS2 (Santa Cruz 
Biotechnology) at a concentration of 1:200, and Iba1 (Abcam) at 1:1000. β-actin (Sigma-
Aldrich) at a concentration of 1:10,000 was used as the loading control. Fluorescent infrared 
dye-tagged secondary antibodies (Molecular Probes) were used to visualize the bands, and 
the membranes were scanned on an Odyssey Infrared Imaging System (Li-Cor Biosciences).  
Microglial nitric oxide detection  
Microglial nitric oxide production was determined indirectly by quantification of 
nitrite in the supernatant using the Griess reagent (Sigma Aldrich). Magnetically separated 
microglia were plated in poly-D-lysine coated 96-well plates at 150,000 cells per well. After 
attachment, cells were treated with 100 ng/mL of LPS for 24 h or pretreated with 100 µM 
apocynin for 30 min. After treatment, 100 μL of supernatant was collected from each well 
and an equal volume of the Griess reagent was added. The samples were incubated on a plate 
shaker at room temperature for 15 min until a stable color was obtained. The absorbance at 
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540 nm was measured using a Synergy 2 multi-mode microplate reader (BioTek Instruments) 
and the nitrite concentration determined using a sodium nitrite standard curve. 
Cytokine assays 
Magnetically separated microglia cells were seeded in poly-D-lysine coated 96-well 
plates at 50,000 cells per well. Cells were treated for 24 h with 100 ng/mL of LPS or 
pretreated with 100µM apocynin for 30 min. After treatment, 50 µL of supernatant from each 
well was collected and frozen at -80°C. Cytokine levels were determined using the Luminex 
immunoassay system using recombinant cytokines as  standards  (Vignali, 2000). 
Intracellular reactive oxygen species (iROS) detection 
Intracellular reactive oxygen species (ROS) were determined using the fluorescent 
probe 2’,7’-dichlorodi-hydrofluorescein diacetate (DCFH-DA) (EMD Chemicals), according 
to previously published protocols (Qian et al., 2007; Zhang et al., 2005). Purified microglia 
were plated on a 96-well plate at 10
5
 cells per well. Before treatment, cells were washed in 
HBSS and incubated with 40 µM DCFH-DA in HBSS containing 2% FBS for 30 min. Cells 
were then treated with 100 ng/mL LPS, 30 ng/mL of recombinant mouse TNF alpha (Sigma-
Aldrich) or 200 nM aggregated alpha synuclein (rPeptide Inc.) for 6 h. For iROS inhibition 
studies with apocynin, cells were pretreated with 100 µM apocynin for 30 min.Shorter 
treatment times were chosen for iROS generation studies based on previously published 
reports (Zhang et al., 2005) and because maximal iROS generation occurs early during 
microglial activation. After treatment, the plate was incubated at 37°C for 1 h and the 
fluorescence intensity determined using a Synergy-2 multi-mode microplate reader at an 
excitation of 485/20 and an emission of 530/25. The fluorescence value from the control 
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cultures was subtracted as background and the increase in fluorescence with treatment was 
expressed as increased iROS (Qian et al., 2007; Zhang et al., 2005). 
Statistics  
The data are expressed as the mean ± SE. Statistical significance was determined by 
ANOVA, followed by Bonferroni t-test using the GraphPad Prism statistical analysis 
software package. Values of p < 0.05 were considered statistically significant. 
 
Results 
Yield and purity of primary microglia by magnetic separation 
Flow cytometry and immunofluorescence studies were performed on parallel cultures 
to evaluate the purity of the microglia before and after magnetic separation. Confluent 14- to 
16-day old mixed glial cultures grown in DMEM-F12 contained 25.55 ± 3.0% CD11b
+
 
microglia. After magnetic separation, the positive fraction contained 97.65 ± 0.83% pure 
CD11b
+
 microglia and the negative fraction contained 1.650 ± 0.34% microglial cells (Table 
1). Using flow cytometry and automated cell counting of the CD11b
+ 
population
 
in the total 
mixed glial cells and magnetically enriched microglial fractions, we estimated the percent 
recovery. With differential adherence it was possible to recover only 25.94 ± 3.9% of the 
total microglial population from the mixed glial cultures. In comparison, our column-free 
magnetic separation procedure recovered about 87.98 ± 2.6% (Table 2). As depicted in 
Figure 2, the quantitative data obtained with flow cytometry were also confirmed by 
immunofluorescence using a different microglial marker, Iba1, which is commonly used to 
identify microglia. GFAP was used to label the astrocytes that were typically the most 
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abundant cells in the mixed glial cultures. Mixed cultures before magnetic separation showed 
distinctive populations of microglia and astrocytes (Fig.2A-B).  Immunofluorescence 
labeling of positive fractions obtained after magnetic separation revealed a co-localization of 
almost all the Hoechst positive cells with Iba1  staining (Fig.2C-D), indicating that most of 
the cells are microglia. Conversely, the negative fractions contained mostly GFAP-positive 
astroglial cells (Fig.2E-F). In terms of purity, both magnetic separation and differential 
adherence had more than 97% microglial purity, as determined by immunofluorescence 
(Fig.3A to F) and quantification of the nuclear stain Hoechst co-localized Iba1-positive 
microglia and GFAP-positive astrocytes (Fig. 3G). 
Morphology, nitric oxide generation and cytokine release 
Since functional validation of the microglia is critical to establishing the utility of our 
method, we examined different aspects of the microglial response in the magnetically 
separated microglia following the activation with known stimuli. Phase contrast microscopy 
revealed the typical microglial morphology normally seen with activation, including 
hypertrophy and extensive branched processes, as compared to the unstimulated microglia 
(Fig. 4B-C). The morphology of the resting microglia showed slight variations depending on 
the cell density and the number of days in vitro. Next we studied the microglial response to 
the bacterial endotoxin LPS (Glezer et al., 2007; Lehnardt et al., 2003), and also used the 
well characterized NADPH oxidase inhibitor apocynin to attenuate LPS-induced activation 
(Bedard and Krause, 2007; Vejrazka et al., 2005). As shown in Fig. 5, nitrite levels were 
profoundly increased upon LPS treatment at 24 h and were attenuated with apocynin 
pretreatment. We also studied the cytokine responses from magnetically separated microglia 
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stimulated with LPS. The levels of two proinflammatory cytokines TNFα and IL-1β, as well 
as the prototypical anti-inflammatory cytokine IL-10, were measured in cell-free 
supernatants after 24 h of LPS treatment. As expected, LPS induced a dramatic increase in 
cytokine levels while apocynin treatment attenuated LPS-induced cytokine production to 
various extents depending on the specific cytokine (Fig. 6). The suppression of microglial 
nitric oxide production and cytokine release by apocynin is consistent with the established 
functions of apocynin as an inhibitor of peroxynitrite formation and cytokine production in 
microglia and other phagocytic cells (Stefanska and Pawliczak, 2008). These results 
demonstrate that the magnetically isolated microglia show expected activation profiles for 
both nitric oxide and cytokine production and have similar responses compared to primary 
microglia obtained by other methods. 
 Intracellular ROS generation  
Rapid intracellular ROS generation by the NADPH oxidase complex is a critical 
regulator of microglial activation since it controls other aspects of the microglial response, 
including proinflammatory gene expression, rapid proliferation and the dynamic morphology 
changes seen in activated microglia. We used the fluorescent probe DCFH-DA to determine 
the production of intracellular ROS (iROS) in the magnetically separated microglia in 
response to alpha synuclein, LPS, and TNFα, which are known to induce iROS generation 
(Wang et al., 2004; Zhang et al., 2005). We observed significant increases in levels of iROS 
production with each of the stimuli at 6 h, with TNFα showing the highest levels of iROS 
(Fig. 7A). Again, apocynin pretreatment significantly attenuated LPS-induced intracellular 
ROS production (Fig. 7B), which would be expected based on its known function as a 
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NADPH oxidase inhibitor in immune cells including microglia (Peng et al., 2009). These 
results demonstrate that the magnetically separated microglia show the expected intracellular 
ROS responses upon activation by various relevant stimuli.  
Western blot analysis of magnetically separated microglia 
One of the current methodological challenges in microglial research is getting an 
adequate number of cells for biochemical investigations by Western blot. To demonstrate the 
versatility of the magnetic separation method for biochemical studies, we performed Western 
blot analysis in the magnetically purified microglia by examining typical signaling events 
associated with microglial activation. We probed the Western blot for the changes in 
expression of the gp91phox subunit of the NADPH oxidase complex as well as the inducible 
nitric oxide synthase (iNOS) and Iba1, which are known to be upregulated upon microglial 
activation. In concordance with our nitric oxide and iROS data, we observed increased levels 
of iNOS and gp91phox protein levels in activated microglia as well as a significant induction 
of Iba1 (Fig. 8A,B). It is important to note that the number of microglial cells required for 
such an experiment can be obtained from as few as 6 postnatal pups, based on the estimated 
yields obtained with our column-free magnetic separation protocol.  
Discussion 
We have developed a novel method to isolate primary microglia from postnatal mixed glial 
cultures by column-free magnetic separation technology based on tertrameric antibody 
complexes (TACS) and dextran-coated magnetic nanoparticles. The utility of our system lies 
in the high yield of microglia obtained (>3x10
6 
cells/mouse pup), with purity levels (>97%) 
comparable to those obtained with current methods. This procedure is simple, quick and 
193 
 
 
reproducible, and requires no special columns or equipment other than the magnet obtained 
with the isolation kit.  A significant constraint of currently available methods for microglial 
isolation from postnatal mixed glial cultures has been the low yield obtained, which limits 
the type and number of studies that can be conducted. Particularly, experiments that require 
large amounts of cells as starting material such as RNA isolation for quantitative PCR, 
Western blot analysis, cell fractionation or proteomic studies cannot be routinely performed 
with primary microglia using current methods because of the unreasonable number of 
postnatal mouse pups that would be required. Our method can overcome these limitations by 
providing more microglial cells for various biochemical experiments.  
The most commonly used differential adherence or plate shaker method yields, at 
best, less than 1 x 10
6 
microglia cells per mouse pup (Floden and Combs, 2007; Marek et al., 
2008; Saura et al., 2003). The trypsinization method developed by Saura et al. yields on 
average 1.75 x 10
6 
microglial cells per mouse pup, which is comparable to that obtained 
recently by Marek et al. (1.6 x10
6 
cells per neonatal brain) using column-based magnetic 
separation with CD11b microbeads (Floden and Combs, 2007; Marek et al., 2008; Saura et 
al., 2003). Our protocol using column-free magnetic separation with tetrameric antibody 
complexes yielded on average >3 x 10
6 
cells per mouse pup, with more than 85% recovery of 
the primary microglia from the mixed glial cultures. We believe that the increased yield of 
microglia obtained with our procedure is the result of optimized conditions that facilitate a 
high microglial cell density in the mixed glial cultures, as well as the efficient recovery of the 
microglia by employing tetrameric antibody complexes in the magnetic separation steps. Our 
pilot studies to optimize our method demonstrated that age of the mouse pups, the medium 
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used for mixed glial cultures and the number of media changes were critical factors 
influencing the proportion of the microglial cells obtained with 14- to 16-day mixed glial cell 
cultures. We observed lower numbers of primary microglia and more astrocytes when 
DMEM was used instead of DMEM-F12, as suggested by other investigators (Saura, 2007). 
Consequently, lower yields of microglia were obtained with DMEM medium (supplementary 
figure 1). The precise reason for higher numbers of microglia in mixed glial cultures grown 
in DMEM-F12 is not known but is likely due to the additional supplements present in the F-
12 fortified media being beneficial for microglial proliferation. We changed the mixed glial 
culture media only once at day 4 to 5 to allow for microglial growth factors produced by 
astrocytes such as colony stimulating factor-1 (CSF-1) to accumulate and promote microglial 
proliferation over the remaining culture period (Hao et al., 1990). As with all protocols for 
isolation of postnatal microglia, the age of the mouse pup is a crucial determinant of the final 
number of viable microglial cells obtained in mixed glial cultures (Giulian and Baker, 1986). 
The use of older mouse pups (P2 or later) usually results in significantly lower amounts of 
microglia in the mixed cultures and subsequently lower yields after magnetic separation. It is 
likely that the viability and proliferative capacity of microglia or their progenitor cells are 
considerably reduced in older mouse pups and could be the reason for the lower yields 
obtained. The yield and purity levels of primary microglia obtained by our method are high 
enough to provide sufficient numbers of cells for key experiments including qPCR analysis, 
Western blotting or proteomic studies which are otherwise problematic using conventional 
isolation protocols because of the inherently low yields obtained.   
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Functional validation of the microglial cells obtained by magnetic separation is 
crucial to demonstrate the feasibility of a new isolation technique. Therefore, we extensively 
tested the microglia obtained by magnetic separation using different functional assays, 
including cytokine production, nitric oxide release and intracellular ROS generation. The 
magnetically separated microglia show typical morphology changes associated with LPS 
stimulation and the expected increases in cytokine release, NO production and iROS 
generation.  More importantly, the NADPH oxidase inhibitor apocynin effectively attenuated 
the LPS-induced cytokine release and ROS generation, demonstrating the utility of 
magnetically separated microglial cells for pharmacological studies.  Aggregated alpha 
synuclein and TNFα treatments also increased intracellular ROS generation in these cells. 
The functional responses associated with microglial activation were also validated by 
Western blot analysis of the associated signaling proteins iNOS and gp91phox, which were 
induced during microglial activation along with Iba1. Collectively, these results demonstrate 
that the microglia obtained by our magnetic separation procedure retain their characteristics 
and function similarly to those isolated by conventional methods.  
Isolation of microglia from adult mouse brain is a more representative model for 
understanding microglial function, particularly in neurodegenerative diseases where age is a 
critical factor.  Indeed, some researchers have shown that adult brain microglia can react 
differently from those obtained from postnatal mice (Floden and Combs, 2006), while others 
have found only subtle differences (Moussaud and Draheim, 2010). However, because of the 
inherent difficulties in isolating microglia from the adult brain and the more complex 
protocols involved, adult brain microglia are still not as commonly used for ex vivo studies as 
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postnatal microglial cultures. Given that adult brain microglia express high levels of the 
CD11b epitope, the column-free magnetic separation procedure outlined here should be 
adaptable for separating microglia from adult mouse brain cell suspensions, similar to 
protocols used with CD11b microbeads (de Haas et al., 2007). We are currently optimizing 
the tissue processing steps in an attempt to develop a method to isolate adult brain microglia 
with this system.   
In summary, we have developed and optimized a simple column-free magnetic cell 
separation technique for high-yield isolation of primary microglia from postnatal mixed glial 
cultures. The higher number of microglial cells obtained by this method allows for studies 
requiring large amounts of microglia to be performed more frequently. It should also reduce 
the number of animals needed, since more experiments can be done with fewer mouse pups 
as starting material. Given the increased interest in understanding microglial function in CNS 
health and disease, this method could be of immense utility for researchers studying 
microglial cell biology.  
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Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Principle of column-free magnetic separation. Schematic illustration of CD11b-PE 
Tetrameric Antibody Complex (TAC) technology used for column-free immunomagnetic 
separation of microglia (A). Flow diagram (B) of steps involved in column free magnetic 
separation of microglia from postnatal mixed glial cultures (Graphics used with permission 
from STEMCELL Technologies Inc) 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Analysis of microglial population before and after magnetic separation. The 
proportion of microglia was determined quantitatively by flow cytometry with direct CD11b-
PE labeling and also confirmed by iba1/GFAP/Hoechst immunofluorescence. Before 
separation, the mixed glial population contained around 26% CD11b
+
 microglia (B,A). After 
magnetic separation, the positive fraction contained more than 97% pure microglia (D,C) 
while the negative fraction had less than 2% microglia with abundant GFAP-positive cells 
(F,E). Results from one representative separation are shown. Data for multiple separations is 
summarized in Table 1. 
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Figure 3. 
 
 
 
 
 
 
 
 
 
Fig. 3. Comparison of microglial cell purity obtained by differential adherence and 
magnetic separation. Triple labeling immunofluorescence was with iba1/GFAP/Hoechst G 
G 
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was used to compare microglial purity obtained by magnetic separation (A,B,C) and 
differential adherence (D,E,F). As shown above both methods had comparable purities with 
greater than 97% iba1-positive microglia. The number of Hoechst co-localized iba1-positive 
microglia and GFAP-positive astrocytes were also counted to quantitatively estimate the 
purity levels (G) 
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Figure 4. 
 
 
 
Fig. 4. Morphological assessment of magnetically separated microglia. Phase contrast 
microscopy was used to study microglial morphology. In confluent mixed glial cultures (A) 
abundant microglia are within the astrocyte layer.  In magnetically separated microglia 
dramatic morphology changes, typical of activated microglia were observed with LPS (100 
ng/ml for 24 h) treatment (C) compared to unstimulated microglia (B). 
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Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Nitrite levels in magnetically separated microglia.  Nitric oxide production was 
estimated by quantification of nitrite using the Griess reagent.  LPS (100 ng/ml, 24 h) 
treatment  induced a significant increase in nitrite production (** p<0.01) compared to 
control, which was attenuated by pretreatment with 100 µM apocynin (** p<0.01 compared 
to LPS). 
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Figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Cytokine release in magnetically separated microglia. Supernatant cytokine levels 
were determined using a Luminex immunoassay system.  LPS (100ng/ml, 24 h) treatment 
induced a significant increase in IL1β (A), TNFα (B) and IL-10 (C) production (** p<0.01) 
compared to control. Pretreatment with 100µM apocynin reduced cytokine release to 
different extents (** p<0.01 , ns - not significant)  
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Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7.  Intracellular ROS generation in magnetically separated microglia.  iROS was 
determined using the DCFH-DA probe. Stimulation with aggregated alpha synuclein 
(200nM), LPS (100ng/ml) and TNFα (30ng/ml) for 6 h induced significant iROS generation 
(* p<0.05, ** p<0.01) compared to control (A). Pretreatment with 100µM apocynin (B) 
significantly blocked LPS-induced iROS generation at 12 h (** p<0.01 ). 
A 
B 
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Figure 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8.  Western blot analysis of magnetically separated microglia. Whole cell lysates 
from magnetically separated microglia were probed for iNOS, iba1 and gp91 phox protein 
levels after treatment.  LPS (100ng/ml, 24 h) increased gp91 phox protein levels (A). Both 
LPS and alpha Synuclein (200nM) also upregulated iNOS and iba1 protein levels in 
magnetically separated microglia stimulated for 24 h. 
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Supplementary Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of microglia yield from mixed glial cultures grown in DMEM and DMEM-
F12 medium. The yield of primary microglia per mouse brain obtained by magnetic 
separation from mixed glial cultures grown in DMEM or DMEM-F12 was determined by 
automated cell counting. Significantly higher yields of microglia (* p<0.05) were obtained 
with DMEM-F12 medium.  
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CHAPTER V 
 
PROKINETICIN-2 IS SECRETED BY DOPAMINERGIC NEURONS FOLLOWING 
NEUROTOXICITY AND IS NEUROPROTECTIVE IN CELL CULTURE MODELS 
OF PARKINSON’S DISEASE 
 
A manuscript in preparation for The Journal of Neuroscience   
 
Richard Gordon, Matthew L. Neal, Anamitra Ghosh, Vellareddy Anantharam, Arthi 
Kanthasamy  and Anumantha G. Kanthasamy  
 
Abstract 
Prokineticin-2 (PK2) is a recently discovered secreted protein that regulates diverse 
physiological functions in a tissue-specific manner. In the brain, PK2 signaling participates in 
olfactory bulb neurogenesis by directing the migration of subventricular zone progenitor cells 
and also controls circadian rhythms by functioning as an output molecule from the 
suprachiasmatic nucleus. PK2 expression however, is undetectable in other regions of the 
adult brain although its receptor PKR2 is ubiquitously expressed at high density. Herein, we 
demonstrate for the first time that PK2 is rapidly induced in nigral dopaminergic neurons in 
the MPTP model of Parkinson’s disease and in dopaminergic N27 cells treated with MPP+ or 
TNFα. We also report elevated levels of PK2 in nigral samples from postmortem PD patients 
demonstrating the clinical relevance of our findings. The PK2 GPCRs PKR1 and PKR2 are 
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both abundantly expressed in nigral tissue lysates, on primary dopaminergic neurons and 
N27 cells. TH-positive dopaminergic neurons in the substantia nigra expressed high levels of 
the PKR2 receptor. Our functional studies demonstrate that PK2 mobilizes calcium in N27 
dopaminergic cells and protects against mitochondrial oxidative stress and neurotoxicity 
induced by MPP
+
. We also demonstrate for the first time, that co-treatment with PK2 induced 
PTEN-inducible kinase-1(PINK1) in N27 cells to protect against MPP
+
. We confirmed the 
neuroprotective functions of PK2 against MPP
+
 using primary embryonic mesencephalon 
cultures. Together, our results identify a novel role for PK2 signaling during dopaminergic 
degeneration in PD. Our studies have implications for therapeutic targeting of the 
prokineticin GPCRs in PD and potentially other neurodegenerative diseases.  
 
Introduction 
Prokineticin-2 (PK2) is a recently discovered member of the AVIT protein family that 
has been shown to regulate diverse physiological processes including angiogenesis, 
hematopoiesis, reproductive functions, circadian rhythms and pain perception. In the CNS, 
PK2 regulates circadian rhythms by functioning as an output molecule from the SCN and is 
required for olfactory bulb biogenesis by directing migration of progenitor cells from the 
subventricular zone (Cheng et al., 2002; Cheng et al., 2005; Ng et al., 2005). The expression 
of PK2 however, has been shown to be largely restricted to the above regions, while its 
receptors are more ubiquitously expressed in the CNS, suggesting that PK-2 signaling could 
have distinct functions in other regions of the brain(Cheng et al., 2006).   
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While studying the gene expression changes induced by TNFα toxicity on 
dopaminergic N27 cells using PCR-array technology, we surprisingly found that the mRNA 
levels of PK2 were highly induced by TNFα. Since TNFα treatment is neurotoxic to N27 
dopaminergic cells similar to MPP
+
, we hypothesized that PK-2 could be a novel signaling 
mediator that is secreted following oxidative stress and neuronal injury. We tested this 
hypothesis with the MPTP animal model of PD and in vitro using MPP+ treated N27 cells. 
Western blot analysis and Immunohistochemistry studies confirmed that PK-2 was rapidly 
induced following MPTP treatment by dopaminergic neurons in the mouse substantia nigra 
in both C57 black mice and the GENSAT PK2-EGFP transgenic mouse model. In N27 cells, 
both MPP
+
 and TNFα treatment increased PK2 expression and its release into the 
extracellular supernatant. We also confirmed that PK2 expression is elevated in the human 
PD brains corroborating the clinical relevance for PK2 signaling in PD.  
PK2 has been shown to signal in both an autocrine and paracrine manner by 
activating two highly-similar G-protein coupled receptors, PKR1 and PKR2, both of which 
are expressed in distinct regions of the CNS (Lin et al., 2002; Soga et al., 2002; LeCouter et 
al., 2003; Shojaei et al., 2007). We characterized the expression of the prokineticin receptors 
in the nigrostriatal system and found that both receptors were expressed in nigral tissue 
lysates, primary dopaminergic neurons and N27 cells. Double-labeling 
immunohistochemistry revealed that dopaminergic neurons express PKR2, suggesting that 
PK2-PKR2 signaling could be functionally relevant during dopaminergic degeneration. Since 
PK2 is secreted following oxidative stress and neuronal injury by dopaminergic neurons and 
since its receptors are expressed by the same cells, we reasoned that PK2 signaling could 
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protect against dopaminergic degeneration. Functional studies revealed that PK2 can activate 
its receptors on dopaminergic neurons and co-treatment with recombinant PK2 protects 
against oxidative stress and neurotoxicity induced by MPP
+
 in N27 cells and primary 
dopaminergic neurons. Mechanistic experiments into the signaling pathways by which PK2 
protects against MPP toxicity showed that PK2-treated dopaminergic cells have increased 
levels of the PINK-1 protein which has been shown to protect dopaminergic cells against 
oxidative stress and mitochondrial dysfunction. Taken together, the results of our studies 
have profound implications for both PK-2 biology and the pathophysiology of PD.  Given 
that the prokineticin GPCRs are prime drug targets and that PK-2 signaling is 
neruoprotective against dopaminergic degeneration, these results of this study have potential 
therapeutic applications to mitigate dopaminergic neuron loss in PD.  
 
Materials and methods 
Chemicals and reagents  
DMEM/F-12, RPMI, fetal bovine serum, L-glutamine, IR-dye tagged secondary 
antibodies, Hoechst nuclear stain, penicillin, and streptomycin and other cell culture reagents 
were purchased from Invitrogen (Gaithersburg, MD). Recombinant TNFα was purchased 
from Peprotech. Antibodies for rabbit PKC, GRP-78 and iNOS were from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA). Mouse TH antibody was purchased from Chemicon 
(Temecula, CA) and rabbit Iba1  antibody was from Wako Chemicals (Richmond, VA). 
32
P-
ATP was purchased from Perkin Elmer (Boston, MA) and the histone substrate from Sigma.  
The Bradford protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA).  
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RPMI, neurobasal medium, B27 supplement, fetal bovine serum, L-glutamine, IR-dye tagged 
secondary antibodies, penicillin, and streptomycin, MitoTracker dye and other cell culture 
reagents were purchased from Invitrogen (Gaithersburg, MD). Antibodies for Actin (1:2000), 
Tubulin (1:2000), Phospho-JNK (1:500) from Promega, Phospho  p42/44 ERK1 (1:500) and 
Phospho p38 MAPK (1:500) from Cell Signalling, and PINK-1(1:500) was obtained from 
abcam (Cambridge, MA). Antibodies for rabbit and goat PK-2 (1:500), PKR1 were from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mouse TH antibody was purchased from 
Chemicon (Temecula, CA). Caspase assay substrates and inhibitors were purchased from MP 
Biomedicals (Solon, OH). The DNA fragmentation assay kit was purchased from Roche 
Applied Science. Bradford protein assay kit was purchased from Bio-Rad Laboratories 
(Hercules, CA). ROS generation determinant DCF-DA was purchased from Calbiochem(San 
Diego, CA). MPTP and recombinant rat TNFα was obtained from Sigma (St. Louis,MO). 
Recombinant murine TNF was from R&D Systems (Minneapolis, MN). 
Animal studies  
The C57/BL/6 mice were housed in a light-controlled (12 h light: 12 h dark cycle) and 
temperature-controlled mouse facility (22 ± 1°C) with food and water available at all times. 
Acute model MPTP injections, as previously described (Zhang et al., 2007b), were used with 
C57/BL/6 mice to determine levels of PK2 in the mouse brain. Intraperital (IP) injections 
into the body cavity of either saline or 18 mg/kg MPTP, dissolved in saline, were used to 
introduce the treatment once every 2 hours with a total of 4 injections. The mice were 
anesthetized with a mixture of ketamine-xylazine (100mg/kg, 10mg/kg), and perfused 
transcardially with 4% Paraformaldehyde (PFA) 24 hours after MPTP or saline treatment. 
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PK2-EGFP transgenic mice 
The PK2-eGFP transgenic FVB/N-Swiss mice were generated at Rockefeller 
University by the GENSAT project using bacterial artificial chromosome (BAC) clone 
RP23-12A18, as described previously. The EGFP reporter cassette included a 
polyadenylation site that would prevent an overexpression of PK2 in the mice. The Mice 
were housed in a light-controlled (12 h light: 12 h dark cycle) and temperature-controlled 
mouse facility (22 ± 1°C) with food and water available at all times. Intraperital (IP) 
injections into the body cavity of either saline or 20 mg/kg MPTP, dissolved in saline, were 
used to introduce the treatment once every 2 hours with a total of 4 injections. The mice were 
anesthetized 24 hours after MPTP or saline treatment with a ketamine-xylaxine (100mg/kg, 
10mg/kg) mixture, and perfused transcardially with 4% PFA. All animal procedures were 
approved by the Iowa State University Institutional Animal Care and Use Committee 
(IACUC). 
Cell cultures 
N27 rat dopaminergic neuronal cells, were grown in RPMI 1640 media supplemented 
with 10% Fetal Bovine Serum (FBS), penicillin (100 units/ml), and streptomycin (100 
μg/ml), and 2 mM L-glutamine in 175mm3 flasks as previously described (Clarkson et al., 
1998; Kaul et al., 2003; Zhang et al., 2007b). N27 cells were kept in an incubator 37°C with 
5% CO2. Primary neurons were isolated from ventral mesencephalon tissue of gestational 14-
day (E14) mouse embryos by dissection under a microscope. Neurons were collected, 
isolated and maintained according to our previously published protocols, using DMEM/F12 
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complete media (10% heat-inactive fetal bovine serum, 100 U/ml penicillin, 100g/ml 
streptomycin Glutamate, 100M non-essential amino acids, and 2mM Sodium Pyruvate)  
Western blotting 
Cells were collected after treatment, lysed using modified RIPA buffer, homogenized, 
sonicated, and centrifuged as previously described (Kaul et al., 2003; Kitazawa et al., 2002). 
The supernatants were collected and protein was normalized, then stored with loading buffer 
and DTT. The samples were run on a Sodium Dodecyl Sulfate (SDS) gel electrophoresis. 
The normalized protein samples were loaded into each well and first separated in a 4% 
stacking gel and then through a 12-18% resolution gel. Proteins were then transferred to a 
Nitrocellulose membrane and allowed to transfer overnight at 4°C fridge at 23-30 volts. After 
transfer the membranes were blocked using either Western blocking buffer (Rockland 
Immunochemicals) or with 5% nonfat dry milk powder. Membranes were washed several 
times using either PBS containing 0.05% Tween (PBST) or Tris buffer saline containing 
0.05% Tween (TBST) wash buffers. Primary antibodies (in either blocking buffer or in a 5% 
BSA solution) were then added to the membranes and put at 4°C overnight. After another 4-5 
wash steps, secondary antibody specific to the primary antibody is added (in either blocking 
buffer or in 5% lowfat dry milk solution) to the membrane for 1 hour. Either β-Actin or α-
tubulin was used to confirm equal loading into each well of the gels. The membranes were 
washed 4-5 times with wash buffer, and then read using an Odyssey infra-red imager. 
SYBR Green qRT-PCR 
N27 cells were seeded out into 75mm
3
 flasks at 2 x 10
6
 cells per flask. Treatments 
were performed in RPMI media supplemented with 2% FBS, penicillin (100 units/ml), and 
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streptomycin (100 μg/ml), and 2 mM L-glutamine. Cells were treated for 8 hours with MPP+, 
or TNFα. After treatment, the cells were collected, pelleted, and resuspended in lysis buffer 
with β-Mercaptoethanol. RNA was isolated using an RNA isolation kit from Stratagene, 
Absolutely RNA Miniprep Kit. RT-PCR was performed using an AffinityScript qPCR cDNA 
synthesis system (Agilent Technologies) to convert the RNA into cDNA. Expression levels 
were determined using real-time PCR with Stratagene RT
2
 SYBR green mastermix and 
prevalidated  qPCR primers (SA Biosciences). Catalog number of the primer used was mouse 
PK2- PPM30250A. For normalization of each sample mouse 18SrRNA gene (catalog 
number-PPM57735E) was used as the housekeeping gene. The amount of each template was 
optimized with experiments to provide the maximum efficiency without inhibition of the 
PCR reaction. By the manufacturer’s guidelines, dissociation curves and melting curves were 
run to ensure a single amplicon peak was obtained without any non-specific amplicons. The 
results are reported in fold change in gene expression, which was determined using the ΔΔCt 
method using the threshold cycle (Ct) value from the housekeeping gene and for the 
respective gene of interest in each sample. 
Caspase and DNA fragmentation assays 
Enzymatic assays for caspase-3 activity were performed using acetyl-DEVD- amino-
4-trifluoromethylcoumarin (Ac-DEVD-AFC, 25 μm) as the fluorometric substrate for the 
reaction as described previously (Anantharam et al., 2002; Kaul et al., 2003). Synergy-2 
Multi-Mode microplate reader was used to detect fluorescent signals generated upon 
cleavage of the AFC peptide substrate by caspase-3 at 510nm and excited at 400nm. Caspase 
activity was normalized by determining protein concentrations with the Bradford assay. For 
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DNA fragmentation assay, N27 cells were plated in 6-well plates at 0.8 x 10
6 
cells/well and 
treated the next day. The cells were pelleted and then gently lysed using the lysis buffer 
provided with the kit. The lysate was then spun down at 200 xg for 10 minutes and the 
supernatant was collected. The DNA fragmentation was quantified according to previously 
published methods (Anantharam et al., 2002; Kaul et al., 2003; Zhang et al., 2007b) using the 
Cell Death Detection
 
ELISA Plus assay kit (Roche Applied Science). The plates were read by 
a Synergy-2 Multi-Mode Microplate Reader (BioTek Instruments, Inc) with absorbance at 
405nm and an ABTS solution (reference wavelength at ~490) as a blank. The amount of 
protein in each lysate served to normalize the raw absorbance values. 
Glutathione assay  
For Glutathione assay, cells were seeded into a 25 mm
3
 flasks at 1 x 10
6
 cells per 
flask in N27 growing media (RPMI with 10%FBS, penicillin (100 units/ml), and 
streptomycin (100 μg/ml), and 2 mM L-glutamine). The next day cells were treated in RPMI 
supplemented with 2% FBS, penicillin (100 units/ml), and streptomycin (100 μg/ml), and 2 
mM L-glutamine. Collected the cells by scraping the flasks and pelleted the cells. The pellet 
was resuspended with PBS to wash off remaining media, and aliquoted into 1.5ml 
microcentrifuge tubes. Pelleted the cells again, and removed any PBS from the tube. Then 
the cells were lysed using 50mM Tris at pH 7.4, 5mM EDTA and 0.001% Butylated 
hydroxytoluene (BHT). The mixture was vortexed and kept on ice for 15 minutes, then 
vortexed again. Cells were then sonicated using a Fisher Sonic Dismembrator model 500. 
Then cells were then put into the centrifuge at high speed (13,000 RPM) for 10 minutes. 
Using 180l of the resulting supernatant, added 22.5l of 1mM Monochlorobimane in 50mM 
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Tris(pH 7.4), and 22.5l Glutathione-S-transferase (10U/ml in 50mM Tris(pH 7.4) and was 
mixed well. Then transferred 200l to a black-walled 96-well plate and incubated in a 
thermoshaker for 30 minutes at 23C. The plate was read at Excitation 380nm and Emission 
470nm.  
Mitochondrial fragmentation analysis 
For Mitochondrial dysfunction experiments, cells were plated out onto dishes coated 
with 0.1% Poly-D-Lysine in RPMI with 10% FBS, penicillin (100 units/ml), and 
streptomycin (100 μg/ml), and 2 mM L-glutamine. Cells were treated in RPMI with 2% FBS, 
penicillin (100 units/ml), and streptomycin (100 μg/ml), and 2 mM L-glutamine for 16 hours. 
After treatment, the MitoTracker dye was added to each dish at a concentration of 1:2000l 
from a stock of 1mM. The cells were incubated with the dye for 15-20 minutes at 37C. After 
incubation, cells were fixed with 4% paraformaldehyde (PFA) for 1 hour and then washed 
several times with PBS. Cells were then imaged using Nikon 2000U microscope, and all 
images were processed in MetaMorph 5.7 from Universal Imaging (Downingtown, PA).  
Detection of intracellular ROS generation in N27 cells 
To determine the level of intracellular reactive oxygen species (iROS) the fluorescent 
probe 2’,7’-dichlorodi-hydrofluorescein diacetate (DCFH-DA) (Calbiochem). This chemical 
was used according to previously published reports (Zhang et al., 2005; Qian et al., 2007). 
Rat dompaminergic immortalized neuronal N27 cells were seeded into a 96-well plate. The 
N27 cells were treated with 200µM MPTP in RPMI media with 2% Fetal Bovine Serum 
penicillin (100 units/ml), and streptomycin (100 μg/ml), and 2 mM L-glutamine for 8 hours. 
The N27 cells were also cotreated with several doses of PK2 ranging from 5 nM up to 50 nM 
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along with the MPTP treatment. After the treatment, the cells were washed with warm HBSS 
media, and then incubated with 100µl of 40µM DCFH-DA in HBSS for 1 hour. The 
fluorescence intensity of the signal was determined using a Synergy-2 multi-mode microplate 
reader at an excitation of 485/20 and an emission of 530/25. The control fluorescent signal 
was treated as a control and subtracted as background. The fluorescence intensity increased 
in treatments was expressed as an increase in iROS as previously described (Zhang et al., 
2005; Qian et al., 2007). 
Fluo-4 calcium mobilization assay 
To Fluo4 NW assay kit was used to test the calcium mobilization in N27 cells and 
primary neurons due to the effects of nanomolar concentrations of recombinant PK2. The 
cells were plated into a 96-well plate in their respective growth media. Cells were then 
washed with HBSS without calcium and magnesium. Then HBSS was added to each well 
along with the 1X Fluo4 NW dye (Molecular probes). The plate was then read kinetically 
using a Synergy-2 multi-mode microplate reader. After 20 seconds of reading the plate every 
50 milliseconds for a background reading recombinant PK2 was added to the HBSS for final 
concentrations of 5nm, 10nm, 15nm, 20nm, or 25nm. The fluorescence was read every 50 
milliseconds for 3 minutes. The net change in fluorescent signal (Dt) was obtained after 
subtracting the background from the maximum signal for each sample.  
Histology and immunocytochemistry.  
For immunocytochemisty, cells were plated onto coverslips in 24 well plates coated 
with 0.1% mg/ml poly-D-Lysine. After cells were treated, 4% formaldehyde was used to fix 
the cells for 30 minutes. The cells were washed 4-5 times with PBS wash buffer. Then block 
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buffer containing 2% BSA, 0.2% Triton X-100, and Tween was then added to the wells for 1 
hour to permeabilize the cells. The cells were incubated with primary PK2 (Rabbit 
polyclonal, 1:500 dilution) and Tyrosine Hydroxylase (mouse monoclonal,1:2000) antibody 
in 2% BSA at 4C overnight. After 4-5 more wash steps an Alexa dye-conjugated secondary 
antibody in 2% BSA was added and incubated at room temperature on a shaker for 1 hour. 
Cells were then washed 4-5 times, then Hoechst counterstain was added for 15-20 minutes to 
label the nucleus. After 4-5 more washes the coverslips were mounted onto slides with 
Fluoromount mounting media. Cells were imaged under a Nikon 2000U microscope with a 
SPOT camera, and all images were processed in MetaMorph 5.7 from Universal Imaging 
(Downingtown, PA).  
For histology, the mice were anesthetized using the ketamine-xylazine mixture and 
the brains were perfused with 4% PFA and then collected into 4% PFA and stored at 4°C for 
48 hours. Brains were then removed, washed 3 times with PBS, and placed into a 30% 
sucrose solution for at least 24 hours. The brains were then put into Optimal Cutting 
Temperature (OCT) compound and frozen into blocks for cutting sections. Sections of the 
brain were cut using the Cryostat sectioning machine at -20°C and placed into Cryosolution 
(30% Sucrose, Ethylene glycol, and PBS). To perform antigen retrieval, the free-floating 
sections were heated for 30 minutes at 90°C in citrate buffer ( 10mM sodium citrate, pH 8.5). 
The sections were then washed with PBS and permeabilized with blocking buffer (2% BSA, 
0.1% Triton X-100, and Tween) for 1 hour at room temperature. Antibodies directed to PK2 
(Rabbit polyclonal, 1:500), PKR1 (Goat polyclonal, 1:1000), PKR2 (Rabbit polyclonal, 
1:1000), Tyrosine Hydroxylase (Mouse monoclonal, 1:2000) were then incubated with the 
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sections overnight at 4°C. After several washes with PBS, the sections were incubated with 
Alexa dye-conjugated secondary antibodies for 1 hour at room temperature. After several 
more washed with PBS, Hoechst dye (1:3000) was added to the sections for 20 minutes at 
room temperature to stain the nucleus. The sections were then mounted on slides using 
prolong antifade gold mounting medium (Molecular probes) according to the manufacturer’s 
instructions. A Nikon inverted fluorescent microscope (TE-2000U) was used to visualize the 
sections, and a spot digital camera was used to capture the images (Diagnostic Instruments 
Inc.). 
Data analysis 
Data analysis was performed using the Prism 4.0 software package (GraphPad 
Software, San Diego, CA). The data was first analyzed using one-way ANOVA and then 
Bonferroni's post-test was performed to compare all treatment groups. Differences of p<0.05 
were considered statistically significant. The Student's t-test was used when differences 
between two groups were being compared. 
 
Results 
Prokineticin-2 is highly induced in dopaminergic neuronal cells during MPP
+
 and 
TNFα-induced cell death in vitro 
While studying the neurotoxic effect TNFα on dopaminergic N27 neuronal cells, we 
made a serendipitous discovery using PCR-array technology that PK-2 mRNA expression 
was highly induced early during TNFα induced cell death. Based on this unexpected 
observation, we hypothesized that PK-2 could be a novel secreted protein that is induced 
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early during dopaminergic neuron injury.  To further validate our hypothesis and the 
relevance of our findings to PD, we tested if PK2 was induced in N27 cells during treatment 
with the Parkinsonian toxin MPP
+
. N27 cells were treated with either TNFα (30 ng/ml) or a 
low dose of MPP
+
 (200 μM) for 12 hours, and the level of PK2 was determined in cell lysates 
and cell culture supernatants. Both TNFα and MPP+ treatment resulted in increased PK2 
protein expression in the N27 cells as determined by Western blotting. PK2 levels in the 
supernatant also increased concomitantly demonstrating that PK-2 is both upregulated and 
secreted by dopaminergic neuronal cells following inflammatory or oxidative stress signaling 
and neurotoxicity (Fig. 1A). We also visualized the expression and localization of PK2 using 
immunofluorescence in N27 cells. A rabbit polyclonal antibody that recognizes an epitope 
within the internal region of PK2 was used for immunofluorescence detection along with a 
species-specific Alexa-488 (green) conjugated secondary antibody. The expression of PK2 
was mostly cytosolic and appeared to localize to the secretory pathway with prominent 
accumulation around the perinuclear zone and the ER network (Fig.1B). The localization 
pattern of PK2 in N27 cells is consistent with that of a secreted protein, which would be 
expected given that PK2 contains a signal peptide at its N-terminus targeting it for 
constitutive secretion (Li et al., 2001; LeCouter et al., 2003). The secreted PK2 protein has 
been shown to signal through two highly similar G protein-coupled receptors, PKR1 and 
PKR2 that are ubiquitously expressed in various tissues including the CNS (Lin et al., 2002; 
Masuda et al., 2002; Soga et al., 2002).  
In the mouse brain, PKR2 was found to be highly expressed in most regions of the 
brain by neuronal cells while PKR1 has been shown to be expressed in only a few brain 
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regions (Cheng et al., 2006). Since the receptors for PK2 were likely to be expressed on 
dopaminergic neurons, we tested if N27 cells expressed PKR1 and PKR2. Western blotting 
of N27 cell lysates probed for PKR1 and PKR2 using a goat and rabbit polyclonal antibody 
respectively revealed that both receptors were expressed by N27 cells (Fig. 1C). The 
expression of PKR1 was less compared to PKR2 and appeared to go down with MPP
+
 
treatment.  
Together, these results demonstrate that dopaminergic neurons secrete PK-2 and 
express receptors for the secreted protein. The activation of the prokineticin GPCRs by PK2 
has been shown to mobilize calcium and activate downstream signaling pathways involving 
PI3K and p44/42 MAPK (Lin et al., 2002; Masuda et al., 2002; Soga et al., 2002; LeCouter 
et al., 2003). We tested the functional activation of the prokineticin receptors by PK-2 on 
N27 cells by measuring calcium mobilization using the recombinant active form of the PK-2 
protein. The calcium flux in N27 cells was determined using the Fluo-4 NW assay system. 
PK-2 mobilized calcium in N27 cells in a dose dependent manner (Fig.1D) in the low 
nanomolar range similar to other cell types. Since both PKR1 and PKR2 are capable of being 
activated by PK-2, the contribution of each specific receptor in mediating the effects of PK-2 
on dopaminergic cells is unclear at this time. Collectively, these results demonstrate for the 
first time that PK-2 is a novel signaling mediator that is highly induced and secreted from 
dopaminergic neurons following oxidative stress and neuronal injury. Further, they 
demonstrate that receptors for PK-2 are highly expressed on N27 dopaminergic cells and can 
be functionally activated by soluble recombinant PK-2 in vitro.  
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PK2 is induced in substantia nigra dopaminergic neurons in the MPTP model of 
Parkinson’s disease.  
To substantiate our in vitro results obtained with PK2 using the N27 dopaminergic 
cell model, we sought to determine the relevance of these findings in vivo. We utilized the 
acute MPTP model of PD to verify our hypothesis that PK2 expression is induced during 
dopaminergic neuron injury and secreted as a novel signaling mediator.  The MPTP model is 
the most widely used and accepted model for PD in rodents and recapitulates many of the 
key pathological aspects of the disease including selective loss of dopaminergic neuron cell 
bodies in the SNpc, striatal terminal degeneration, dopamine depletion and motor deficits. 
Significantly, a strong neuroinflammatory response also occurs in this model with TNF 
levels reported to peak at around 24 hours after MPTP dosing. We first examined if there was 
increased expression of the PK-2 protein in SNpc lysates obtained from MPTP-treated mice. 
We used an established acute MPTP dosing regimen was with 18mg/kg MPTP injected i.p. 
every two hours for a total of 4 doses. Control mice received saline and mice were sacrificed 
at the indicated time points. As shown in fig. 2A, there is a significant increase in PK-2 
expression in the substantia nigra 24 hours after MPTP treatment compared to saline treated 
mice. Importantly, no PK-2 expression was observed in the striatum of either saline or MPTP 
treated mice indicating that the dopaminergic neuron cell bodies in the SNpc rather than their 
striatal terminals could be the source of PK-2 induction. We then determined the expression 
levels of PK-2 in the mouse SNpc at different time points (3, 12, 24 and 72hr) following 
MPTP treatment to verify if PK2 induction is an early response to dopaminergic neuron 
injury. As shown in fig 2B, PK-2  expression was significantly increased over saline treated 
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mice as early as 3hrs and remained elevated upto 3 days later, the last time point studied, 
suggesting that increased expression of PK-2 by dopaminergic neurons is an early and 
persistent signal in the SNpc following dopaminergic neuron insult. To verify that 
dopaminergic neurons in the SNpc were the specific cell type expressing PK-2, we used 
double immunofluorescence labeling in mouse midbrain SNpc sections for PK-2 and tyrosine 
hydroxylase (TH), a specific marker for dopaminergic neurons. As shown in fig.2C, there is 
greater than 98% co localization between TH and PK2 expressing cells as well as a 
remarkable increase in PK2 expression in the entire SNpc tract. Interestingly, a few cells that 
are not TH-positive but adjacent to dopaminergic neurons also express PK2 in the SNpc but 
these are less than 2% of the total PK2 expressing cells and their identity remains to be 
defined. In saline treated mice we observed little to no expression of PK-2 without any 
distinct cellular staining patterns, although in the western blot experiments there appears to 
be a low level of expression. This observation however is in good agreement with a previous 
published report by Cheng et al., which characterized the expression of PK-2 in the entire 
adult mouse brain by in situ mRNA hybridization and reported no significant expression in 
the SNpc although the prokineticin receptor PKR2 was expressed. Further, the recently 
completed GENSAT (Gene Expression Nervous System Atlas) project; a publicly available 
gene expression atlas of the adult mouse brain based on BAC-eGFP reporter transgenic mice 
also reports no detectable PK-2 expression in the midbrain SNpc region in the PK-2 eGFP 
transgenic mouse line. Together, our results demonstrate that PK-2 expression is highly 
induced in dopaminergic neurons in the SNpc following MPTP injury and as such represents 
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the first in vivo evidence suggesting a function for this protein in PD and neurodegeneration 
in general.  
Induction of PK2 and eGFP expression in the substantia nigra of the GENSAT EGFP 
transgenic mouse model  
To further validate and characterize the secretion of PK-2 by dopaminergic neurons in 
the MPTP model of PD, we used the GENSAT bacterial artificial chromosome PK-2 EGFP 
transgenic mouse model [Tg (Prok2-EGFP) FH64Gsat] specifically (Gong et al., 2003). The 
transgenic mouse generated as part of the GENSAT project, contains an EGFP reporter 
transgene and a polyadenlyation sequence introduced between the PK-2 promoter and the 
first coding exon of the PK-2 gene. The transcription of the EGFP reporter therefore is driven 
by activation of the PK2 promoter. Further, EGFP transcription is terminated at the 
polyadenylation site so that its expression occurs without any changes in native PK-2 
expression. In a recent study (Zhang et al., 2009) these transgenic mice were used to reveal 
the projections of PK2-expressing neurons in the SCN to different target structures. 
Significantly, this study found no EGFP positive neurons or PK-2 mRNA expression 
anywhere in the midbrain in normal adult transgenic PK2-EGFP mice suggesting that PK-2 
is not expressed or is undetectable in this region of the brain. In concordance with this study, 
our experiments with C57 black mice (Fig.1) demonstrate that the expression of PK-2 is low 
or absent in the substantia nigra of saline controls but is highly upregulated following MPTP-
induced dopaminergic neuron injury. To substantiate these novel findings and visualize the 
expression of PK-2 in the subtantia nigra we used the MPTP model of PD to study the PK-2 
EGFP transgenic. All mice used in the study were genotyped according to the donor’s 
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recommended PCR protocol and confirmed to be transgenic based on the presence of the 600 
bp strain-specific PCR product (Fig.3A). We further confirmed the veracity of the EGFP 
reporter for PK-2 in the transgenic mouse brain by visualizing EGFP expression in the 
olfactory bulb and the suprachiasmatic nucleus where PK-2 is constitutively expressed at 
high levels in the normal mouse brain. As expected, we observed extensive neuronal EGFP 
fluorescence in both the olfactory bulb and SCN (Fig. 3B) demonstrating that the expression 
of the transgenic EGFP reporter correlates accurately with the expression of PK-2 in the 
brain. The PK2-EGFP transgenic mice were treated with MPTP (4 x 20 mg/kg at 2 h 
intervals) and controls received equivalent volumes of saline. Nigral tissue was dissected 24 
h later and lysates were probed for both EGFP and PK-2 protein levels by Western Blotting. 
We observed a substantial increase in the levels of the EGFP protein in MPTP-treated nigral 
tissue lysates along with a concomitant increase in the expression of PK-2. Actin was used as 
the internal control to demonstrate equal amount protein loading (Fig. 3C). Next, we imaged 
EGFP fluorescence directly in the substantia nigra using free floating tissue sections obtained 
from transgenic mice treated with saline and MPTP. The dopaminergic neurons in the 
substantia nigra were labeled with TH (red, Alexa 555) and EGFP/PK-2 expression was 
visualized directly by GFP fluorescence imaging (green). In nigral sections from saline 
treated mice, the amount of EGFP fluorescence was almost absent or barely above that of 
tissue autofluorescence (Fig. 3D). However, in MPTP-treated mice, intense EGFP 
fluorescence was evident along the nigral tract. Further, most of the EGFP-positive cells 
were also TH-positive indicating that nigral dopaminergic neurons produce the EGFP 
reporter for PK2 following MPTP treatment indicative of active PK-2 transcription in these 
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cells. Together, these results demonstrate that PK-2 is highly expressed in substantia nigra 
dopaminergic neurons of the PK2-EGFP transgenic mouse in the MPTP model of PD. They 
also demonstrate that the induction of PK-2 by dopaminergic neurons is not strain specific 
with similar results were also obtained in C57 black mice (Fig.1).  
PK2 is elevated in the substantia nigra of PD brains  
The primary pathological hallmark of Parkinson’s disease involves a selective loss of 
melanized dopaminergic (DA) neurons in the substantia nigra compacta of the midbrain. 
Emerging studies suggest that PD is the outcome of complex pathological mechanisms 
involving environmental, genetic and cellular processes that result in dopaminergic cell death 
over time (Obeso et al., 2010). Although the precise etiologies involved are complex, 
oxidative stress and mitochondrial dysfunction have been identified as common downstream 
effector mechanisms that can drive dopaminergic degeneration in the SNc. Further, recent 
studies suggest that reactive microgliosis and the chronic neuroinflammatory response that 
occurs in the SNc can sustain dopaminergic degeneration and result in progressive neuronal 
loss (Block et al., 2007). Both clinical studies and animal models of PD have strongly 
implicated a role for TNFα signaling in modulating the neuroinflammatory responses in PD 
with elevated levels of TNF seen in human PD brains and all animal models of the disease 
(Wu et al., 2007; McCoy et al., 2008; De Lella Ezcurra et al., 2010; Harms et al., 2011). Our 
initial discovery that PK-2 is induced and secreted from dopaminergic neuronal cells in vitro 
following MPP
+
 and TNFα treatment led us to believe that PK-2 could be a novel secreted 
factor induced early during oxidative or inflammatory stress in dopaminergic neurons. We 
then confirmed these findings in vivo using the MPTP model of PD in two different strains of 
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mice. Although the MPTP model does not recapitulate all the clinical or pathological features 
of idiopathic PD, oxidative stress and mitochondrial dysfunction are the primary mechanisms 
that account for the selective vulnerability of dopaminergic neurons observed in this model.  
In order to establish the clinical relevance of PK-2 signaling in PD, we determined if 
elevated levels of PK-2 were also present in PD brains. SNc lysates from PD patients and 
age-matched controls were obtained from the University of Miami Brain Endowment Bank. 
The amount of PK-2 in the lysates was determined by Western blotting with 50 μg of total 
protein per sample. Actin was used as the internal control to demonstrate equal protein 
loading. Increased PK-2 expression was evident in most PD brains with low to undetectable 
levels in most age-matched controls (Fig 4A). We also observed some intrinsic variability in 
the PK-2 expression levels as would be expected with human clinical samples. To objectively 
quantify if PK-2 was elevated in PD brain lysates, we used densitometric analysis. The PK-2 
band intensities from all six controls and PD samples were quantified using the Fujifilm 
Multi Gauge software and were normalized to those of actin. The normalized band intensities 
for the PD brain samples were then plotted as a fold-change over controls (Fig. 4B). As 
shown, PK-2 was increased almost 3-fold in the PD brain lysates compared to controls 
despite some intrinsic variability in expression levels. We also studied the localization of PK-
2 in human PD brain sections using double-labeling fluorescence immunohistochemistry for 
PK-2 and TH. Nigral brain sections from postmortem PD patients and age-matched controls 
were processed for immunohistochemistry with a rabbit polyclonal antibody against PK-2 
(green, Alexa-488) and a mouse monoclonal to TH (red, Alexa-555). Both primary 
antibodies detect the human epitope of the respective target protein. Species-specific Alexa-
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dye conjugated secondary antibodies were used to visualize each protein and Hoechst stain 
was added to label the nucleus (blue). As shown in Fig. 4C, PK-2 staining was almost absent 
around the melanized TH-positive dopaminergic neurons in control sections where extensive 
TH staining is apparent. However in PD brain sections, intense and specific PK-2 staining 
was apparent and localized to the few surviving TH-positive dopaminergic neurons. PK-2 
staining was also apparent in few cells (less than 5%) that were not TH-positive similar to the 
expression pattern for PK-2 observed in mice treated with MPTP (Fig. 1).  
Together these results demonstrate for the first time that PK-2 expression is elevated 
in the SNc of PD patients and provides immense clinical relevance to our findings. Further, 
since PK-2 is a constitutively secreted protein, these findings suggest that PK-2 levels may 
be elevated in the CSF of PD patients. This could be particularly relevant for PK-2 as a 
potential PD biomarker since PK-2 appears to be induced and secreted as early as 3 hours 
after MPTP treatment in the mouse substantia nigra. More detailed time course studies would 
be ecessary to determine if the elevated levels of PK-2 correlate with onset and disease 
progression and if there are changes in CSF or serum PK-2 levels with the onset of PD.  
Receptors for secreted prokineticin-2 are expressed in the mouse substantia nigra and 
on primary dopaminergic neurons 
Having established that PK-2 is induced and secreted from dopaminergic neurons in 
vitro, in the MPTP mouse model of the disease and in postmortem PD patients, we sought to 
identify the target cells for the secreted protein in order to understand its potential functions. 
Two highly similar G protein coupled receptors for PK-2, have been identified and cloned by 
independent groups (Lin et al., 2002; Masuda et al., 2002; Soga et al., 2002). The two 
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GPCRs, PKR1 and PKR2 share around 85% amino acid identity between them although they 
are expressed on different chromosomes. Both PKR1 and PKR2 have are widely expressed in 
the gasterointestinal system, the reproductive organs and other peripheral tissues (Soga et al., 
2002; LeCouter et al., 2003). Within the central nervous system the expression patterns of 
both receptors have been previously characterized. While PKR2 has been shown to be 
ubiquitously expressed throughout the brain, PKR1 appears to be restricted mostly to the 
olfactory region, dentate gyrus, subventricular zone and the dorsal motor vagal nucleus 
(Cheng et al., 2006). We determined the expression of prokineticin receptors in the mouse 
substantia nigra and in primary EVM neuronal cultures. Nigral tissue was dissected from C57 
black mice treated with saline or MPTP (4 x 18 mg/kg) and lysates were prepared. Western 
blot analysis revealed that both prokineticin receptors were expressed in the substantia nigra 
tissue. Interestingly, the amount of PKR1 appeared to go down in MPTP-treated animals 
while that of PKR2 remained the same after treatment (Fig.5A). Primary microglia and 
astrocytes have been reported to express high levels of PKR1 compared to PKR2 (Koyama et 
al., 2006) which may account for the expression of PKR1 seen in nigral tissue lysates. We 
also confirmed the expression of both prokineticin receptors on primary microglia and 
astrocytes in our preliminary studies by Western blotting (data not shown). Our own studies 
with the N27 dopaminergic cell line revealed that the dopaminergic neurons themselves 
expressed both prokineticin receptors (Fig.1C) suggesting potential autocrine or paracrine 
functions for secreted PK-2 in the substantia nigra. We determined the expression of 
prokineticin receptors on dopaminergic neurons in the substantia nigra by double-labeling 
immunohistochemistry using TH as a marker for dopaminergic neurons. We found that TH-
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positive dopaminergic neurons expressed high levels of PKR2 (Fig. 5B) which was evident 
as punctate staining around the periphery of the cells at high magnification. The secreted PK-
2 from dopaminergic neurons that is induced following neuronal injury or oxidative stress 
therefore could potentially act on adjacent dopaminergic neurons expressing PKR2 to 
activate intracellular signaling pathways. We also tested the expression of prokineticin 
receptors on dopaminergic neurons in primary EVM cultures by double-labeling 
immunofluorescence. Primary EVM cultures were obtained from E14 timed-pregnant mice 
and grown in neurobasal medium to obtain pure neuronal cultures (>95% glial-cell free). 
Four-day old cultures were fixed and processed for immunocytochemistry with TH to label 
dopaminergic neurons and either PKR1 or PKR2. Hoechst was used to label the nucleus. 
PKR1 and PKR2 were expressed on all primary dopaminergic neurons as evidenced by 
colocalization with TH (Fig 5C). Both PKR1 and PKR2 were expressed by non-
dopaminergic neurons as shown in the merged images with Hoechst staining. Together, these 
results confirm that the secreted PK-2 can act directly on dopaminergic neurons presumably 
via the PKR2 receptor which is expressed at high levels in vivo. In the light of previous 
reports showing high levels of PKR1 expression in microglia and astrocytes, our results here 
also suggest novel functions for secreted PK-2 in mediating neuron-glia communication 
following dopaminergic degeneration in PD. In this context, PK-2 that is secreted from 
dopaminergic neurons following neuronal injury could be a chemotactic factor for microglia 
and astrocytes via PK2-PKR1 signaling other than directly acting on adjacent dopaminergic 
neurons via PK2-PKR2 signaling pathways. Further, given the wealth of literature supporting 
a role of PK-2 in neurogenesis and as a cell survival factor, our finding that E-14 
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dopaminergic neurons express high levels of both PK-2 receptors implicate a potential role 
for PK-2 during neurogenesis and development and of the nigrostriatal system. The specific 
signaling pathways activated downstream of the PK-2 receptors in glial cells and 
dopaminergic neurons are currently under investigation in our laboratory.  
Soluble exogenous PK2 protects dopaminergic N27 cells from MPP
+
 induced cell death 
and increases PINK1 protein levels.  
Having confirmed that the receptors for PK-2 being secreted from dopaminergic 
neurons are indeed expressed in the substantia nigra and that PKR2 is expressed on 
dopaminergic neurons themselves, we sought to determine the functional role of secreted 
PK-2. Within the brain, PK-2 signaling has been shown to regulate circadian rhythms by 
functioning as an output molecule from the SCN (Cheng et al., 2002; Cheng et al., 2005; Hu 
et al., 2007) and is also required for olfactory bulb biogenesis by acting as a chemoattractant 
for migration of progenitor cells from the subventricular zone (Ng et al., 2005; Prosser et al., 
2007; Zhang et al., 2007a). Recently, PK-2 has been shown to cause excitability of the 
subfornical organ neurons and area postrema neurons and also depolarize parvocellular and 
magnocellular neurons further validating its role as a circadian output molecule.(Cottrell et 
al., 2004; Yuill et al., 2007; Ingves and Ferguson, 2010).  However, unlike in the SCN and 
olfactory bulb where PK-2 is constitutively expressed, PK-2 is not detectable in the SN of 
normal mice but is upregulated in dopaminergic neurons following MPTP-induced oxidative 
stress and neuronal injury. The two receptors for PK-2 on the other hand are both expressed 
in the susbtantia nigra under normal conditions with PKR2 being present on dopaminergic 
neurons at high levels.  
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Since prokineticin has been strongly implicated in cell survival and angiogenesis 
(Kisliouk et al., 2005; Urayama et al., 2007; Li et al., 2010) and since PK-2 is secreted 
following dopaminergic degeneration, we hypothesized that soluble exogenous PK-2 could 
be a survival factor and protect against dopaminergic  degeneration. We initially tested our 
hypothesis in N27 dopaminergic cells and determined if recombinant PK-2 could protect 
against oxidative stress and neurotoxicity induced by MPP+. N27 cells upregulate and 
secrete PK-2 in response to MPP+ similar to the nigral dopaminergic neurons in response to 
MPTP in vivo. Further, these cells express prokineticin receptors and mobilize calcium in 
response to exogenous PK-2 demonstrating that the receptors can be functionally activated 
by low nanomolar doses of the ligand (Fig.1-2). MPP+ toxicity on N27 dopaminergic cells 
has been well characterized with the primary mechanism of cell death being mitochondrial 
oxidative stress and activation of the intrinsic apoptotic cascade as a result of mitochondrial 
complex I inhibition. MPP+ treatment typically results in increased mitochondrial ROS 
generation, downstream activation of caspase-3, mitochondrial fission and DNA 
fragmentation. N27 cells were treated with 200 μM MPP+ and co-treated with recombinant 
PK-2 in 2% serum-containing medium. Total intracellular ROS levels were quantified using 
the DCFDA fluorescence assay. Caspase-3 activity was determined using a fluorimetric 
enzyme assay with a peptide substrate and DNA fragmentation was analyzed by a sensitive 
ELISA-based method. Co-treatment of N27 cells with PK-2 attenuated the generation of 
intracellular ROS by MPP+ in a dose-dependent manner at 8 h (Fig 6A). PK-2 treatment also 
reduced the activation of caspase-3 and DNA fragmentation induced by MPP+ treatment at 8 
h and 16 h respectively (Fig. 6 B, C). We also qualitatively visualized mitochondrial fission 
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caused by MPP+ treatment using the fluorescent MitoTracker Red stain (Fig.6D). While 
MPP+ treatment alone caused evident fragmentation of mitochondria compared to untreated 
controls, cells cotreated with PK2 had intact mitochondria suggesting that PK-2 signaling 
counteracts the toxic effect of MPP
+
 in these cells. 
 Taken together, these results demonstrate for the first time that PK-2 signaling can 
protect dopaminergic cells against MPP
+
 mediated oxidative stress, mitochondrial 
dysfunction and cell death. They also suggest that the secreted PK2 from dopaminergic 
neurons could be a protective factor that acts locally in the substantia nigra to protect against 
acute oxidative stress and neurontoxic insults. The protective effect of PK2 treatment was 
also evident in the activation of pro-apoptotic signaling pathways in N27 with MPP
+
 
treatment. The early stages of mitochondrial membrane permeabilzation induced by MPP
+
 is 
typically associated with activation of pro-apoptotic signaling pathways including ERK, 
JNK, MAP kinases and increased levels of pro-apoptotic bcl2 family proteins (Galluzzi et al., 
2009). MPP
+
 treatment resulted in increased levels of active JNK, ERK1/2 and the pro-
apoptotic short form of MCL-1 (MCL1s) all of which were reduced in cells co-treated with 
10 and 25 nM of recombinant PK2 (Fig. 6E). Since the activation of JNK and ERK are 
typically associated with the early stages of pro-apoptotic signaling following mitochondrial 
membrane permeabilization, it is likely that PK2 exerts its protective effect by modulating 
early protective signaling pathways or increasing antioxidant defense mechanisms within the 
cell to protect against mitochondrial oxidative stress.  
Having established that exogenous recombinant PK2 can protect against MPP
+ 
neurotoxicity in N27 cells, we sought to determine potential signaling pathways involved. 
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Since oxidative stress is a primary mechanism by which MPP
+
 cell death proceeds and 
because co-treatment with PK-2 significantly reduced total intracellular ROS levels in these 
cells, we determined if PK-2 modulates antioxidant defense mechanisms or other pro-
survival signaling pathways associated with mitochondrial integrity. PINK1 (PTEN-induced 
putative kinase 1) is a well-studied mitochondrial serine/threonine kinase that has been 
associated with mitochondrial integrity and pathology.  Mutations in PINK-1 that result in a 
loss of function of the kinase have been linked to autosomal recessive Parkinsonism. Further, 
a loss of PINK-1 by either germline deletion or siRNA knockdown leads to significant 
functional impairment of the mitochondria with increased mitochondrial fragmentation and 
susceptibility to oxidative stress.  Since co-treatment of N27 dopaminergic cells with PK-2 
attenuated MPP+ induced intracellular ROS generation and mitochondrial fragmentation, 
both of which are dependent on PINK-1 signaling, we determined if PK-2 treatment affected 
the levels of PINK-1 within these cells by Western blot analysis. To our surprise, we found 
that the 55 kDa processed form of the PINK-1 protein (Fig. 6F) was increased in PK-2 
treated cells that were being protected from MPP+ toxicity (Fig. 6). Mutation in the parkin 
gene have also been shown to have almost identical effects on mitochondrial morphology 
and function as PINK-1 and parkin could functionally compensate for the loss of PINK-1 
suggesting that the two proteins operate in a common or overlapping genetic pathway. 
However, unlike PINK-1, the levels of parkin did not change with PK-2 treatment in the 
same lysates indicating that PK-2 signaling modulates the levels of PINK-1 but not parkin to 
protect against MPP+ induced oxidative stress and mitochondrial dysfunction. Taken 
together, our results here demonstrate for the first time that PK-2 signaling can protect 
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dopaminergic cells from oxidative stress, mitochondrial dysfunction and cell death induced 
by MPP+. More importantly, our results identify a novel link between PK-2 signaling and 
increased PINK-1 protein levels as a major compensatory response that mediates protection 
against MPP+ neurotoxicity in dopaminergic cells. These findings have immense 
implications for therapeutic targeting of the prokineticin receptors to prolong cell survival of 
dopaminergic neurons in PD by protecting against oxidative stress.  
PK2 protects primary dopaminergic neurons from MPP
+
 induced degeneration  
Previous reports have demonstrated that PK-2 can act as a trophic factor for primary 
cells including cardiomyoctes and hippocampal neurons either by enhancing cell survival or 
by protecting against cell death induced by neurotoxic agents. To extend the results of our 
neruoprotective studies with PK-2 in dopaminergic N27 cells to a more relevant model 
system, we tested if soluble PK-2 could protect primary dopaminergic neurons from MPP+ 
induced neurotoxicity. Having first confirmed that both prokineticin receptors, PKR1 and 
PKR2, were expressed on primary dopaminergic neurons in culture (Fig. 4C), we validated 
the functional activation of the receptors by verifying the calcium flux generated by PK-2 in 
primary cultures using the Fluo-4 NW assay system. As shown (Fig. 7A), nanomolar 
amounts of PK-2 generated a dose-dependent calcium flux in primary neuron cultures. For 
neuroprotection studies, primary EVM cultures obtained from E14 timed-pregnant mice were 
grown in neurobasal medium and treated 4 days after plating. Cultures were routinely 
verified to be >95% glial-cell free at the time of treatment. Primary neuronal cultures at DIV-
4 were treated with 5 μM MPP+ for 24 h or co-treated with 25 nM PK-2. For the co-treatment 
group, PK2 was added again 12 h later. Dopaminergic neurotoxicity was quantified by the 
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dopamine uptake assay and TH-positive neuron counting. Dopamine uptake was reduced 
following MPP
+
 treatment to almost 30% of the control levels at 24 h indicative of extensive 
dopaminergic degeneration. In cells co-treated with PK-2, dopamine uptake was significantly 
(#, p<0.05 vs MPP
+
 alone) improved at around 50% of control cultures (Fig.7B). Similar 
results were obtained with TH+ neuron counts with PK-2 co-treated cultures having 
significantly (##, p<0.01 vs MPP+ alone) higher numbers of viable dopaminergic neurons 
compared to cultures treated with MPP
+
 alone (Fig. 7C). The morphology of dopaminergic 
neurons in PK2 co-treated cultures as revealed by TH-immunofluorescence also displayed 
less degeneration with increased processes compared to cultures treated with MPP
+
 alone. 
Together, these results demonstrate that PK-2 can protect primary dopaminergic neurons 
from MPP
+
 toxicity. Further, they suggest that the secreted PK-2 from dopaminergic neurons 
can function as a local survival factor to protect against acute oxidative stress and neurotoxic 
insults. 
 
Discussion 
This report describes a novel role for prokineticin-2 signaling during dopaminergic 
degeneration with clinical relevance to the pathophysiology of Parkinson’s disease. Herein, 
we demonstrate for the first time that PK2 is induced following dopaminergic degeneration 
and is highly expressed by dopaminergic neurons in cell culture and animal models of PD. 
We also confirmed that PK-2 is elevated in nigral tissue lysates of postmortem PD patients 
compared to age-matched controls, establishing the clinical relevance of our findings. We 
show that receptors for the secreted PK2 ligand are expressed on dopaminergic neurons in 
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the substantia nigra, in primary mesencephalic cultures and N27 cells and also that 
recombinant PK2 can functionally activate its receptors to mobilize calcium in dopaminergic 
neurons. Significantly, our functional studies demonstrate that PK-2 signaling can protect 
dopaminergic cells from MPP
+
 induced oxidative stress and neurotoxicity by a PINK-1 
dependent pathway.  
The basis for these studies was an unexpected discovery that the prokineticin-2 
mRNA is induced by more than 7-fold in N27 dopaminergic cells following exposure TNFα. 
Since TNF treatment is associated with dopaminergic neurotoxicity similar to MPP
+
 in this 
model system, we hypothesized that PK2 could be a novel secreted neuropeptide that is 
released from dopaminergic neurons following neurotoxicity insult and oxidative stress. 
Indeed, both TNF and MPP+ increased the synthesis of PK-2 in N27 cells and its release into 
the culture supernatant, therefore confirming the validity of our hypothesis in vitro.  We used 
the MPTP mouse model of PD to further investigate PK2 signaling in the nigrostriatal system 
since this model recapitulates many of the important pathophysiological features of PD, 
particularly with respect to nigral dopaminergic degeneration and oxidative stress (Jakowec 
and Petzinger, 2004; Fox and Brotchie, 2010). We demonstrate that PK2 was highly 
expressed as early as 3 h after MPTP treatment in substantia nigra tissue lysates but not in the 
striatum. Time course experiments revealed that increased PK2 expression was evident upto 
3 days after MPTP treatment in the substantia nigra. Double labeling immunohistochemistry 
studies reveal that PK2 is specifically upregulated in TH-positive dopaminergic neurons of 
the substantia nigra. It must be noted that PK2 expression in saline-treated control mice was 
almost undetectable in nigral tissue lysates and brain sections suggesting that PK2 is not 
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expressed in this region of the adult brain under normal conditions but is induced following 
neuronal injury. This is in agreement with two previous reports that characterized the 
expression of PK-2 across the entire adult mouse brain and found no expression in regions of 
the midbrain (Cheng et al., 2006; Zhang et al., 2009). We also obtained identical results with 
the GENSAT PK-2 EGFP transgenic mouse model [Tg (Prok2-EGFP) FH64Gsat] where PK-
2 expression could be traced using the fluorescent EGFP reporter protein. Since these 
transgenic white mice are on a Swiss Webster genetic background, which is distinct from that 
of the commonly used C57bl6 strain, the reproducibility of our results in this strain of mice 
further support the validity of our findings.  
The transcriptional mechanisms by which PK2 induction occurs in dopaminergic 
neurons remain to be determined and would also be of therapeutic value given that our 
mechanistic studies suggest that PK2 has neuroprotective functions in vitro. The PK2 
promoter has been shown to be replete with multiple E-box sequences (CACGTG) that are 
binding sites for by basic helix-loop-helix (bHLH) transcription factors such as HIF1α which 
has been shown to regulate the expression of PK-2 during angiogenesis (LeCouter et al., 
2003). Previous studies have shown that the expression of PK-2 in the CNS is regulated by 
the CLOCK/BMAL1 in SCN in a circadian fashion and by Ngn1/MASH1 during olfactory 
bulb biogenesis. We posit that the induction of PK2 in dopaminergic neurons would most 
likely be under the control of HIF1α, which has been shown to be activated by oxidative 
stress and by TNFα under normoxic conditions (Jiang et al., 2010). Further, HIF1α activation 
has been reported in nigral dopaminergic neurons following MPTP treatment and also in N27 
cells treated with MPP+, making it a likely candidate for transcriptional regulation of PK-2 in 
243 
 
 
this system (Sharp and Bernaudin, 2004; Lee et al., 2009; Correia and Moreira, 2010). The 
detailed transcriptional mechanisms regulating the induction of PK2 in dopaminergic neurons 
are currently under study in our laboratory.  
Our data also demonstrate that both receptors for PK2, PKR1 and PKR2 are present 
in the substantia nigra with PKR2 being expressed on nigral dopaminergic neurons. While 
PKR1 could be detected in nigral tissue lysates in Western blots, we failed to detect its 
expression on nigral dopaminergic neurons by immunohistochemistry. Microglia and 
astrocytes have been shown to express high levels of PKR1 (Koyama et al., 2006) and it is 
possible that these are the primary PKR1-expressing cells in nigral tissue lysates. We also 
detected expression of both PKR1 and PKR2 on N27 dopaminergic cells and primary 
dopaminergic neurons in EVM cultures. Previous reports have shown that PKR2 is the 
dominant prokineticin receptor present in the brain and that a PK2-PKR2 signaling axis 
mediates the known functions of PK2 such as olfactory bulb biogenesis and regulation of 
circadian rhythms (Cheng et al., 2006; Zhou, 2006). It is likely that the same ligand-receptor 
combination is relevant to PK-2 signaling in nigral dopaminergic neurons.  
A wealth of evidence supports a role for prokineticin signaling in cell survival in 
various tissues and PK2 is a known mediator of angiogenesis, hematopoiesis and 
neurogenesis(LeCouter et al., 2003; Battersby et al., 2004; LeCouter et al., 2004; Kisliouk et 
al., 2005). In a recent study, PK2 signaling was also shown to protect cardiomyocytes against 
oxidative stress and promote cardiomyocyte survival by activating the Akt pathway 
(Urayama et al., 2007). Since PK2 is upregulated and secreted in response to oxidative stress 
and neurotoxicity by dopaminergic neurons and since its receptors are expressed on the same 
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cells in vivo, we reasoned that the secreted PK2 could function as a neuroprotective factor 
and activate intracellular signaling pathways that mediate oxidative stress resistance and 
survival of dopaminergic neurons. We tested this hypothesis in N27 dopaminergic cells and 
primary neuron cultures and demonstrate for the first time that co-treatment with PK2 
attenuates the generation of intracellular ROS by MPP
+
 in dopaminergic cells. Further, PK2 
treated cells were protected against downstream caspase-3 activation and DNA fragmentation 
by MPP+ providing clear evidence for activation of anti-apoptotic survival signaling by PK-
2. The mechanism of MPP
+
 toxicity in dopaminergic cells is primarily through the inhibition 
of complex I (NADH/ubiquinone oxidoreductase) of the mitochondrial electron transport 
chain and usually results in activation of the intrinsic apoptotic pathway and is accompanied 
by mitochondrial fission. In PK2 co-treated cells, the activation of pro-apoptotic kinases JNK 
and ERK were both attenuated compared to cells treated with MPP
+
 alone. Further, the 
mitochondrial fragmentation that occurred 16 h after MPP+ exposure was significantly 
reduced in PK-2 treated cells where an intact mitochondrial network was evident at the same 
time point. The dopaminergic neruoprotective effect of PK2 against MPP
+
 toxicity was also 
evident in primary mesencephalic neuronal cultures in which co-treatement with PK2 
resulted in higher TH-positive neuron counts and increased uptake of tritiated dopamine 
compared to cultures treated with MPP+ alone. The protective effect of PK-2 on primary 
dopaminergic neurons against MPP+ toxicity was also evident morphologically when 
visualized using TH immunofluorescence.  
To further characterize the mechanisms by which PK-2 protects dopaminergic cells 
against MPP+ toxicity, we looked at various protective signaling pathways relevant to 
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oxidative stress and mitochondrial dysfunction. In an unexpected finding, we noticed 
increased levels of the anti-apoptotic PINK-1 protein in N27 cells co-treated with PK2 and 
MPP
+ 
compared to cells treated with either MPP
+
 alone or untreated controls suggesting that 
PK2 signaling can protect dopaminergic cells by a PINK-1 dependent mechanism. In recent 
years, the role of PINK-1 in protecting cells against oxidative stress and maintaining 
mitochondrial integrity has been well established (Clark et al., 2006; Gautier et al., 2008). Of 
particular importance to our results here, are studies which have demonstrated that cells 
deficient in PINK-1 have increased susceptibility to oxidative stress and mitochondrial 
dysfunction accompanied by increased fragmentation of the mitochondria (Lutz et al., 2009). 
On the other hand, overexpression of PINK-1 has been shown to protect cells against 
oxidative stress indicating that the expression levels of this kinase could be critical in 
determining the susceptibility or resistance of cells to mitochondrial dysfunction and 
oxidative stress (Petit et al., 2005; Mai et al., 2010). Our results demonstrating that PK2-
treated cells are protected against MPP
+
 induced oxidative stress and mitochondrial 
fragmentation are well explained by the fact that these cells have increased expression of 
increased PINK-1 expression and identify a previously unknown link between PK2 and 
PINK-1 signaling. Interestingly, the levels of Parkin, which has been shown to function 
analogous to PINK-1, did not change with PK2 treatment. Although further studies would be 
required to elucidate the detailed mechanism by which PK-2 increased PINK-1 levels in N27 
cells, these finding suggests that there could be immense therapeutic value to developing 
PK2 mimetics as prokineticin GPCR agonists to increase the survival of dopaminergic 
neurons in PD 
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Taken together, the results of our studies presented here, have far-reaching 
implications for dopaminergic degeneration in PD and for PK2 biology in general. To our 
knowledge, this is the first report showing that PK2 can be rapidly induced following 
neurotoxic insults or neurodegeneration in the adult mammalian brain. Given that the 
prokineticin receptors, are ubiquitously expressed in the brain it is likely that the upregulation 
and release of PK-2 from neurons could be an early response to neuronal injury in different 
areas of the brain and could be associated with other neurodegenerative besides PD.  
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Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Induction and release of PK-2 in dopaminergic N27 cells and calcium 
mobilization by recombinant PK-2. A, Western blots for intracellular and secreted PK2 
protein by N27 cells.  N27 cells were treated with TNF (30 ng/ml) and MPP
+
 (200 μM) for 
12 h. At the end of the treatment, supernatants were collected and concentrated using a 
Vivaspin centrifugal concentrator with a 3 kDa molecular weight cutoff. Cell lysates were 
prepared using a modified RIPA buffer. Equal amounts of protein (50 μg/well) were loaded 
and samples were immunoblotted for PK-2 using a rabbit polyclonal antibody. Actin was 
A B 
C D 
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used as the internal control to verify equal protein loading. PK-2 expression was induced in 
N27 cells following exposure to TNF and MPP
+
 in both cells and the extracellular 
supernatants indicating that these cells upregulate and secrete PK-2 similar to dopaminergic 
neurons in vivo. B, PK2 immunofluorescence in N27 cells. Intracellular localization of PK2 
was determined using immunocytochemistry following exposure to TNF and MPP
+
 for 12 h. 
Cells were incubated overnight in a PK2 primary antibody and visualized using a species-
specific  Alexa-488 (green) secondary antibody. Hoechst dye was used to stain the nucleus 
(blue). Images were captured using a Nikon TE-2000 fluorescence microscope at 60X 
magnification. Cytosolic expression of PK-2 (green) was evident and appeared to be 
localized in the secretory pathway. C, Western blot of prokineticin receptors PKR1 and 
PKR2 in N27 cells. Lysates were probed for PKR1 and PKR2 expression by Western 
blotting using a goat polyclonal antibody to PKR1 (red) and a rabbit polyclonal antibody to 
PKR2. Bands were visualized using a IR-dye tagged secondary antibodies. Tubulin was used 
as the internal control to demonstrate equal protein loading. Both PKR1 and PKR2 were 
expressed by N27 dopaminergic cells. D, Calcium mobilization by PK2 in N27 cells. 
Calcium flux induced by recombinant PK-2 in N27 cells was determined using the Fluo-4 
NW assay kit with nanomolar doses of the recombinant PK-2 protein. Calcium-free HBSS 
was used on the control group. The calcium-flux data was expressed as the net change in 
fluorescence signal (Df) representing the maximum signal after background subtraction for 
each dose of PK-2. As shown, PK2 mobilized calcium downstream of its two GPCRs in a 
dose-dependent manner in N27 cells. Asterisks denote a significant (* p<0.05 and *** 
p<0.001) difference between control and PK-2 treated groups.  
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Prokineticin-2 is highly induced in substantia nigra dopaminergic neurons 
following MPTP treatment in a mouse model of Parkinson’s disease. C57bl/6 mice were 
injected with 4 doses of MPTP (18 mg/kg) at 2 h intervals. Mice were sacrificed at various 
time points after the last injection. A, Double labeling immunohistochemistry for PK-2 and 
258 
 
 
TH in mouse substantia nigra sections. Mice were anesthetized and perfused transcardially 
with 4% PFA 24 h after MPTP treatment and 30 micron sections were cut using a freezing 
microtome. Substantia nigra sections were stained for TH (red - Alexa 555) and PK-2 (green 
- Alexa 488). High levels of PK-2 expression was evident in almost all TH-positive neurons 
as seen in the merged image (yellow color). A few adjacent cells with neuronal morphology 
that were not positive for TH also displayed PK-2 in the nigral region. Representative images 
at 20X magnification are shown. B, Western blots for PK-2 protein expression. Increased 
nigral PK-2 expression was also confirmed by Western blotting. Mice were sacrificed at 3 , 
12 , 24 and 72 hours after MPTP treatment. Nigral and striatal tissues were dissected out 
using a brain matrix and lysates were probed for PK-2 by Western blotting with a rabbit 
polyclonal antibody. Increased PK-2 expression in the substantia nigra (top panel) was 
evident as early as 3 h after the last MPTP injection and remained elevated upto 72 hours 
later. Interestingly, while PK-2 expression was increased in the substantia nigra lysates at 24 
h (bottom panel), its level in the striatum remained the same after MPTP treatment. 
Representative blots are shown and experiments were repeated more than three times C, 
Realtime qRT-PCR for PK-2 mRNA expression in the substantia nigra. PK-2 mRNA 
expression in substantia nigra tissues was determined 24 h after MPTP treatment by real-time 
SYBR green qRT-PCR using pre-validated primers. 18S rRNA was used as the internal 
standard for normalization and the fold increase in gene expression was determined by the 
ΔΔCt method. Significantly higher expression of PK-2 (***p<0.001) was evident in nigral 
tissues following MPTP treatment. Data represent the group mean ± SEM from four mice. 
Experiments were repeated twice. 
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Figure 3.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Visualization of PK-2 induction in vivo using the GENSAT Prok2-EGFP 
reporter transgenic mouse model. Prok2-EGFP transgenic mice were generated as part of 
the GENSAT project on a FVB/N-Swiss Webster hybrid genetic background using bacterial 
artificial chromosomes (BAC) . A, Validation of the PK-2 EGFP reporter transgenic mouse 
model by genotyping. All mice were genotyped for presence of the transgene prior to 
experiments according to the recommended PCR protocolusing mouse tail genomic DNA. B, 
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PK-2 expression in the olfactory bulb and suprachiasmatic nucleus (SCN). Expression of the 
EGFP reporter was determined in the olfactory bulb and the SCN where PK-2 is known be 
constitutively expressed  at high levels. Free-floating sections (30 microns) from the 
olfactory bulb and the SCN were cut using a freezing microtome, mounted on glass slides 
and directly visualized for EGFP fluorescence. High levels of EGFP fluorescence was 
evident in both target regions confirming the veracity of PK-2 expression in the transgenic 
mice. C, Increased EGFP expression in the substantia nigra following MPTP-treatment. 
Prok2-EGFP transgenic mice were injected with four doses of MPTP (20 mg/kg) at 2 h 
intervals or saline and were sacrificed 24 h after the last injection. Nigral tissue was dissected 
and lysates were probed for GFP and PK-2 protein expression by Western blotting. Increased 
protein levels of GFP along with a concomitant increase in PK-2 protein expression was seen 
in MPTP-treated mice confirming that PK-2 is highly induced in this mouse strain following 
MPTP treatment similar to results obtained with C57 black mice. D, Visualization of EGFP 
expression in the Prok2-EGFP transgenic mouse substantia nigra. Free-floating nigral 
sections (30 microns) were obtained from  saline or MPTP-treated transgenic mice sacrificed 
24 h after the last injection. Sections were stained for TH on the red channel using an Alexa-
555 secondary antibody and EGFP fluorescence was directly imaged on the green channel 
(488 nm excitation). Increased EGFP expression is evident in the MPTP-treated mouse 
substantia nigra as seen in the merged image with TH. In saline controls little or no 
expression of EGFP was evident in these mice similar to results obtained with C57 black 
mice. Image magnifications are 20X. Representative images are shown and all experiments 
were repeated at least three times. 
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Figure 4.  
 
 
 
 
 
Figure 4. PK-2 expression is increased in the substantia nigra of human PD patients. A, 
Western blot for PK-2 protein levels in PD brain tissue lysates and age-matched controls. 
Substantia nigra lysates from PD brain tissue and age-matched controls were probed for PK-
2 expression using a rabbit polyclonal antibody directed against an internal region of the 
human  PK-2 protein. A total of 50 μg protein was loaded for each sample and actin was used 
as the internal loading control. Increased levels of PK-2 was evident in most PD samples 
compared to controls although some variability in PK-2 expression levels was observed in 
both control and PD patients. A representative blot is shown and experiments were repeated 
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twice. B, Densitometric analysis of PK-2 protein levels. Band intensities for PK-2 were 
determined from six control and PD samples and were normalized using actin as the internal 
control. The data was expressed as a fold change over control. Asterisks denote a significant 
(* p<0.05) difference between control and PD samples. C, PK-2 immunohistochemistry in 
human nigral tissue sections. Sections from PD brains and age-matched controls were 
processed for immunohistochemistry using a rabbit polyclonal antibody that detects human 
PK-2 (green - Alexa488). Tyrosine hydroxylase (Red - Alexa555) was used as a marker for 
dopaminergic neurons and Hoechst stain (blue) was used to label the nucleus. PK-2 
expression was low or almost absent around melanized dopaminergic neurons in control 
midbrain  nigral sections while high levels of PK-2 was evident in sections from PD brains. 
More than 90% of the PK-2 positive cells (green) were also TH-positive (red) as seen in the 
merged image. Representative images are shown and experiments were repeated twice.  
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Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Expression of prokineticin receptors in the mouse substantia nigra and 
primary mesencephalic neurons. A, Western blot for prokineticin receptors PKR1 and 
PKR2 in mouse nigral tissue lysates. C57 black mice were treated with 4 doses of MPTP (18 
mg/kg, i.p.) and sacrificed at the indicated time points. Nigral tissues were dissected and 
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lysates probed for the two prokineticin receptors PKR1 and PKR2 using rabbit polyclonal 
antibodies. Tubulin was used as the loading control. Both PKR1 and PKR2 were highly 
expressed in the substantia nigra. Representative blots are shown and experiments were 
repeated at least three times. B, Expression of PKR2 on substantia nigra dopaminergic 
neurons. Free floating nigral sections (30 microns) were cut and processed for PKR2 and TH 
immunohistochemistry. PKR2 (green - Alexa488) was detected using a rabbit polyclonal 
antibody and TH (red – Alexa555) using a mouse monoclonal antibody. PKR2 expression in 
nigral sections was evident as punctate staining and was highly expressed on TH-positive 
dopaminergic neurons as seen in the merged image. Image magnification is 60X.  C, 
Expression of prokineticin receptors in primary neuronal cultures. Primary mouse embryonic 
(E14) ventral mesencephalic neuron cultures were processed for immunocytochemistry at 4 
days in vitro. Cells were fixed with 4% PFA for 15 minutes and stained with rabbit 
polyclonal antibodies to PKR1 and PKR2 (green – Alexa488). Dopaminergic neurons were 
labeled with TH (red – Alexa555). Species-specific Alexa dye-tagged secondary antibodies 
were used to detect each primary antibody and Hoechst (blue) was used to stain the nucleus. 
As seen in the merged image on the right, both PKR1 and PKR2 were highly expressed by 
TH-positive dopaminergic neurons (merged yellow). PKR1 was also expressed along 
neuronal processes besides the neuron cell body while PKR2 expression was localized more 
the neuronal cell bodies. PKR1 and PKR2 were expressed on non-dopaminergic neuronal 
cells as well as seen from the merged image although several Hoechst-positive neuronal cells 
were negative for prokineticin receptor expression. Image magnifications are 20X and 
representative images are shown. Experiments were repeated three times.  
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Figure 6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Exogenous recombinant PK-2 protects N27 cells against MPP+ mitochondrial 
neurotoxicity and increases PINK-1 protein. A, Recombinant PK-2 attenuates intracellular 
ROS generation by induced by MPP
+ 
or co-treated with various doses of recombinant PK-2. 
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N27 cells were treated with 200 μM MPP+ in 2% serum RPMI for 8 hours and total 
intracellular ROS levels were determined by quantifying the DCFDA dye fluorescence using 
a plate reader. MPP+ induced a significant increase in ROS generation which was reduced 
with PK-2 cotreatment in a dose-dependent manner suggesting that PK-2 signaling via its 
GPCRs activates survival signaling that protects against MPP
+
 oxidative stress. B-C, PK-2 
signaling attenuates MPP
+
 induced caspase-3 activation and DNA fragmentation. N27 cells 
were treated with MPP
+
 (200 μM) or co-treated with PK-2 (25 nM) and cells were collected 
for caspase-3 activity assays (B) at 8 h and DNA fragmentation analysis (C) at 16 h.  
Caspase-3 activity was determined using a fluorescent peptide substrate (Ac-DEVD-AFC) 
and DNA fragmentation was quantified using a sensitive ELISA. The raw data was 
normalized to the total amount of protein per sample (in mg) determined using a Bradford 
protein assay and expressed as fluorescence units per mg of protein (FU/mg protein) for 
caspase-3 activity and absorbance units per mg protein (AU/mg protein) for the DNA 
fragmentation ELISA. MPP
+
 treatment induced robust activation of caspase-3 at 8 h (B) and 
resulted in DNA fragmentation at 16 h (C). Co-treatment with PK-2 significantly attenuated 
both the activation of caspase-3 and DNA fragmentation induced by MPP
+
. Data represents 
the group mean ± SEM. Asterisks denote a significant difference (** p<0.01 and *** 
p<0.001) difference between control and MPP
+
 treatment groups. # # p <0.01 between MPP+ 
treatment and the PK-2 co-treatment groups. D, PK-2 signaling blocks MPP
+
 induced 
mitochondrial fragmentation. N27 cells were treated with MPP+ (200 μM) for 16 h in 2% 
serum media and then incubated with MitoTracker Red dye for 15 minutes to label the 
mitochondria. Cells were fixed in 4% PFA and the nucleus was stained using Hoechst (blue). 
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Mitochondrial fragmentation was visualized by fluorescence microscopy using a Nikon TE-
2000 fluorescence microscope and images were captured at 60X magnification. MPP
+
 
treatment resulted in highly fragmented mitochondria (center panel) which was attenuated by 
cotreatement with PK-2 as seen by the presence of an intact mitochondrial network and 
significantly less fragmented mitochondria. E, PK-2 attenuates activation of pro-apoptotic 
signaling pathways by MPP
+
. N27 cells were treated with MPP
+
 (200 μM) or co-treated with 
PK-2 for 12 h and lysates were probed for the activation of pro-apoptotic signaling pathways. 
MPP+ treatment induced activation of ERK and JNK as seen by increased phosphorylation at 
their respective active sites. MPP+ also caused an increase in the levels of the short MCL-1 
isoform (MCL-1S) which is known to drive prop-apoptotic signaling following activation of 
the mitochondrial cell death pathway. Consistent with the results obtained with caspase-3 
activity and DNA fragmentation assays, co-treatment with recombinant PK-2 decreased the 
levels of active (phospho) JNK and ERK1/2 and also suppressed the increase in MCL-1S 
induced by MPP
+
.F, PK-2 modulates PINK-1 and FOXO-3A signaling to protect against 
MPP
+
 neurotoxicity. Lysates from N27 cells treated with either MPP
+
 or co-treated with PK-
2 were probed PINK-1, PARKIN and phospho FOXO-3A (Thr-32) by Western blotting. 
Cells co-treated with PK-2 expressed higher levels of the PINK-1 protein and increased 
phospho FOXO-3A (Thr-32) compared to either untreated controls or MPP
+
 treated cells 
suggesting that these survival signaling pathways might be relevant in PK-2 mediated 
protection of N27 cells from MPP+ induced cell death. Representative blots are shown and 
experiments were repeated twice. 
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Figure 7.  
 
 
 
 
 
 
 
Figure 7. PK-2 protects primary dopaminergic neurons from MPP
+
 neurotoxicity. A, 
Calcium mobilization by PK-2 in primary EVM neuronal cultures. Primary EVM neuron 
cultures were treated with nanomolar doses of recombinant PK-2 and the calcium flux 
quantified using the Fluo-4 NW calcium assay kit. Control cells were treated with calcium-
free HBSS. Calcium-flux data was expressed as the net change in fluorescence signal (Df) 
representing the maximum signal after baseline subtraction for each dose of PK-2. As shown, 
PK-2 mobilized calcium in a dose-dependent manner in primary neuron cultures, which also 
express both prokineticin receptors (Fig. 4). Data represent the group mean ± SEM. Asterisks 
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denote a significant (*** p<0.001) difference between HBSS-treated controls and PK-2 
treated groups. B,C Dopamine uptake assay and TH+ neuron counts in primary EVM 
neuronal cultures. Primary EVM cultures were grown in neurobasal medium in 24 well plates 
on poly-D-lysine coated coverslips and treated 4 days after plating (DIV-4). Cells were 
treated with MPP
+
 (5 μM) for 24 h or co-treated with recombinant PK-2 (25 nM). PK-2 was 
added at the beginning of the treatment and again 12 hours later. For dopamine uptake assays 
(B) cells were washed in Krebs-Ringer buffer and then incubated with 5 μM [3H]-Dopamine 
for 20 minutes at 37°C. Cultures were then washed in ice-cold KRB, dissolved in 1 N NaOH 
and mixed with scintillation fluid. Radioactivity counts were determined using a Tricarb 
scintillation counter. The non-specific uptake of dopamine determined in paralell wells in the 
presence of mazindol was subtracted and the specific dopamine uptake was plotted for each 
group as percent control (B). For TH-positive neuron counts, cultures were fixed in 4% PFA 
at the end treatment and dopaminergic neurons were visualized by TH-immunocytochemistry 
using an Alexa-555 secondary antibody (red). Cells from  eight independent fields were 
counted from each group in triplicate and data was expressed as percent control (C).Data 
represent the group mean ± the SEM. Asterisks denote a significant (*** p<0.001) difference 
between the control and MPP
+
 treated group. # # denotes p<0.01 and # denotes p<0.05 PK-2 
between the MPP
+
 and PK-2 co-treatment groups. Co-treatment with PK-2 significantly 
improved dopaminergic neuron survival and function compared to MPP
+
 treatment alone.  D, 
Representative images of dopaminergic neurons in primary EVM cultures. Images were 
acquired at 20X magnification. As shown, MPP+ treatment caused extensive degeneration of 
dopaminergic neurons which was attenuated in the presence of recombinant PK-2  
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CHAPTER VI 
GENERAL CONCLUSION 
 
This section presents a general overview of the results and findings described in the 
thesis herein, with a special emphasis on future directions and overall implications of these 
findings for the pathogenesis and progression of Parkinson’s disease.  The major findings 
pertaining to each research manuscript and their specific implications are covered in the 
‘results and discussion’ sections of the relevant chapter.  
Distinct PKCδ activation mechanisms in dopaminergic neurons and microglia 
Taken together, the results from chapter 2 and 3 demonstrate that PKCδ is activated 
in both dopaminergic neurons and microglial cells by two distinct mechanisms. In 
dopaminergic neurons, PKCδ is proteolytically activated by caspase-3 via the extrinsic 
apoptotic cascade downstream of TNFR1 signaling and promotes apoptosis. In microglial 
cells however PKCδ protein expression is highly induced following microglial activation by 
LPS, TNFα or aggregated alpha-synuclein with a concomitant increase in kinase activity, 
indicative of a classical PKC activation mechanism involving phosphorylation at the 
activation loop. While proteolytic activation of PKCδ in dopaminergic neurons promotes 
apoptosis, the induction of PKCδ in microglial cells promotes activation and 
proinflammatory responses.  Further, the induction of PKCδ in microglia appears to be a 
common downstream target of distinct microglial activation stimuli, LPS via TLR4, TNFα 
through its TNF receptors and aggregated alpha  synuclein via phagocytosis (Zhang et al., 
2005b).  
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Previous studies from our laboratory have shown that during dopaminergic cell death 
induced by oxidative stress or neurotoxic insults such as MPP+, proteolytic activation of 
PKCδ occurs via the intrinsic mitochondrial apoptotic pathway and promotes apoptosis. 
Proteolytic activation of PKCδ by TNFR1 signaling lends further support for a direct 
neurotoxic role for TNFα signaling on dopaminergic neurons in addition to potentiating 
microglial neurotoxicity. Our finding that PKCδ is proteolytically activated in the substantia 
nigra following stereotaxic LPS infusion demonstrates that this signaling pathway is relevant 
to dopaminergic degeneration initiated by inflammatory insults in vivo. It also indicates that 
proteolytic activation of PKCδ could be a common downstream mediator during 
dopaminergic cell death induced by diverse neurotoxic signaling mechanisms that converge 
on the extrinsic and mitochondrial apoptotic pathways.  
A TNFα-PKCδ signaling loop between microglia and neuronal cells during 
progressive dopaminergic degeneration and sustained microglial activation is also evident 
from these findings (Figure 1). Dopaminergic degeneration is initiated by various neurotoxic 
factors and injured dopaminergic cells release factors such as MMP-3 and alpha synuclein 
aggregates, which can activate microglia and induce the upregulation of PKCδ.  PKCδ most 
likely regulates the proinflammatory response in the microglia by activating the p65/NFκB 
pathway. Activation of the NFκB pathway leads to the sustained upregulation of PKCδ in 
these cells and the induction of proinflammatory mediators including iNOS and TNFα (Jin et 
al., 2011). The microglial TNFα can then act on compromised dopaminergic neurons by 
signaling through its TNFR1 receptor and lead to activation of caspase-3 via caspase-8. 
Activation of caspase-3 leads to downstream activation of PKCδ in dopaminergic cells 
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resulting in proteolytic cleavage of PKCδ into its catalytic fragment (CF) and regulatory 
fragment (RF). The catalytic fragment translocates to the nucleus and promotes cell death in 
dopaminergic neurons.  This leads to release of further soluble mediators from dopaminergic 
neurons which activate microglial cells, potentially amplifying the signaling loop and leading 
to sustained reactive microgliosis (Block et al., 2007a) 
 
Figure 1: Distinct mechanisms of PKCδ activation in microglia and dopaminergic cells 
 
 
 
  
 
 
 
 
 
 
 
 
PKCδ substrates and signaling pathways  
 The downstream substrates of PKCδ proapoptotic signaling have been identified 
including laminin, DNA-PK and histone H1 in the nucleus (Kanthasamy et al., 2003b) and 
273 
 
 
these are likely to be involved in PKCδ signaling during TNF-induced dopaminergic cell 
death. The upstream signaling pathway that results in proteolytic activation of PKCδ by TNF 
in N27 cells remains to be defined. Since there is substantial cross talk between the extrinsic 
and intrinsic apoptotic pathways downstream of TNF death receptor signaling via t-bid (Chen 
and Goeddel, 2002), TNF signaling could synergize with other neurotoxic mediators that 
initiate dopaminergic degeneration via mitochondrial apoptosis, with PKCδ being a common 
downstream target (Korsmeyer et al., 2000; Anantharam et al., 2002; Kaul et al., 2003b; 
Afeseh Ngwa et al., 2009). This could be one potential mechanism by which TNF can sustain 
reactive microgliosis and promote dopaminergic cell death resulting in progressive 
neurotoxicity (Block et al., 2007a).  
The precise signaling mechanism and downstream targets of PKCδ during microglial 
activation are currently under investigation. However, potential downstream targets for 
regulation by PKCδ can be inferred based on the known substrates and functions of PKCδ in 
innate immune cells. Both NFκB/p65 and the p47-PHOX subunit of the NADPH oxidase 
complex are substrates for PKCδ in other cell types (Cheng et al., 2007; Mut et al., 2010) and 
regulate multiple arms of the microglial activation response including cytokine release, 
superoxide production and iNOS activation. Our findings suggest that microglia isolated 
from PKCδ knockout (PKCδ-/-) mice have attenuated nitric oxide and  intracellular ROS 
generation, as well as reduced levels of proinflammatory cytokines and chemokines 
compared to microglia from wildtype (PKCδ +/+) mice. This suggests that NFκB or NADPH 
oxidase activity may be affected in microglia isolated from PKCδ knockout mice. The 
serine/threonine and tyrosine phosphorylation status of PKCδ during microglial activation is 
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also currently being investigated and may provide novel insight into understanding the 
detailed mechanism of PKCδ activation in these cells and help define substrate specificity of 
the kinase.  
PKCδ signaling in regulation of systemic inflammatory responses  
Recent studies have shown that the brain has a heightened sensitivity to systemic 
inflammatory insults. In particular, the systemic injection of LPS causes an elevation of TNF 
alpha in the brain for up to ten months, while the peripheral levels of TNF return to basal 
levels in less than a week. Further, TNFα signaling was found to be important for the transfer 
of peripheral systemic inflammation into the brain (Qin et al., 2007). We obtained similar 
results with LPS-injected PKCδ wildtype mice, which showed elevated levels of TNFα 
mRNA in the brain (20- to 40-fold over saline controls). Further, these mice showed 
significant LPS-induced sickness behavior typical of LPS activation at 48 hours. PKCδ 
knockout (PKCδ -/-) mice however, recover rapidly from LPS-induced sickness and are 
almost normal at 48 hours with behavioral parameters similar to those of saline controls. 
Importantly, the brain TNF mRNA levels are significantly reduced in these mice (two to 
threefold over saline controls) suggesting an important role for PKCδ signaling in mediating 
the systemic inflammatory response to LPS and the heightened inflammatory state in the 
brain. Our results from the behavioral studies with PKCδ knockout mice using the systemic 
LPS injection model are intriguing in the light of similar results published recently in a 
model of lung injury induced by polymicrobial sepsis (Kilpatrick et al., 2011). Targeted 
inhibition of PKCδ in this model effectively prevented lung injury following polymicrobial 
sepsis suggesting that PKCδ is a crucial regulator of proinflammatory events in the lung. The 
275 
 
 
specific immune cell types and the mechanisms involved are yet to be defined although based 
on the existing literature, neutrophils and monocytes/macrophages are likely to be the 
primary innate immune cells involved 
Dual neuroprotective outcome of targeted PKCδ inhibition 
 The simultaneous activation of PKCδ in both microglia and dopaminergic neurons by 
distinct mechanisms during dopaminergic degeneration suggests that the use of small-
molecule inhibitors could be an effective therapeutic strategy against dopaminergic 
degeneration. Targeted kinase inhibition of PKCδ using TAT-PKCδ peptides or small 
molecule inhibitors has shown to be effective in inhibiting PKCδ signaling in vivo (Zhang et 
al., 2007c; Kilpatrick et al., 2011).  Importantly, our findings reported here suggest that 
inhibition of PKCδ could result in significant dopaminergic neuroprotection by acting on 
both the microglial neurotoxic response and directly preventing dopaminergic neuron loss. 
Targeted PKCδ inhibition could therefore be very effective at shutting down the self-
perpetuating neurotoxicity that is believed to drive sustained reactive microgliosis and 
dopaminergic neurotoxicity. Our neuroprotection experiments with the MPTP model in 
PKCδ knockout mice demonstrate this mechanistically. In PKCδ knockout mice, the 
microglial activation response in the substantia nigra is blunted in both LPS and MPTP 
models. The nigrostriatal system is also effectively preserved in these mice in the MPTP 
model of PD with significant protection in terms of neurochemical and behavioral 
parameters. Similar results were obtained in previous studies from our research group using 
the PKCδ inhibitor rottlerin, demonstrating the feasibility of this approach. Although the 
276 
 
 
neuroinflammatory responses were not evaluated in that study, significant protection of the 
nigrostriatal system against MPTP was evident in rottlerin-treated mice. 
 Dominant negative inhibitors to soluble TNFα have recently shown tremendous 
efficacy in protecting dopaminergic neurons from nigrostriatal degeneration in animal 
models of PD. This is likely due to a similar dual-neuroprotective effect of TNF inhibition 
that prevents both direct dopaminergic neurotoxicity and a potentiation of the microglial 
inflammatory responses. Our results here identify that PKCδ signaling could act downstream 
of TNF in dopaminergic neurons and upstream of microglial TNFα release. Taken together, 
the findings reported here provide further rational for targeting PKCδ in PD and could be an 
effective therapeutic strategy to mitigate microglial neurotoxicity and progressive 
dopaminergic degeneration.  
Relevance of PK2 signaling to Parkinson’s disease  
The findings reported in chapter V demonstrate that PK2 is highly induced following 
dopaminergic neuron injury in cell culture and animal models of PD and is also elevated in 
the postmortem human PD brains. These findings suggest intriguing new functions for PK2 
in the pathophysiology of Parkinson’s disease and neurodegeneration in general by providing 
the first evidence for the induction of PK2 expression in neurons following injury or in a 
neurodegenerative disease. We believe that the induction of PK2 in the MPTP model of PD 
is most likely mediated by oxidative stress-induced activation of the basic helix-loop-helix 
transcription factor HIF1α that has previously been shown to occur in the MPTP model of 
PD (Lee et al., 2009). HIF1α can activate E-box elements, which are abundantly expressed 
on the PK2 promoter proximal to the transcription start site. This hypothesis is being tested 
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using HIF1 activators and inhibitors in cell culture and animal models of PD. Our 
preliminary results using HIF1α agonists in N27 cells suggest that PK2 can be induced in 
dopaminergic cells by HIF1α activation. Further studies are being performed to validate this 
hypothesis in vitro and in the MPTP mouse model.  
PK2 as a potential neuroprotective factor for dopaminergic  neurons  
We verified that receptors for PK2 are expressed on primary dopaminergic neurons, 
N27 dopaminergic cells and in the mouse substantia nigra confirming that the dopaminergic 
neurons themselves could be the target of secreted PK2 in the nigra. Our functional studies 
demonstrate that PK2 protects dopaminergic neurons in vitro from MPP
+
 induced oxidative 
stress and cell death by a novel mechanism involving the upregulation of the mitochondrial 
survival kinase PINK1. The activation of two important survival kinases, the Akt and MAPK 
pathways, have been consistently reported in several studies using different cell types from 
neurons to hematopoietic cells. In almost all studies to date, prokineticin signaling has been 
associated with cell survival and differentiation or cell migration and activation. To date, 
there is no evidence linking prokineticin signaling with apoptotic or other cell degenerative 
signaling pathways. Rather, PK2 signaling in the CNS has been associated with adult 
neurogenesis in the subventicular zone and olfactory bulb suggesting that PK2 can function 
as a neurotrophic factor and a chemoattractant in the brain.  Interestingly, receptors for 
prokineticins, (particularly PKR2) are constitutively expressed across the brain at high 
density even in areas such as the midbrain where no prokineticin ligand is normally 
detectable.  It is possible that PK2 is induced locally at sites of neuronal injury or 
degeneration in the brain and functions as a neuroprotective factor by signaling through 
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PKR2. Taken together, the results of our mechanistic studies clearly demonstrate that PK2 
can effectively protect against mitochondrial oxidative stress and neurotoxicity in 
dopaminergic neurons. These findings thus have immense therapeutic implications for 
targeting the prokineticin GPCRs expressed on these cells using PK2 agonists 
Potential functions of PK2 signaling in microglia and astrocytes 
Both microglia and astrocytes have been shown to express prokineticin receptors 
(Koyama et al., 2006). Therefore, PK2 released from dopaminergic neurons may also play a 
role in regulating microglia and astrocyte responses. Based on previous studies and known 
functions of PK2 on immune cells, it is likely that the PK2 released from injured 
dopaminergic neurons is a chemoattractant or aproliferation signal for microglia and 
astrocytes in the substantia nigra. Secreted PK2 can therefore direct the migration of 
astrocytes and microglia to sites of neuronal injury and facilitate neuron survival by 
potentially eliciting glial neurotrophic factors. PK2 can also function as a pro or anti-
inflammatory mediator on microglia and astrocytes and thus regulate dopaminergic neuron-
glia interactions. Our preliminary studies suggest that indeed PK2 functions as a 
chemoattractant for microglia and astrocytes in vitro. Current studies are focused on 
establishing the overall neuroprotective functions of PK2 signaling in vivo using adenoviral 
overexpression of PK2 in the mouse substantia nigra and the MPTP model of PD. The effect 
PK2 on astrocyte and microglial migration and a potential mechanisms of neuroprotective 
glial responses is also being evaluated in cell culture and animal models.  
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